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Abstract
Alzheimer’s disease is the most common form of dementia, accounting for approxi-
mately 60-80% of cases. Pathologically, the disease is characterised by the accumu-
lation of amyloid plaques and neurofibrillary tangles in brain tissue, which give rise
to downstream neurodegeneration and cognitive deficits. Biomarkers, such as volu-
metric measures of neurodegeneration derived from Magnetic Resonance Imaging,
allow the progression of Alzheimer’s disease to be monitored in vivo. Hypothetical
models have been proposed that describe a distinct sequence of biomarker changes,
but also heterogeneity in this sequence across different population subgroups. How-
ever, the quantitative evolution and heterogeneity of these biomarker changes has
yet to be determined.
This thesis investigates the progression and heterogeneity of Alzheimer’s dis-
ease by developing mathematical models of disease progression that characterise
the evolution of biomarker measurements from cross-sectional data. Three key con-
tributions are made. First, the application of data-driven models to sporadic and
dominantly-inherited Alzheimer’s disease to determine the sequence of biomarker
changes in each form of Alzheimer’s disease, and to ascertain the utility of patient
staging systems derived from the models. Second, the development of a simu-
lation framework that produces synthetic neurodegenerative disease datasets, al-
lowing the evaluation of the performance of mathematical models of disease pro-
gression. Third, the formulation of a data-driven subtyping model that uniquely
uncovers population subgroups with distinct biomarker trajectories, enabling the
separation of disease subtype from disease stage. Application of this model to spo-
radic Alzheimer’s disease provides a novel data-driven classification of Alzheimer’s
6 Abstract
disease into subtypes with distinct patterns of regional volume loss, as well as fine-
grained subtyping and staging information.
The models proposed in this thesis have wide potential further application to
advance disease understanding and to provide precise patient staging information
for other diseases and developmental processes.
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Chapter 1
Introduction
1.1 Alzheimer’s disease
1.1.1 Background
Alzheimer’s disease (AD) is a progressive neurodegenerative disease that is charac-
terised by the build up of amyloid plaques and neurofibrillary tangles in brain tissue.
It is the most common cause of dementia, accounting for approximately 60-80% of
cases [1–3], with the term dementia referring to the group of symptoms caused by
various brain disorders, rather than the underlying condition. The symptoms of de-
mentia include memory loss, language difficulties, loss of problem solving abilities,
behavioural problems, and difficulty performing activities of daily living. In the ad-
vanced disease stages there is a loss of bodily functions, which ultimately becomes
fatal. Each different type of dementia is associated with a particular set, severity,
and sequence of symptoms. AD typically presents with short-term memory loss,
with a broader range of symptoms developing as the disease progresses, such as im-
paired communication, disorientation, confusion, and behavioural issues. There is
however considerable overlap between the symptoms of different dementias, which,
together with the possible presence of mixed dementia, complicates differential di-
agnosis. In addition to the devastating personal impact of dementia, the economic
impact is huge, costing an estimated US $818 billion worldwide [4]. The number of
people living with dementia globally was estimated to be 46.8 million in 2015, with
this number being predicted to almost double every 20 years [4]. Currently there
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are no disease modifying treatments available; treatments only mask the symptoms
of dementia temporarily.
1.1.2 History
In 1906 Alois Alzheimer presented the case of Auguste D. [5], a woman admitted to
a mental institution at the age of 51 with progressive cognitive impairment that in-
cluded memory problems and hallucinations [6]. Autopsy examination of her brain
revealed the presence of plaques and neurofibrillary tangles [6, 7]. This particular
type of dementia became known as Alzheimer’s disease following the introduction
of the eponym by Emil Kraeplin in 1910 [6, 8].
AD was initially thought to be a rare form of presenile dementia [6]; it wasn’t
until 1968 that it was shown that the neuropathology of many common senile de-
mentia cases was indistinguishable from that of AD [9], leading to widespread
recognition that AD is in fact a very common brain disorder [10]. From 1975 there
has been a surge in AD research, with the number of publications increasing ex-
ponentially each year [11]. The National Institute of Aging, founded in 1974, and
the Alzheimer’s Association, founded in 1979, greatly increased the scientific and
public awareness of AD [10], as did Robert Katzman’s editorial in 1976 [12], which
brought attention to the disease as an impending public health challenge [10].
1.1.3 Pathology
Aβ plaques (amyloid plaques) and neurofibrillary tangles are the hallmark patholo-
gies that define AD. They are thought to cause damage to neurons (Figure 1.1a)
and neuroglial cells (Figure 1.1b) in the brain, although their precise mechanism of
action remains unclear [13]. Neurons transmit information in the brain; neuroglia
provide support for neurons.
1.1.3.1 Aβ plaques
Aβ plaques are extracellular deposits of Aβ , which can broadly be classified as
dense-core (neuritic, meaning that they consist of deteriorating neuronal material)
or diffuse [14]. Dense-core plaques tend to be surrounded by dystrophic neurites
(axons or dendrites - parts of neurons - shown in Figure 1.1a), reactive astrocytes
1.1. Alzheimer’s disease 25
(a) Neuron. (b) Types of neuroglia.
Figure 1.1: Diagram of a neuron1 and neuroglial cells2.
and activated microglial cells (types of neuroglia - see Figure 1.1b), and are as-
sociated with synaptic loss [15–18]. Diffuse plaques are usually non-neuritic and
are not associated with glial activation or synaptic loss [14]. The presence of dense-
core plaques is necessary for the pathological diagnosis of AD [19], whereas diffuse
plaques are relatively common in cognitively normal elderly people [20–22]. The
spatiotemporal pattern of amyloid deposition varies, but general patterns have been
proposed that can be used to stage patients, such as that of Thal et al. in 2002
(Figure 1.2) [23].
1.1.3.2 Neurofibrillary tangles
Neurofibrillary tangles are intraneuronal aggregates of hyperphosphorylated and
misfolded tau [14]. They become extraneuronal following the death of tangle con-
taining neurons [24,25]. Neuropil threads accompany neurofibrillary tangles, which
are segments of axons and dendrites that contain aggregated and hyperphsphory-
lated tau [24]. The spatiotemporal pattern of neurofibrillary tangle progression is
generally quite homogeneous, as described by Braak and Braak in 1991 (Figure
1.3) [26]. However, there are atypical cases. In 2011 Murray et al. [27] proposed
that there are three subtypes of AD based on neurofibrillary tangle distribution: typ-
ical AD, hippocampal sparing AD, and limbic-predominant AD, with typical AD
1Image from User:BruceBlaus at Wikimedia Commons. CC BY 3.0.
2Image from Blausen.com staff (2014). “Medical gallery of Blausen Medical 2014”. WikiJournal
of Medicine 1 (2). DOI:10.15347/wjm/2014.010. ISSN 2002-4436. CC BY 3.0.
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Figure 1.2: Phases of β -amyloidosis proposed by Thal et al. in 2002 [23]. In phase 1 there
are Aβ deposits in the frontal, parietal, temporal, or occipital neocortex (shown
in black). For each phase after phase 1 the red arrows indicate the presence of
new Aβ deposits. Reprinted from [23], Copyright 2002, with permisson from
Wolters Kluwer Health, Inc.
accounting for around 75% of cases.
1.1.3.3 Co-occurring pathologies
Several other pathologies commonly co-occur in AD: cerebral amyloid angiopathy,
where amyloid deposits accumulate on the walls of cortical blood vessels; granuo-
vacuolar degeneration, consisting of intraneuronal clusters of small vacuoles found
in the hippocampal pyramidial neurons; Hirano bodies, which are perineuronal le-
sions found in the hippocampal CA1 region; glial responses in the form of reactive
astrocytes and activated microglial cells; neuronal and synapse loss [14].
1.1.3.4 Associated conditions
Other conditions commonly coexist with AD, such as vascular dementia and Parkin-
son’s disease. Consequently, non AD neuropathological lesions, e.g. ischemic in-
farctions and Lewy bodies, are frequently found alongside AD lesions. In the pres-
ence of mixed pathology it is difficult to disentangle the relative contribution of each
condition to cognitive impairment [31].
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Figure 1.3: Neurofibrillary tangle staging system proposed by Braak and Braak in 1991
[26]. The density of the shading indicates the severity of the neurofibrillary
changes. Reprinted from [26], Copyright 1991, with permisson from Springer.
1.1.4 Genetics
AD consists of two forms: an early onset dominantly-inherited form, which typi-
cally begins before the age of 60, and a late onset sporadic form, for which disease
risk increases with age [32].
1.1.4.1 Dominantly-inherited Alzheimer’s disease
Mutations in three genes: the amyloid precursor protein (APP) gene [33], the pre-
senellin 1 (PSEN1) gene [34], and the presenellin 2 (PSEN2) gene [35, 36], are
known to cause early onset AD. All but one of the ∼200 pathogenic mutations in
these three genes are autosomal-dominant [32], meaning that if you inherit one copy
of the gene you will get the disease. The consequence of this is that a parent with
early onset AD has a 50% chance of passing the condition on to their children. Most
pathogenic AD mutations lead to a common molecular phenotype: an increase in
the ratio of Aβ42 to Aβ40 [37]. Aβ40 and Aβ42 are the two most common isoforms
of Aβ , of which Aβ42 is considered to be the most associated with disease states.
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1.1.4.2 Sporadic Alzheimer’s disease
Late onset AD is more complex, with disease risk likely resulting from the interac-
tion of a variety of genetic, environmental and lifestyle factors [32]. The most well
established risk gene for AD is the apolipoprotein E (APOE) gene [38]. It is thought
that APOE modifies disease risk by influencing Aβ metabolism. APOE has three
possible isoforms: ε2, ε3 and ε4, of which ε3 is the most common. The ε4-allele of
APOE increases the risk of AD, whereas the ε2-allele is protective [39]. Carrying
either one or two APOE ε4-alleles increases disease risk 3-fold, or 8- to 10-fold,
respectively [32]. Many other genes have been implicated in AD, but none of them
have strong effects [32].
1.1.5 Mechanism
The biological mechanisms that give rise to the pathological hallmarks of AD, amy-
loid plaques and neurofibrillary tangles, are not well understood. It remains to be
determined how the different pathologies propagate and interact, and how they give
rise to downstream neurodegeneration and cognitive deficits.
1.1.5.1 The amyloid hypothesis
The amyloid hypothesis (Figure 1.4), which postulates that Aβ is the causative
agent in AD, was first formalised in 1991 and 1992 [40–43] following the discovery
of fully penetrant pathogenic mutations in the APP gene [33]. These mutations alter
APP metabolism such that relatively more Aβ42 is produced [37,44], demonstrating
that AD can result from an increase in the production of Aβ42. However, 25 years
later, the amyloid hypothesis is still a contentious subject [13].
There is strong evidence that Aβ is the initiating event in dominantly-inherited
AD: mutations in the three major dominantly-inherited AD genes, APP, PSEN1,
and PSEN2, all cause a relative increase in Aβ42 production [37]. Moreover, these
three genes are all mechanistically involved in the production of Aβ : APP encodes
the amyloid precursor protein from which Aβ is generated; PSEN1 and PSEN2
encode presenellin 1 and 2, which are subunits of the β - and γ-secratase complex
that generates Aβ by cleaving APP. The potential role of these genes and other AD
1.1. Alzheimer’s disease 29
Figure 1.4: The amyloid cascade hypothesis. Reproduced from [13]. CC BY 4.0.
genes in Aβ -related pathogenesis is summarised in Figure 1.5. There is however
some debate as to whether Aβ42 itself contributes to dominantly-inherited AD, or
whether the pathogenic mechanism is another process related to APP and its pro-
cessing by presenellin [45]. The applicability of the amyloid cascade hypothesis
to sporadic AD is disputed because of the genetic heterogeneity of the disease, but
the major risk allele for sporadic AD, APOE ε4, has been shown to decrease Aβ
clearance, leading to a build up of Aβ [46].
Another major argument in favour of the amyloid hypothesis is that amyloid
plaques are more specific to AD than neurofibrillary tangles, which are involved in
a range of tauopathies. However, the temporal and anatomical discord of amyloid
plaques and tau pathology and neurodegeneration is difficult to explain [48]. Tem-
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Figure 1.5: The possible role of different Alzheimer’s disease genes in Aβ -related
pathogenic processes. Reprinted by permission from Macmillan Publishers
Ltd: Nature Reviews Neuroscience [47], Copyright 2008.
porally, biomarker studies show that amyloid plaque deposition begins long before
tau deposition and neurodegeneration [49]. Anatomically, tau pathology correlates
closely with neuronal loss, but amyloid plaque deposition does not correlate well
with either [14, 29, 50].
A further concern is that the pathogenic mechanism of Aβ has yet to be de-
termined, as has the function of Aβ and APP in the brain [13]. Recent versions of
the amyloid hypothesis propose that the pathogenic process might be the formation
of soluble Aβ42 oligomers [13]. Oligomeric Aβ may have subtle effects on the
efficacy of synapses by decreasing synapse function and number, and may initiate
tauopathy.
Critics of the amyloid hypothesis postulate that AD is a complex multifactorial
disease that is not initiated by Aβ in isolation, with the presence of amyloid being
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a necessary but not a sufficient cause [45].
1.1.5.2 Tau and neurodegeneration
Evidence strongly suggests that dysfunction of tau causes neurodegeneration, how-
ever the exact mechanism by which this happens remains unclear. Dominantly in-
herited mutations in the MAPT gene [51–53], which encodes tau, cause frontotem-
poral dementia (FTD), demonstrating that dysfunction of tau is sufficient to cause
neurodegeneration. Additionally neurofibrillary tangles, which are intraneuronal
aggregates of hyperphosphorylated and misfolded tau, show better correlation with
neurodegeneration than amyloid plaques [14, 29, 50].
1.1.5.3 Propagation of pathology
Increasing evidence suggests that AD pathology, particularly abnormal forms of tau,
propagates in a prion-like manner [13], i.e. that Alzheimer’s pathologies are trans-
mitted from one neuron to another. However, the physical mechanism by which
pathology is transported between neurons has not been identified [54]. The major
alternative hypothesis is that of selective vulnerability, meaning that certain neu-
rons are intrinsically more vulnerable to the pathogenic disease process than oth-
ers [13, 54].
1.1.5.4 Alternative mechanisms
A multitude of other mechanisms have been suggested to be involved in the patho-
genesis of AD, such as immune responses and inflammatory, metabolic, and vas-
cular factors. One suggestion is that there is a complex feedback loop between
different mechanisms that causes AD [45] (Figure 1.6).
1.1.6 Biomarkers
The only direct measurement of AD pathology is through autopsy examination of
the brain. Biomarkers are variables that can be measured in vivo to provide informa-
tion about these pathological changes; these measurements are indirect indicators
that the pathology exists. Disease biomarkers can be divided into a number of dif-
ferent groups. In the case of AD there is particular interest in those biomarkers
that can assess the core pathologies of Aβ -plaque deposition and tau aggregation.
32 Chapter 1. Introduction
Figure 1.6: Hypothetical model of Alzheimer’s disease as a complex interaction between
cellular, molecular and genetic imbalances. Reprinted by permission from
Macmillan Publishers Ltd: Nature Neuroscience [45], Copyright 2015.
Tau aggregation is not specific to AD, but is thought to mediate neurodegeneration.
Whilst a stricter definition of the term biomarker is used here, which refers only to
biological indicators of pathology, in the rest of this thesis a broader definition of the
term is used, which encompasses any marker of the disease process. This includes
measurements of higher level cognitive processes obtained from neuropsychologi-
cal tests.
1.1.6.1 Aβ plaque deposition
The two most well validated biomarkers of brain Aβ plaque deposition are cere-
brospinal fluid (CSF) Aβ1−42 and positron-emission tomography (PET) Aβ imag-
ing. CSF Aβ1−42 (Aβ42, Abeta, Aβ ) is a measure of the toxic amyloid-β peptide
implicated in AD. Low concentrations of CSF Aβ1−42 correlate with the clinical
diagnosis of AD and Aβ pathology at autopsy [55–57]. A number of PET Aβ
tracers are available, which allow the spatial pattern of amyloid deposition to be ob-
served non invasively. The earliest tracer was Pittsburgh compound B (PiB), which
binds to fibrillar Aβ , and shows a strong correspondence with Aβ deposition at
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autopsy [58, 59].
1.1.6.2 Neurodegeneration
CSF total tau (t-tau, τ-tau) and phosphorylated tau (p-tau, ρ-tau), fluorodeoxyglu-
cose PET (FDG-PET) and structural magnetic resonance imaging (MRI) all pro-
vide different measures broadly implicated in neurodegeneration. Both CSF t-tau
and p-tau increase in AD [60] and correlate well with neurofibrillary tau tangles at
autopsy [61]. CSF t-tau concentration correlates with the severity of neurodegenera-
tion, which is not specific to AD, whereas CSF p-tau reflects the formulation of AD-
related neurofibrillary tangles [62]. FDG-PET is a measure of brain metabolism,
in particular glucose uptake, and so can be used as an indication of the impaired
synaptic activity associated with AD, with combined imaging and autopsy studies
supporting this hypothesis [63]. The impairment of synapses is thought to begin
before the observation of clinical symptoms but is also common to other neurolog-
ical diseases. Measures of brain atrophy, a downstream consequence of neuronal
cell loss, calculated from structural MRI scans also display a good correlation with
neurodegeneration [64]. MRI based measures of atrophy (rate of volume loss) are
not specific to AD but correlate well with Braak and Braak staging of tau pathology
at autopsy [65, 66], and can be used to determine the regional patterns of neurode-
generation characteristic to AD [67].
The recent development of tau tracers allows non invasive imaging of the pat-
tern of neurofibrillary tangles [68–70]. These imaging techniques are undoubtedly
exciting but require further validation of their reliability, quantitative performance
and binding selectivity before they are widely used in research studies [71].
1.1.6.3 Evolution of Alzheimer’s disease biomarkers
Understanding the quantitative evolution of biomarkers in AD is of great interest for
clinical trials in order to provide outcome measures and strategies for cohort selec-
tion. It is thought that clinical trials to date have taken place too late in the disease
time course [72, 73]. Biomarkers can potentially be used to identify and monitor
the presymptomatic disease stages, during which treatments may be more effective.
Additionally, a quantitative picture of biomarker progression can provide insights
34 Chapter 1. Introduction
into the underlying disease biology by, for example, indicating which is the ini-
tiating disease pathology, or elucidating interactions between different pathogenic
processes.
Numerous hypothetical models of the progression of AD biomarkers have been
proposed [74–79]. The most influential of these hypothetical models was published
in 2010 by Jack et al. (Figure 1.7) [74], and has had a large impact within the
neurology community. This model postulates that AD changes occur in the order:
Aβ , tau-mediated neuronal injury and dysfunction, brain structure, memory, clinical
function. Aβ is measured using CSF Aβ or amyloid PET; tau-mediated neuronal
injury and dysfunction is measured using CSF p-tau, t-tau and FDG-PET; brain
structure is measured using structural MRI; memory and cognition are measured
using various cognitive tests.
Figure 1.7: Hypothetical model of Alzheimer’s disease biomarker progression proposed by
Jack et al. in 2010 [74]. Reprinted from [74], Copyright 2010, with permission
from Elsevier.
Validation of hypothetical models is difficult because of the long disease
time course, which is thought to span several decades [49, 80–82]. This means
that it is challenging to follow subjects longitudinally, particularly during the pre-
symptomatic phase, which can only be observed in large population-based obser-
vational studies. Whilst studies have provided support for some of the features
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of hypothetical models [49, 80, 83, 84], they typically use crude staging measures
based on clinical diagnoses or cognitive test scores. The result is a coarse picture
of biomarker progression, which is unable to provide fine-grained disease staging
information. Studies in dominantly-inherited AD [49] can provide a more fine-
grained picture by identifying subjects who carry a pathogenic APP, PSEN1 or
PSEN2 mutation presymptomatically, and indexing them by their estimated years to
onset, which is based on parental age of onset. However, the applicability of these
results to sporadic AD has yet to be determined.
1.1.7 Diagnostic criteria
1.1.7.1 NINCDS-ADRDA criteria for probable Alzheimer’s disease
A definitive diagnosis of AD requires microscopic examination of brain tissue at
autopsy. The most widely used clinical diagnostic criteria for AD were established
in 1984 by the National Institute of Neurological and Communicative Disorders and
Stroke (NINCDS) and the Alzheimer’s Disease and Related Disorders Association
(ADRDA) [85], commonly referred to as the NINCDS-ADRDA criteria. The crite-
ria distinguish between probable, possible, and definite AD, where only a probable
or possible diagnosis of AD can be made in vivo. The criteria for probable AD
include: dementia established by clinical examination and confirmed by neuropsy-
chological tests; deficits in two or more areas of cognition; progressive worsening
of memory and other cognitive functions; onset between ages 40 and 90, most often
after age 65; additional criteria that rule out other conditions.
1.1.7.2 Updated probable Alzheimer’s disease criteria
More recent diagnostic criteria for probable AD include the use of biomarker evi-
dence of AD as a supportive feature [86–89]. The criteria proposed by McKhann
et al. in 2011 [88], for example, subdivide the diagnosis of probable AD into prob-
able AD with and without evidence of the AD pathophysiological process, where
the core criteria for probable AD are similar to the NINCDS-ADRDA criteria. Ev-
idence of the AD pathophysiological process is divided into biomarker evidence of
Aβ from PET or CSF, and biomarker evidence of neuronal injury from CSF tau,
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FDG-PET or structural MRI, with evidence of both Aβ and neuronal injury provid-
ing stronger support for the diagnosis.
1.1.7.3 Mild cognitive impairment
A more subtle diagnostic entity, mild cognitive impairment (MCI), has also been
proposed [90]. Although this label is widely used in research studies, the definition
and subcategorisation of the term varies. Criteria for MCI typically consist of sub-
jective memory or cognitive symptoms, objective memory or cognitive impairment,
and unaffected activities of daily living [86]. Often a distinction is made between
amnestic and non-amnestic MCI, depending on the presence of significant memory
complaints. Amnestic MCI is intended to be more specific to AD, however, clinical
follow-up and neuropathological studies show that all of the aforementioned diag-
noses lack specificity for AD [91,92]. In 2011 Albert et al. [93] proposed the use of
two sets of criteria for diagnosing MCI: core clinical criteria that can be used with-
out access to biomarker information, and research criteria for use in research set-
tings and clinical trials. The criteria have four levels of confidence depending on the
presence and strength of biomarker findings. The core clinical and cognitive criteria
include cognitive concerns and objective evidence of cognitive impairment, together
with preserved activities of daily living and severity not reaching the threshold for
a dementia diagnosis. If biomarker measurements are available, three more specific
diagnoses can be made: (A) MCI due to AD with intermediate likelihood, (B) MCI
due to AD with high likelihood, (C) MCI unlikely due to AD. Positive biomarker
evidence of either Aβ or neuronal injury supports (A), positive biomarker evidence
of both Aβ and neuronal injury supports (B), and negative biomarker evidence of
both Aβ and neuronal injury supports (C). Biomarker evidence of Aβ is measured
using CSF or PET; biomarker evidence of neuronal injury is measured using CSF
tau, FDG-PET or structural MRI.
1.1.7.4 Preclinical Alzheimer’s disease
In recent years the development of presymptomatic diagnostic criteria has been ad-
vocated following the accumulation of evidence suggesting that biomarker changes
in AD begin decades before symptom onset [49, 80–82]. Presymptomatic diagnos-
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tic criteria therefore focus on identifying the AD pathophysiological process rather
than the AD dementia syndrome. In 2011 Sperling et al. [94] proposed preclini-
cal criteria consisting of three stages: (1) asymptomatic cerebral amyloidosis, with
evidence of Aβ from PET or CSF, (2) asymptomatic amyloidosis and downstream
neurodegeneration, with additional evidence of markers of neuronal injury from
CSF tau, FDG-PET or structural MRI, (3) amyloidosis, neuronal injury and subtle
cognitive/behavioural decline, with additional evidence of subtle cognitive change.
These preclinical criteria are not well established due to their dependence on hypo-
thetical models of the evolution of biomarker measurements in AD.
1.1.7.5 Neuropathologic Alzheimer’s disease
The growing consensus on the need to distinguish the AD pathophysiological pro-
cess from the AD dementia syndrome has lead to the revision of the neuropathologic
criteria for assessing AD at autopsy. The guidelines proposed by Hyman et al. in
2012 [19] remove the requirement of a history of dementia from the criteria, instead
focussing on the evaluation of three different neuropathologic parameters: (A) Aβ
plaque score (evaluated using Thal et al. 2002 [23]), (B) neurofibrillary tangle stage
(evaluated using Braak and Braak 1991 [26] or Braak et al. 2006 [95]), (C) neuritic
plaque score (evaluated using CERAD proposed by Mirra et al. 1991 [96]). The
presence of both Aβ plaques and neurofibrillary tangles is necessary for the identifi-
cation of AD neuropathologic change. Neuritic plaques are a particular type of Aβ
plaque that consist of a dense Aβ protein core surrounded by dystrophic neurites.
This form of Aβ plaque is the most closely associated with neuronal injury. The
neuropathologic criteria proposed by Hyman et al. also emphasise the importance
of assessing non-AD brain lesions to identify the presence of comorbid conditions.
1.1.8 Treatments
The are currently five FDA-approved drugs for AD, which mask the symptoms of
the disease, but do not modify the underlying disease process. They fall into two
categories: cholinesterase inhibitors and memantine [97]. Cholinesterase inhibitors
slow down the process that breaks down the neurotransmitter acetylcholine; me-
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mantine regulates the activity of glutamate, a neurotransmitter involved in learning
and memory. The major focus of drug companies is developing disease modifying
treatments, with promising targets including Aβ , β -secretase, γ-secretase, tau pro-
tein, inflammation, and insulin resistance [97]. The results of clinical trials to date
have been disappointing, which is thought to be due to treatments being adminis-
tered too late in the disease, at which point irreversible pathogenic processes have
already taken place [72, 73].
1.2 Research problem
1.2.1 Problem statement
The temporal progression of AD is not well understood. There are two key aspects
to this problem.
1. The underlying biological mechanisms that cause AD have not been deter-
mined.
2. The quantitative evolution of biomarkers in AD has yet to be characterised.
The work presented in this thesis focusses on problem 2.
1.2.2 Justification
Despite 110 years of Alzheimer’s research and an exponential growth in the amount
of research since 1975 [11], still relatively little is understood about the causes and
progression of AD.
Although a vast number of molecular, cellular and genetic imbalances have
been implicated in AD, how these imbalances give rise to AD is still unknown
(Problem 1, Section 1.2.1) [45]. In particular, the precise mechanism by which the
two major proteins involved in AD, Aβ and tau, produce downstream neurodegen-
eration and cognitive deficits remains unclear [13], as does the mechanism by which
they spread to different brain regions [13, 54].
At the biomarker level, the quantitative evolution of AD has yet to be deter-
mined (Problem 2, Section 1.2.1). Hypothetical models have been proposed that
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describe how biomarkers evolve with disease progression [74–79], but these mod-
els are not quantitative and their validation to date has typically been at a coarse
scale [83, 84].
1.2.3 Motivation
Better understanding of the causes and progression of AD will facilitate drug de-
velopment. A mechanistic understanding of AD (Problem 1, Section 1.2.1) would
identify the key targets for drug development, and the appropriate window in the
disease for intervention. A quantitative model of biomarker evolution (Problem
2, Section 1.2.1) is essential for precision medicine. Such a model could enable
patient stratification into targeted groups for particular therapies, and provide out-
come measures for clinical trials, which can monitor the effectiveness of different
treatments. If a disease-modifying treatment is discovered, quantitative biomarker
models could be used in the clinic to provide disease staging and prognostic infor-
mation, and to assign patients to different treatments. Besides enabling personalised
medicine, quantitative models of biomarker evolution can provide insights into the
underlying disease mechanisms by indicating which are the earliest pathologies,
and by elucidating interactions between different pathogenic processes.
1.3 Thesis contributions
This thesis investigates the progression and heterogeneity of AD by develop-
ing mathematical models that can characterise the temporal evolution of disease
biomarkers. The models only require cross-sectional or short-term longitudinal ob-
servations to reconstruct the full temporal progression of the disease, meaning that
they can be fit to widely available datasets such as the Alzheimer’s Disease Neu-
roimaging Initiative (ADNI) dataset. Three key contributions are made, as follows.
1.3.1 Data-driven models of biomarker changes in sporadic and
dominantly-inherited Alzheimer’s disease
The first contribution of this thesis is the development of data-driven models of
disease biomarker changes for application to sporadic and dominantly-inherited
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AD. These models extend the event-based model (EBM) developed by Fonteijn et
al. [98] to allow for heterogeneity in the control and disease population, and miss-
ing biomarker values. The EBM describes disease progression as a series of events,
where each event corresponds to a new biomarker becoming abnormal. Applica-
tion of these models to sporadic and dominantly-inherited AD reveals the sequence
in which biomarkers become abnormal in each form of AD. This thesis further
explores the utility of the models for patient staging. Specifically, the following
sub-contributions are made.
(a) Adaptation of the EBM in [98] to allow for heteroegenity in the control and
disease populations. Without this adaptation the EBM is not applicable to
sporadic AD due to its reliance on a well-defined control population.
(b) Application of (a) to sporadic AD to determine the sequence in which
biomarkers become abnormal, and to demonstrate the utility of the model
for patient staging. Previous attempts to determine biomarker ordering were
dependent on the use of clinical diagnoses to stage patients, or on the use of
thresholds to define biomarker abnormality.
(c) Adaptation of the EBM in [98] to allow for missing data. Prior to this adap-
tation the EBM was not applicable for modelling the evolution of multimodal
biomarker data collected in dominantly-inherited AD datasets due to small
numbers of subjects with data spanning multiple biomarkers.
(d) Application of (c) to dominantly-inherited AD to determine the sequence of
biomarker abnormality in dominantly-inherited AD. Previous studies estimat-
ing biomarker ordering in dominantly-inherited AD relied on the use of esti-
mated years to onset (based on parental age of onset) to stage participants.
1.3.2 A simulation system for biomarker evolution in neurode-
generative disease
The second contribution of this thesis is the development of a simulation framework
for biomarker evolution in neurodegenerative disease, facilitating the evaluation of
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the performance of data-driven disease progression models. The following sub-
contributions are made.
(a) Development of a simulation framework that can generate synthetic neurode-
generative disease datasets for evaluating the performance of data-driven dis-
ease progression models. In particular, the simulation system can synthesise
heterogeneous neurodegenerative disease populations, including disease sub-
types that have distinct patterns of biomarker evolution.
(b) Application of the simulation framework to perform a stability analysis of
the EBMs developed in Contribution 1.3.1 to ascertain the sensitivity of the
EBM to different types of heterogeneity. A stability analysis of another data-
driven disease progression model - a differential equation model (DEM) - is
performed to compare the robustness of the two data-driven models.
1.3.3 A data-driven model of disease subtypes with distinct pat-
terns of biomarker evolution in frontotemporal dementia
and Alzheimer’s disease
The final contribution of this thesis is the development of a data-driven model of
disease subtypes with distinct patterns of biomarker evolution. This model de-
scribes disease progression as groups of individuals who have a common sequence
of events, where each event corresponds to a biomarker reaching a particular z-score
compared to controls. This model is validated using data from genetic frontotempo-
ral dementia (FTD), which has distinct genetic subtypes. Application of this model
to sporadic AD reveals data-driven subtypes of AD that have distinct sequences in
which biomarker measurements reach different severity levels (modelled as z-scores
relative to a control population). The utility of this subtyping model for patient stag-
ing is further demonstrated. More specifically, the following sub-contributions are
made.
(a) Development of a dynamic clustering technique that allows population sub-
groups with distinct sequences of biomarker changes to be recovered. In this
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model biomarker changes are indexed as z-score events, such that each z-
score event corresponds to a biomarker reaching a particular z-score relative
to a control population. Previous modelling techniques depended on the as-
sumption that all subjects follow a single common pattern of biomarker evo-
lution, or that all subjects are at a single disease stage.
(b) Validation of the dynamic clustering technique using data from genetic FTD.
The sequence of biomarker changes for each genetic subgroup is determined
by fitting a single dynamic cluster to each of the genetic subgroups: GRN,
MAPT and C9orf72 mutation carriers. The ability of the dynamic clustering
model to recover the sequence of each subgroup without prior knowledge of
the group labels is demonstrated.
(c) Application of dynamic clustering to sporadic AD to determine subtypes of
AD with distinct sequences of biomarker changes, and to establish the utility
of these subtypes for patient stratification. Prior studies that clustered AD
biomarker measurements depended on the assumption that subjects were at
a single disease stage, meaning that the temporal evolution of each subtype
could not be determined.
1.4 Structure of this thesis
This chapter (Chapter 1) has provided background information, motivation and
context for the research problem and contributions of this thesis. The rest of this
thesis is structured as follows.
Chapter 2 reviews the state of the art in AD progression modelling. This
chapter critically assesses the range of different progression models that have been
applied to AD to establish which models are the most promising for evaluating the
quantitative evolution of AD biomarkers, and to identify the limitations of current
modelling techniques.
Chapter 3 presents sub-contributions (a) and (b) of contribution 1.3.1. I pro-
pose an adaptation of the EBM [98] for use with multi-modal sporadic disease
datasets. I apply this model to determine the sequence of biomarker abnormality
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in sporadic AD, and further demonstrate the models utility as a patient staging sys-
tem.
Chapter 4 details sub-contributions (c) and (d) of contribution 1.3.1. I develop
an adaptation of the EBM [98] for use with missing data. I apply this model to
determine the order in which biomarkers become abnormal in dominantly-inherited
AD without reliance on the use of estimated years to onset to stage participants.
Chapter 5 formulates a simulation framework for biomarker evolution in neu-
rodegenerative disease (contribution 1.3.2). I use this framework to perform a sta-
bility analysis of the EBM and a DEM of disease progression by fitting the models
to synthetic datasets with different types of heterogeneity.
Chapter 6 presents an initial formulation of the dynamic clustering technique
developed in Chapter 7.
Chapter 7 builds on the work in Chapter 6 to develop a more parsimonious dy-
namic clustering model (contribution 1.3.3) that can elucidate population subgroups
with distinct patterns of biomarker evolution, enabling the identification of data-
driven disease subtypes. This technique is validated by demonstrating the ability
to recover the progression patterns of known genetic subgroups in FTD. Dynamic
clustering is then applied to sporadic AD data to reveal different subtypes of AD
and the sequence in which biomarkers reach various z-scores for each subtype. The
utility of the model for patient staging and stratification is further demonstrated.
Chapter 8 discusses opportunities for further work arising from this thesis, as
well as interesting future directions for data-driven disease progression modelling
in general.
Chapter 9 summarises the work presented in this thesis.

Chapter 2
State of the art in Alzheimer’s disease
progression modelling
This chapter reviews the state of the art in AD progression modelling to provide
context for the contributions of this thesis (Section 1.3, Chapter 1). Section 2.7 is
based on a review article I wrote for Advances in Clinical Neuroscience and Reha-
bilitation, in collaboration with Neil Oxtoby, Jonathan Schott and Daniel Alexander.
2.1 Associated publications
A. L. Young, N. P. Oxtoby, J. M. Schott, and D. C. Alexander. Data-driven models of
neurodegenerative disease. Advances in Clinical Neuroscience and Rehabilitation,
14(5):6–9, 2014
2.2 Introduction
This thesis addresses the problem of characterising the temporal progression of AD
by developing mathematical models that quantify the evolution of disease biomark-
ers. This review examines the range of different progression models that have been
applied to AD. In this review I first summarise the literature on two types of non-
biomarker model: neuropathological models and animal models, which provide
interesting qualitative biological insights but do not directly provide quantitative
measures of disease stage. I then review various biomarker models to establish
what is known about the quantitative evolution of AD biomarkers. I first review
46 Chapter 2. State of the art in Alzheimer’s disease progression modelling
scalar biomarker models that use single dimension biomarkers and traditional sta-
tistical analysis techniques, which require subjects to be indexed by disease stage. I
then review high dimensional biomarker models, which learn new biomarkers from
high dimensional data but still require subjects to be indexed by disease stage. Fi-
nally, I review the literature on data-driven biomarker models, which develop novel
statistical methodology to allow the temporal progression of biomarkers to be re-
constructed without prior knowledge of each individual’s stage along the disease
time course. These data-driven models provide the basis for the novel techniques
developed in this thesis.
2.3 Neuropathological models
The earliest models of AD progression are those derived from neuropathologi-
cal studies (e.g. [23, 26, 96]). Models of neurofibrillary tangle accumulation and
amyloid deposition have been proposed based on the cross-sectional distribution of
pathology at autopsy. These models typically depend on the assumption that there
is a common pattern of pathology for all subjects, with each subject representing a
particular stage along this single progression pattern.
2.3.1 Neurofibrillary tangle accumulation
The most influential model of neurofibrillary tangle accumulation is that of Braak
and Braak in 1991 (Figure 1.3) [26], which is still used to diagnose pathological
AD at autopsy [19]. Braak and Braak proposed a model that consists of six stages
based on the distribution of neurofibrillary tangles and neuropil threads: stages I-II
are confined to the transentorhinal region, stages III-IV involve both the entorhinal
and transentorhinal layer, stages V-VI consist of isocortical destruction. Braak and
Braak also proposed three stages of amyloid plaque deposition, but they chose to in-
dex their model by neurofibrillary tangle stage as they observed that the distribution
of amyloid plaques varied widely between architectonic units and individuals. In
2006 Braak et al. updated the model to incorporate methodological developments in
neuropathology [95]. This model was subsequently incorporated into neuropatho-
logical AD diagnostic criteria [19].
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The Braak model [26, 95] assumes that there is a common pattern of neurofib-
rillary tangle deposition across subjects. More recently, Murray et al. [27] found
that approximately 25% of AD cases do not follow the stereotypical pattern of neu-
rofibrillary tangle deposition described by the Braak model. By considering cases
with a Braak stage of greater than IV, and constructing an algorithm that classi-
fies AD cases into ‘typical’, ‘hippocampal sparing’ or ‘limbic predominant’, they
found that 11% of the 889 AD cases they analysed were hippocampal sparing, and
14% of cases were limbic predominant. This percentage is somewhat artificial as
their algorithm is based on percentile cut-offs for the ratio of hippocampal to cor-
tical neurofibrillary tangle count, but this study does clearly indicate the presence
of atypical AD pathology. This heterogeneity may represent a pathological spec-
trum ranging from hippocampal sparing to limbic predominant, or three distinct
subgroups. Another interesting finding of this study was that clinical presentation,
age at onset, disease duration and rate of cognitive decline differed between the dif-
ferent AD subtypes. Hippocampal sparing cases more commonly had an atypical
clinical diagnosis, a younger age of onset, a shorter disease duration and a faster
rate of cognitive decline than typical and limbic predominant AD cases.
2.3.2 Amyloid plaque deposition
There are two widely used models of amyloid plaque deposition for neuropatho-
logical AD diagnosis [19]: the Consortium to Establish a Registry for Alzheimer’s
Disease (CERAD) criteria proposed by Mirra et al. in 1991 [96] and the model
proposed by Thal et al. in 2002 [23].
The CERAD criteria are coarse semi-quantitative criteria based on the assess-
ment of neuritic amyloid plaques in the neocortex. The procedure involves taking
samples of brain tissue from three areas of the neocortex: the superior and middle
temporal gyri, the middle frontal gyrus, and the inferior parietal lobule, and rating
them as having either ‘sparse’, ‘moderate’ or ‘frequent’ neuritic amyloid plaques.
The overall plaque density is the maximum plaque density across the three regions
of the neocortex. The age-related CERAD plaque score: 0, A, B or C, where C indi-
cates the most confident evidence of neuropathological AD, is derived by comparing
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the overall plaque density with the expected plaque density for that age group. The
CERAD criteria are used as a measure of dense-core neuritic plaques in modern
pathological AD diagnostic criteria [19].
The model proposed by Thal et al. in 2002 (Figure 1.2) [23] has five stages and
is based on the spatial distribution of Aβ deposits, which include diffuse as well as
neuritic plaques. Phase 1 of their model consists of Aβ deposits in any region of the
neocortex. In the subsequent phases there are additional Aβ deposits in allocortical
regions (phase 2), diencephalic nuclei and the striatum (phase 3), some brainstem
nuclei (phase 4), and finally the cerebellum and other brainstem nuclei (phase 5).
2.3.3 Critical assessment
Neuropathological models provide interesting qualitative insights into the spatial
progression of AD pathology and are essential for the neuropathological confirma-
tion and staging of AD. In particular, they show that the distribution of neurofib-
rillary tangles is more stereotypical across subjects than the distribution of amyloid
plaques. Moreover, they demonstrate that whilst the overall amyloid plaque and
neurofibrillary tangle burden are correlated, their spatial progression patterns are
markedly different, and the relative amount of amyloid plaque and neurofibrillary
tangle pathology varies across individuals.
The utility of neuropathological models for in vivo patient staging is limited
by several factors. First, the models are ex vivo. For application in vivo biomark-
ers would have to be used, which are correlated with, but do not measure exactly
the same pathology. Second, the models are not quantitative, which limits their ac-
curacy. Third, the time scale and spatial resolution of the models is coarse, with
typically six or fewer stages and large brain regions. Finally, each model only mea-
sures a single pathology, so it is not straight forward to integrate the stages from the
two different pathologies.
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2.4 Animal models
Genetically modified mouse models1 have provided insights into the underlying
mechanisms of AD [100].
2.4.1 Transgenic mouse models
In transgenic mouse models a foreign gene is introduced, which can be from an-
other species. In transgenic mice that overproduce mutant APP, Aβ accumulates
into extracellular plaques. This accumulation is accelerated when Aβ42 is prefer-
entially cleaved from APP compared to Aβ40, and leads to earlier and more severe
cognitive decline [100]. Most transgenic Alzheimer’s mouse models show cog-
nitive decficits before extracellular Aβ plaques accumulate. This observation led
to the hypothesis that soluble Aβ oligomers may be the pathogenic mechanism in
AD [100]. Interestingly, APP-overexpressing mice do not develop neurofibrillary
tangles, but do show hyperphosphorylation of tau. Additional gene alterations, such
as mutated human tau, are necessary to induce neurofibrillary tangles in mice [100].
2.4.2 Knockout mouse models
In knockout mouse models a particular gene is removed. These mice do not model
the disease process itself, but are instead used to elucidate the function of specific
genes. Presenellin 1 knockout mice suggest that presenilin and the γ-secretase com-
plex might have additional functions that are not related to the production of Aβ ,
with PS1 knockout mice having developmental defects in the central nervous and
skeletal systems [100]. Another interesting finding is that when APP transgenic
mice are crossed with tau knockout mice, the cognitive deficits associated with
APP and Aβ are prevented [101], even though the absence of tau does not affect
the development of Aβ plaques. This suggests that tau is necessary to mediate the
pathogenic effects of Aβ on cognition.
1An interactive summary of the findings from different mouse models of AD can be found at
www.alzforum.org/research-models.
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2.4.3 Critical assessment
There are several concerns regarding the translatability of animal models [100].
First, the models are based on dominantly-inherited AD, rather than sporadic AD.
Second, the synapse and cell loss in the models is not substantial, so they may only
be representative of the prodromal phase of AD. Third, there is discordance between
the results of preclinical animal models and human clinical trials.
2.5 Scalar biomarker models
The simplest AD biomarker models are those that use scalar biomarkers and tradi-
tional statistical analysis techniques, which require knowledge of a subjects disease
stage in order to position them along the time axis.
2.5.1 Comparing diagnostic groups
There have been a large number of studies comparing biomarkers between diag-
nostic groups (e.g. [102–106]). These studies provide a coarse picture of which
biomarkers are dynamic at each disease stage, with evidence suggesting that CSF
Aβ and PiB-PET become abnormal while subjects are still cognitively normal (CN),
and MRI, FDG-PET and CSF tau are already abnormal in those with mild cognitive
impairment (MCI) [74]. However, the use of clinical diagnoses to stage patients
limits the temporal resolution of these studies, typically to just three stages: CN,
MCI and AD. Iturria-Medina et al. [107] perform a more complex statistical anal-
ysis of the expected biomarker trajectories for subjects at different disease stages,
which takes into account age, gender, education and number of APOE ε4 alleles.
Their results broadly agree with other studies, but suggest that vascular dysregula-
tion may also play an early role in AD. However, the temporal resolution of their
model is still fundamentally limited by the accuracy of the clinical diagnoses.
2.5.2 Using cut points to define biomarker abnormality
Jack et al. [83] have proposed that the sequence in which biomarkers become abnor-
mal can be inferred by observing the proportion of subjects within each diagnostic
group that have abnormal biomarker levels. They used this technique to validate
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the ordering of a subset of the biomarkers (CSF Aβ1−42, CSF tau and hippocampal
volume) proposed by their hypothetical model a year previously (Figure 1.7) [74].
They concluded that CSF Aβ1−42 becomes abnormal first, then CSF tau, and then
hippocampal volume. However, their results are dependent on choosing cut points
defining abnormal biomarker levels, which are not easy to establish [108], and are
likely to affect the sequence of biomarker abnormality predicted by their model.
Moreover, their method does not easily extend to larger numbers of biomarkers.
2.5.3 Indexing by cognitive test scores
An obvious approach to reconstructing fine-grained biomarker trajectories is to in-
dex subjects by their cognitive test scores rather than their clinical diagnoses. Caroli
et al. [109] used such an approach to investigate the dynamics of four AD biomark-
ers: CSF Aβ1−42, CSF tau, hippocampal volume and FDG-PET, as a function of
the Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-cog). They
found that CSF Aβ1−42 was the first to become abnormal and stabilises early on
in the disease time course, whereas CSF tau, hippocampal volume and FDG-PET
become abnormal later in the disease time course and continue to change as the dis-
ease progresses. Sabuncu et al. [110] performed a similar analysis of hippocampal
volume loss and cortical thinning as a function of Mini Mental State Exam (MMSE)
score. They found that hippocampal volume loss and cortical thinning both accel-
erate early on in the disease and have a sigmoidal shape. However, there are two
major limitations to using cognitive test scores as a measure of disease progression.
First, cognitive test scores are known to have floor and ceiling effects, in particular
they can’t be used to measure the presymptomatic disease stages. Second, the accu-
racy of the recovered progression patterns is limited by the accuracy of the cognitive
test scores, which are imprecise and often have practice effects.
2.5.4 Indexing by estimated years to onset
In dominantly-inherited AD it is possible to identify subjects presymptomatically
by genetically screening families known to carry a pathogenic mutation. In those
that carry the genetic mutation, it is also possible to estimate their time to disease
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onset based on their parent’s age of onset. In 2012 Bateman et al. (Figure 2.1) [49]
constructed a model of biomarker changes in dominantly-inherited AD from 128
participants in the Dominantly Inherited Alzheimer Network (DIAN) study. By re-
gressing participants biomarker values against their estimated years to onset, they
found that: CSF Aβ42 levels became abnormal 25 years before expected onset;
Aβ deposition (measured on PiB-PET), CSF tau and hippocampal volume became
abnormal 15 years before expected onset; cerebral hypometabolism (measured on
FDG-PET) and episodic memory (measured using story A from the Logical Mem-
ory subtest of the Wechsler Memory Scale-Revised) became abnormal 10 years
before expected onset; global cognitive impairment (measured using the MMSE
and the Clinical Dementia Rating scale) became abnormal 5 years before expected
onset; participants met the criteria for an AD diagnosis 3 years after expected onset.
However, the applicability of these results to the more common sporadic form of
AD remains to be determined. An additional concern is the validity of estimating
the participants time to onset from their parent’s age of onset.
2.5.5 Indexing by conversion between diagnoses
Several studies have constructed population-level biomarker trajectories by retro-
spectively indexing subjects according to their time to conversion between diagnos-
tic categories. This approach requires that subjects are observed until conversion.
Buchhave et al. [80] performed such an analysis of CSF measures in 137 subjects
with MCI who converted to AD. Their study had a median follow-up time of 9.2
years (range 4.1 to 11.8 years). By indexing subjects according to whether they
were between 0 and 2.5, 2.5 and 5, or 5 and 10 years from conversion they found
that CSF measures of Aβ1−42 were already abnormal between 5 and 10 years before
disease onset. They found that CSF p-tau and t-tau changes also became abnormal
early, but that the changes were more gradual. More advanced statistical models
have also been proposed by Schmidt-Richberg et al. and Guerrero et al. based on
the idea of indexing subjects by time to conversion [111, 112]. These models allow
probabilistic estimation of a new patient’s disease progress and prediction of their
time to conversion between diagnoses. However, all of the aforementioned models
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Figure 2.1: Biomarker changes in dominantly-inherited Alzheimer’s disease estimated by
Bateman et al. in 2012 [49] by regressing against expected years to onset.
Reproduced with permission from [49], Copyright Massachusetts Medical So-
ciety.
are limited by the accuracy of the clinical diagnoses used to stage patients. More-
over, the requirement that a large population are observed until conversion limits
the datasets that these models can be fitted to, as well as their ability to model popu-
lation heterogeneity. The long follow-up requirement further prevents these models
from being applied to new biomarkers.
2.5.6 Critical assessment
Scalar biomarker models are highly relevant clinically as they can be used to amal-
gamate information from well-established disease biomarkers in order to provide
patient staging and prognostic systems. Models to date suggest that CSF Aβ and
PiB-PET become abnormal early in AD, followed by CSF tau, FDG-PET and hip-
pocampal volume, and then cognitive test scores.
The temporal resolution of current models is limited by their dependence on
clinical staging information to determine an individual’s position along the disease
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time course. Positioning subjects based on their clinical diagnosis limits the accu-
racy of the recovered progression pattern to just three stages: CN, MCI and AD.
Alternative techniques for modelling scalar biomarker trajectories either require the
use of cut points to define abnormal biomarker levels, are based on cognitive test
scores and so cannot track the long prodromal period of AD, are only applicable
to dominantly-inherited AD, or require large retrospective studies of subjects who
convert between clinical diagnoses.
2.6 High dimensional biomarker models
More complex AD biomarker models consider high-dimensional data, such as im-
age data, allowing more subtle patterns of disease progression to be uncovered.
However, these models still use statistical analysis techniques that require knowl-
edge of a subject’s disease stage in order to position them along the time axis.
2.6.1 Comparing diagnostic groups
Numerous studies have looked at voxelwise imaging differences, or other derived
measures such as shape changes, between different diagnostic groups and con-
trols [67, 113–120]. Structural MRI studies (e.g. [67, 113–116]) have shown that
the pattern of atrophy mirrors the sequence of neurofibrillary tangle deposition esti-
mated by neuropathological models such as the Braak and Braak model [26], with
the entorhinal cortex and hippocampus being the earliest structures to atrophy. In
PiB-PET studies, PiB retention has been observed in the frontal cortex, the pre-
cuneus and posterior cingulate, the temporal and parietal cortices, the occipital cor-
tex and lateral temporal cortex, and the striatum [118,119]. In FDG-PET studies, it
has been found that cerebral metabolism is reduced, particularly in the temporal and
parietal cortices. The spatial resolution of PiB-PET and FDG-PET is not as high as
structural MRI and so patterns are frequently reported as an overall level of amyloid
deposition or glucose metabolism [118,119]. Diffusion imaging can also be used to
look at white matter microstructure in AD, but is less well established [120]. Whilst
the aforementioned studies are able to provide detailed spatial pictures of AD pro-
gression, their temporal resolution is limited by the requirement that subjects are
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indexed by disease stage.
2.6.2 Prediction of conversion between diagnoses
A multitude of studies have looked at predicting conversion between different diag-
nostic categories using images from various modalities [117, 121] or by combining
different biomarkers [122]. These studies can provide valuable insights into which
regions are the most discriminative for predicting conversion between two diag-
noses at a particular snapshot in the disease time course: X years to conversion.
However, they are typically limited to modelling a single disease stage.
2.6.3 Network models
Network models describe how a disease propagates along structural or functional
brain networks [123–127]. The data they require are high dimensional regional
connectivity patterns, but this dimensionality is reduced by using a mechanistic
approach, which physically constrains the solution, or by considering major com-
ponents of the network, for example by using independent component analysis to
extract intrinsic connectivity networks. In 2009, Seeley et al. [123] performed a
study that compared intrinsic functional and structural networks in healthy subjects
with the atrophy patterns of five neurodegenerative diseases. They found that the in-
trinsic functional and structural networks were correlated with the different atrophy
patterns. Their results suggest that each structural and functional brain network has
a selective vulnerability to a particular neurodegenerative disease. Other network
models [124,125,127] have supported the transneuronal spread hypothesis (i.e. the
prion hypothesis), whereby misfolded proteins physically spread from one neuron
to another along brain networks. One approach [125, 127] is to use mechanistic
network diffusion models and compare predicted atrophy patterns from a particular
seed region with actual atrophy patterns. An alternative approach [124] is to derive
hypotheses about the expected atrophy patterns under different network spreading
mechanisms and compare the predicted patterns to observed atrophy patterns. Net-
work models provide valuable mechanistic insights into AD, which are important
for drug development, but they are not directly applicable for disease staging and
56 Chapter 2. State of the art in Alzheimer’s disease progression modelling
monitoring. Raj et al. [126] have provided some evidence that network diffusion
models can be used to predict future atrophy and hypometabolism patterns, but the
clinical utility of these predicted patterns has yet to be established. Additionally,
the validity of network models is based on their alignment with a single coarse end
stage disease atrophy pattern, and the use of a group-level functional or structural
network connectivity pattern from healthy subjects.
2.6.4 Critical assessment
High dimensional biomarker models can provide valuable new insights into disease
progression patterns by finding complex relationships within or between different
data types. They are less directly clinically applicable because novel biomarkers
require further validation before being widely used. Models to date have suggested
that the pattern of regional atrophy mirrors the sequence of neurofibrillary tangle
deposition, and that misfolded proteins may spread in a prion-like manner from one
neuron to another.
As with the scalar biomarker models, the temporal resolution of current high-
dimensional biomarker models is limited by their dependence on clinical staging
information to determine an individual’s position along the disease time course.
2.7 Data-driven biomarker models
Traditional statistical analysis techniques estimate biomarker trajectories by assum-
ing a priori knowledge of where each data point lies along the disease time course.
Hence, the majority of studies of neurodegenerative disease biomarker progression
(e.g. [67, 114]) rely on the use of a priori clinical classification as a patient stag-
ing measure and then compare biomarkers across groups. This reliance on clinical
staging limits the temporal resolution of the biomarker progression to only a few
stages, e.g. in AD there are typically just three stages: CN, MCI and AD. Recently
a new family of truly data-driven statistical models (e.g. [81,98,128]) have emerged
that do not require prior knowledge of the stage of each individual along the dis-
ease time course. This is a major advantage, as it allows for a complete picture of
disease progression incorporating the full set of biomarkers, and with much higher
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temporal resolution.
2.7.1 The event-based model
The event-based model (EBM) (Figure 2.2) [98] describes disease progression as a
series of events, where each event corresponds to a particular biomarker becoming
abnormal. The unique property of the EBM is that it directly encodes, and thus esti-
mates from the data, the ordering in which biomarkers become abnormal, or, more
strictly, observably different from normal levels. This sequence of events provides
a simple and intuitive description of disease progression, as well as a natural patient
staging system - at stage X, the first X events have occurred. The EBM has been
applied to recover the sequence of regional neurodegeneration in both dominantly-
inherited AD and Huntington’s disease [98]. Another key strength of the EBM is
its probabilistic formulation, which provides measures of confidence in both the se-
quence of biomarker abnormality events across the population, and an individual’s
model stage. The EBM naturally extends to differential diagnosis by providing a
likelihood of each candidate neurodegenerative disease, which is achieved by fitting
an individual’s set of biomarker measurements to each corresponding biomarker se-
quence. One limitation of the EBM is that it doesn’t incorporate information on the
time between events or the rate of biomarker decline, which somewhat limits its
utility for prognosis and monitoring. Another limitation is its reliance on a well-
defined control population, which means the EBM is not currently applicable to
sporadic AD.
2.7.2 Differential equation models
Differential equation models (DEMs) [81, 82, 110, 129–131] can be used to recon-
struct an average cohort-level biomarker trajectory, which is continuous in con-
trast to the discrete description of the EBM. The models use short-term follow up
biomarker measurements to provide samples of the gradient of a single common
biomarker trajectory and integrate a differential equation to determine a best-fit or
‘average’ trajectory for the cohort. For example, Jack et al. [82] determine the
time taken for amyloid accumulation to go from a normal to an abnormal level by
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Figure 2.2: Sequence of events, S¯, in dominantly-inherited Alzheimer’s disease estimated
by the event-based model proposed by Fonteijn et al. in 2012 [98]. Reprinted
from [98], Copyright 2012, with permission from Elsevier.
fitting a DEM to data from serial amyloid-PET scans, finding that it takes approx-
imately 15 years to go from a normal standard uptake value ratio (SUVR) of 1.5
to an abnormal SUVR of 2.5. Villemagne et al. [81] (Figure 2.3) perform a simi-
lar analysis to determine the time taken for several biomarkers to go from normal
to abnormal, including amyloid-PET, hippocampal atrophy, episodic memory, gray
matter volume and non-memory cognitive domains. DEMs have potential as a dis-
ease staging, monitoring and prognostic tool as they provide the rate of biomarker
decline over the disease time course. Stochastic DEMs [131] can further express de-
viations from this average, providing prognostic information at the individual level.
However, they model each biomarker individually, and so there is no guarantee
of correspondence across disease stage and prognosis estimates between different
biomarkers.
2.7.3 Self-modelling regression
Self-modelling regression approaches [128, 132] bring together data from multiple
biomarkers to estimate biomarker trajectories over a common disease timescale.
Short-term follow up data from each individual provides samples of a common set
of biomarker curves, which are used to estimate the population-level shape and rate
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Figure 2.3: Differential equation model of amyloid deposition proposed by Villemagne
et al. in 2013 [81]. The figure shows the estimated accumulation of amy-
loid plaques (measured using amyloid-PET imaging) with disease progression.
Reprinted from [81], Copyright 2013, with permission from Elsevier.
of biomarker decline, as well as each individual’s position and rate of decline. As
with DEMs, the biomarker curves represent the average biomarker dynamics for a
population. Donohue et al. [128] (Figure 2.4) use self-modelling regression to deter-
mine the trajectories of cognitive test scores, regional brain volumes from MRI, PET
imaging measures, and CSF levels of amyloid-beta and tau. Jedynak et al. [132] for-
mulate a similar model that uses cognitive test scores, CSF amyloid-beta and tau,
and hippocampal volume on MRI to estimate a ‘disease progression score’, which
is a continuous measure of disease stage that can be used as a time proxy. Bilgel
et al. [133] have recently extended the ‘disease progression score’ model to work
with voxelwise imaging data. However, this extension requires that biomarker tra-
jectories are modelled as a linear function of disease stage, limiting the applicability
of the model to multi-modality data where biomarkers may be dynamic at different
points along the disease time course. Self-modelling regression approaches provide
continuous disease staging, monitoring and prognostic measures that incorporate
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information from multiple biomarkers. A key advantage of these models is that
they provide a very complete picture of the disease, which can aid detailed disease
understanding. Potential disadvantages are that they have many more parameters to
estimate than simpler models like the EBM, so may be less stable; and the complex
picture has a less straightforward interpretation than the discrete description, which
may limit clinical utility.
Figure 2.4: Alzheimer’s disease biomarker trajectories estimated using the self-modelling
regression technique proposed by Donohue et al. in 2014 [128]. Reprinted
from [128], Copyright 2014, with permission from Elsevier.
2.7.4 Critical assessment
To date, these data-driven models have shown compelling results that provide valu-
able insights into neurodegenerative disease progression patterns, particularly in
AD. However, they remain an emerging area of research, and all the current mod-
els share a number of limitations and assumptions that are important to consider
when interpreting results. One strong assumption that all the aforementioned mod-
els make is that all subjects follow a common progression pattern. Although some
models allow for subjects to deviate from this common progression pattern, these
deviations are assumed to be small, and none allow for subgroups of subjects that
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follow completely different progression patterns. Such outliers are likely given the
inherent heterogeneity of sporadic disease data sets, which contain some proportion
of subjects with alternative neurodegenerative diseases, as well as mixed patholo-
gies and a wide range of subject demographics. For this reason, practical appli-
cations of data-driven models often focus on more homogeneous population sub-
groups [81,82,128], for example subjects with increased genetic risk of developing
the neurodegenerative disease of interest. Another assumption is the independence
of biomarkers: although the models express temporal correlation of biomarker tra-
jectories over the disease time course, they typically assume independence at any
given time point. In practice, biomarkers often co-vary, for example amyloid-PET
and CSF measures of amyloid-beta are measures of the same underlying pathol-
ogy and are therefore strongly correlated. Failure to model this covariance tends to
cause underestimation of the variance of progression patterns across the population.
Data-driven models further assume that data is available from the full disease time
course when in reality the data points may be sparse at the beginning and end of the
disease progression, which may influence the estimation of biomarker trajectories.
Data-driven models are an emerging area of technology with major potential
benefits to neurodegenerative disease research and clinical practice, and with wide
potential further application to a range of other diseases or developmental processes.
They can provide quantitative multi-modal pictures of the full disease time course
for improved understanding of disease mechanisms to inform drug discovery; they
naturally combine different types of information for earlier and more accurate dif-
ferential diagnosis, and subject-specific prognostic information; they provide fine-
grained staging scores or systems for more precise patient stratification supporting
clinical trials for developing treatments and ultimately treatment deployment.
2.8 Summary
A wide range of models have been applied to AD. Neuropathological models and
animal models have provided important insights into underlying disease mecha-
nisms, but are not directly applicable for patient staging. Biomarker models have
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been developed to allow subjects to be monitored in vivo. Simple scalar biomarker
models are the most directly clinically applicable as they use well established
biomarkers. However, their temporal resolution is limited by their reliance on a
priori knowledge of a subject’s disease stage, typically to just a few stages. High
dimensional biomarker models have the potential to uncover more complex rela-
tionships within or between different data types, but again their temporal resolution
is limited by their reliance on a priori disease staging. Data-driven models have been
developed to allow biomarker trajectories to be recovered without a priori disease
staging information. Such models have the potential to recover complex disease
progression patterns and can be used as a fine-grained patient staging mechanism.
However, they are still an emerging technology, and will require further validation
and refinement before they are translated into a useful clinical tool.
Chapter 3
A data-driven model of biomarker
changes in sporadic Alzheimer’s
disease
This chapter details sub-contributions (a) and (b) of contribution 1.3.1 (see Chap-
ter 1, page 39). The work presented in this chapter was published in Brain and
presented at the Alzheimer’s Association International Conference in 2014. I de-
veloped the methodology, performed the analysis and wrote the manuscript; my
co-authors provided feedback on the methodology and the manuscript.
3.1 Associated publications
A. L. Young, N. P. Oxtoby, P. Daga, D. M. Cash, N. C. Fox, S. Ourselin, J. M.
Schott, and D. C. Alexander. A data-driven model of biomarker changes in sporadic
Alzheimer’s disease. Brain, 137(9):2564–2577, 2014
3.2 Introduction
Existing biomarkers of AD provide complementary information for disease staging
and differential diagnosis. Determining the particular sequence and evolution of
biomarker abnormality potentially provides a mechanism to stage and stratify pa-
tients throughout the full disease time course, and in particular, during the presymp-
tomatic phase. This helps reduce heterogeneity in trial groups, match individuals
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to putative treatments, and monitor treatment outcomes. Whilst new diagnostic cri-
teria now incorporate biomarkers to allow earlier diagnosis [94], the evidence base
for this is relatively limited. A major challenge of current AD research [75] is to
construct models of disease progression that estimate biomarker ordering and dy-
namics directly from real-world datasets enabling quantitative evaluation of patient
state.
The recently introduced event-based model (EBM) [98] provides a generative
model of disease progression that can learn the ordering of biomarker changes from
large cross-sectional (or short-term longitudinal to enable measurement of rates of
atrophy) datasets, as well as providing insights into the uncertainty of the recon-
structed ordering. The EBM defines the disease progression as a sequence of events
at which individual biomarkers become abnormal. The EBM is probabilistic in the
sense that it learns normal and abnormal distributions of biomarker values from the
data, and so does not require a-priori staging or cut points. The EBM further enables
the assignment of each subject to a disease stage. Previous work [98] demonstrated
the EBM’s ability to order biomarkers and generate staging measures derived from
imaging data, in genetically defined disease and control populations (familial AD
and Huntington’s disease). However, the original EBM is not directly applicable to
sporadic disease datasets, which have significant proportions of misdiagnosed cases
in the patient group; and, particularly in AD research, a poorly defined control
group because a significant number (estimated to be a third by the eighth decade)
of apparently healthy elderly individuals have biomarker evidence consistent with
presymptomatic AD [135, 136].
Here I reformulate the EBM for multi-modal data from a heterogeneous spo-
radic disease population. The new EBM accommodates a modest proportion of
misdiagnosed patients as well as allowing for presymptomatic cases contaminat-
ing the control group. I apply this EBM to the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) dataset to obtain characteristic biomarker orderings from various
subgroups, as well as their uncertainty. I demonstrate the fine-grained staging po-
tential of the EBM and its ability both to classify cognitively normal (CN) and AD
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subjects and to predict conversion from mild cognitive impairment (MCI) to AD
and CN to MCI.
3.3 Materials and methods
3.3.1 Data description
3.3.1.1 Subjects
I downloaded data from LONI1 on 5 February 2013, and included all 285 sub-
jects (CN, MCI or AD) that had a CSF examination at baseline, standardised cog-
nitive assessment at baseline2, which included: the Mini Mental State Examina-
tion (MMSE) [85], the Alzheimer’s Disease Assessment Scale-Cognitive Subscale
(ADAS-Cog) [137] (modified 13 item ADAS-Cog, which omits item 13), and the
Rey Auditory Verbal Learning Test (RAVLT) [138] (immediate recall score, i.e. the
sum of trials 1 to 5), and useable 1.5T MRI imaging at baseline and 1 year. Clin-
ical diagnosis (CN/MCI/AD) was also recorded. Other possible biomarkers, e.g.
FDG PET and amyloid PET, were not included in the present analysis because they
limit the number of available subjects: less than half of the subjects with CSF and
MRI data at baseline underwent an FDG PET scan at baseline, and very few had
baseline amyloid PET imaging. CSF measures of Aβ1−42, p-tau and t-tau were per-
formed centrally, as previously described [139]. The CSF t-tau and p-tau data were
log transformed to improve normality. I downloaded APOE genotype, for which
methods have been published previously [140], for each individual from the LONI
website. For validation of the staging system derived from the EBM, I downloaded
the aforementioned set of imaging, clinical and CSF data at 12 and 24 month follow
up time points. CSF values are known to only be comparable when they are all pro-
cessed at the same time. Therefore I downloaded longitudinal CSF data collected
over 4 years that had been reprocessed at the end of the 4 years, so as to obtain
baseline, 12 and 24 month CSF data which were processed in the same batch. As
an outcome measure, I downloaded clinical diagnoses at all available time points up
1www.loni.ucla.edu/ADNI/
2For details see www.adni-info.org/Scientists/Pdfs/adniproceduresmanual12.pdf.
66 Chapter 3. A data-driven model of sporadic Alzheimer’s disease
to 72 months.
3.3.1.2 MRI methods
Details of the MRI methodology have previously been described [141]. Cross-
sectional regional measures of brain volumes known to be affected in AD: the hip-
pocampus, entorhinal cortex, middle temporal gyrus, fusiform, ventricles and whole
brain, as well as total intracranial volume (TIV), were calculated at baseline using
FreeSurfer Version 4.3, which is documented and freely available for download on-
line3. All regional volumes were normalised by dividing by TIV for each subject.
Longitudinal measures of regional volume change between 0 and 12 months
were obtained using the boundary shift integral (BSI): volume change was measured
for the whole brain using the KN-BSI method [142], and for the hippocampus using
the MAPS-HBSI method [143].
3.3.1.3 Event set
The biomarkers available for all the subjects provide the following set of 14
biomarker transition ‘events’, each of which corresponds to a biomarker becom-
ing abnormal, i.e. changing from the ‘control’ to ‘AD’ state
• Three CSF events: Aβ1−42 (Abeta), P-tau and T-tau
• Three cognitive events: ADAS-Cog, RAVLT and MMSE
• Six regional brain volume events: Brain, Ventricles, Hippocampus, Entorhi-
nal, Mid Temporal and Fusiform volumes
• Two rates of atrophy events: rates of Hippocampal and Brain Atrophy
3.3.2 Event sequences
I defined four population subgroups:
• Whole population: all subjects.
• Amyloid positive (Aβ+): subjects with CSF Aβ1−42 < 192 pg/ml. This cut
point was chosen according to the results of Shaw et al. [139] who determined
3http://surfer.nmr.mgh.harvard.edu/
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cut points using a maximum accuracy classification of autopsy confirmed AD
and CN subjects.
• APOE4 positive (APOE4+): subjects with one or more APOE4-ε4 alleles.
• Amyloid positive APOE4 positive (Aβ+APOE4+): subjects who are both
Aβ+ and APOE4+.
3.3.2.1 The event-based model
I estimated the most likely ordering of events and its uncertainty in each sub-
group using the EBM [98]. The EBM treats each biomarker as either ‘normal’,
i.e. non-pathological, or ‘abnormal’, i.e. as seen in AD. The switch from nor-
mal to abnormal is termed an ‘event’. The occurrence of any particular event, Ei,
i = 1 . . . I, is informed by the corresponding measurements xi j of biomarker i in
subject j, j = 1 . . .J. The whole dataset X =
{
xi j|i = 1 . . . I, j = 1 . . .J
}
contains
measurements of each biomarker in each subject. The most likely ordering of the
events is the sequence S that maximises the data likelihood
P(X |S) =
J
∏
j=1
[
I
∑
k=0
(
P(k)
k
∏
i=1
P(xi j|Ei)
I
∏
i=k+1
P(xi j|¬Ei)
)]
, (3.1)
where P(x|Ei) and P(x|¬Ei) are the likelihoods of measurement x given that
biomarker i has or has not become abnormal, respectively, and P(k) is the prior
likelihood of being at stage k, i.e. events E1, . . . ,Ek have occurred, and events
Ek+1, . . . ,EI have yet to occur, which I assume is uniform. This uniform prior as-
sumes no knowledge of any patient’s disease stage a-priori, which imposes the least
information possible on estimated orderings.
In addition to finding the most likely sequence, P(X |S) can be evaluated for any
sequence to establish the relative likelihood of all sequences. This provides insight
into the uncertainty of the ordering. The positional variance diagram [98] (Figure
3.1 A-D) visualises both the maximum likelihood sequence and its uncertainty by
plotting the likelihood that each event appears in each position in the sequence, i.e.
the entry of each position is ∑S∈Sik P(X |S) where Sik is the set of all sequences with
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event i at position k.
3.3.2.2 Model of the event distribution
Evaluation of Equation (3.1) requires models for each of the event distributions,
P(x|Ei) and P(x|¬Ei). The original EBM in [98] used a familial AD dataset for
which the control group was well defined allowing direct estimation of P(x|¬Ei).
In sporadic AD, however, a significant proportion of the CN control group may
have presymptomatic AD. To counter this, I reformulated the EBM approach so
that the event distributions are estimated by fitting a mixture of two normal distri-
butions (a gaussian mixture model). I fitted this mixture of normal distributions to
each biomarker separately using data from all subjects to obtain the parameters of
the two models. To ensure a robust fit, particularly for biomarkers where the dis-
tributions of the healthy and diseased population overlap significantly, I constrain
the standard deviations so that the standard deviation of P(x|¬Ei) and P(x|Ei) is
less than or equal to that of the CN and AD group respectively. This is a weak
constraint designed simply to guide the mixture model away from physically unre-
alistic solutions. Importantly, whilst this modelling approach can be used to deter-
mine fixed cut points for each biomarker, the model here is not dependent on these
cut-points, using a probability function to determine the most likely sequencing of
event switches.
3.3.2.3 Summary of estimation procedure for the EBM
The model fitting procedure for the EBM is as follows.
1. Fit a mixture model to the data for all subjects to estimate the parameters of
the event distributions, P(x|Ei) and P(x|¬Ei).
For each population subgroup:
2. Find the characteristic event sequence S¯ that maximises the data likelihood
P(X |S) by performing a greedy ascent algorithm.
3. Take Markov Chain Monte Carlo (MCMC) samples of the data likelihood
P(X |S), initialised from the maximum likelihood event sequence S¯, to esti-
mate the uncertainty in the characteristic event sequence.
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3.3.2.4 Implementation of EBM estimation procedure
All experiments were performed using Matlab on a standard workstation (Intel Core
i7, 3.1 GHz, 8GB memory). The event distribution (gaussian mixture model) pa-
rameters were optimised using the ‘fmincon’ constrained optimisation solver with
the ‘sqp’ - sequential quadratic programming - method. All of the gaussian mixture
model fits were assessed visually to ensure the solutions were physically plausible.
To find the characteristic event sequence S¯, I performed 10,000 iterations of a greedy
ascent algorithm (as in [98]), initialised from 25 random start points. I checked that
the start points converged to a single maximum to ensure the global optimum had
been found. I then ran an MCMC algorithm (as in [98]) to draw samples from the
posterior distribution P(S|X). I ran the MCMC algorithm for 100,000 iterations,
checking that the MCMC trace showed good mixing properties. I initialised the
MCMC algorithm at S¯ so a burn-in period was not required.
The computational complexity of the gaussian mixture model fitting is O(I),
where I is the number of biomarker events, and the full optimisation procedure for
each biomarker takes less than 0.2 seconds. The computational time for the greedy
ascent and MCMC algorithms depends on (i) the time taken to compute the data
likelihood P(X |S), and (ii) the number of samples required for the algorithm, i.e.
for the greedy ascent algorithm to reach the maximum likelihood solution, or for
the MCMC chain to sample P(S|X). Calculating the value of P(X |S) involves com-
puting a product over all I biomarker events, summing this over all I + 1 possible
stages in the sequence, and then taking the product over all J subjects, which is of
order O(I2J), as P(xi j|¬Ei) and P(xi j|Ei) can be computed ahead of time. Although
the space of all possible sequences has a size of I!, the maximum pairwise distance
between any pair of sequences is I(I−1)2 . This means that the number of iterations
required for convergence of the greedy ascent algorithm, and for the MCMC chain
to sample P(S|X), should scale with approximately O(I2). For the set of biomarker
events used here, running 10,000 iterations of the greedy ascent algorithm takes
approximately 1.5 seconds, and taking 100,000 samples for the MCMC algorithm
takes approximately 15 seconds (i.e. computing P(X |S) takes approximately 1.5
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×10−4 seconds).
3.3.2.5 Cross-validation of the event sequence
I performed cross-validation of the maximum likelihood event sequence returned by
the EBM (Figure 3.1 E-H) by re-estimating the event distributions and maximum
likelihood sequence (Figure 3.1 A-D) for 100 bootstrap samples of the data. The
positional variance diagrams for the cross validation results show the proportion of
bootstrap samples in which event i appears at position k of the maximum likelihood
sequence.
3.3.3 Patient staging
Once the characteristic sequence S¯ has been determined using the EBM, the sim-
plest way to assign a stage for a particular subject, which I adopt here, is to find the
stage which is assigned the highest probability by the model, i.e. the stage,
argmaxkP(X j,k|S¯) = argmaxkP(k)
k
∏
i=1
P(xi j|Ei)
I
∏
i=k+1
P(xi j|¬Ei), (3.2)
that maximises the probability of the data given the maximum likelihood event se-
quence. As before, I make no a-priori assumptions about model stage by assuming
the prior, P(k), is uniform. The stage ranges from 0 to I (the number of events).
Thus the idealised model for stage k is that all events up to and including k have oc-
curred and the events after k have not occurred. However, the assignment of stage
k to a particular patient does not mean they fit the model exactly; it is simply the
stage most compatible with their measurements.
3.3.3.1 Longitudinal validation
To assess the consistency of patient staging measures longitudinally (Figure 3.3) I
evaluated each patient’s stage at all follow up time points which met the inclusion
criteria: subjects had to have measurements for all biomarkers, including an MRI
scan 12 months later in order to calculate the BSI over a consistent time frame.
There were two follow up time points which met these criteria: 12 months (Figure
3.3 A) and 24 months (Figure 3.3 B). I compared each subject’s EBM stage at follow
3.3. Materials and methods 71
up with their baseline EBM stage, which was re-evaluated using the reprocessed
CSF measures so as to ensure that the CSF was processed consistently for all time
points.
3.3.3.2 Prediction of conversion
Patient staging derived from the EBM can be used to predict conversion from MCI
to AD or CN to MCI (Table 3.2) by categorising subjects according to their EBM
stage at baseline. I performed a binary classification of subjects into MCI-stable
and MCI-converters, and CN-stable and CN-converters, by thresholding on patient
EBM stage. Stable subjects were defined as those with an MCI or CN diagnosis
who remained with an MCI or CN diagnosis at the end of a 12, 24, 36, 48 or 60
month follow up period. Converters were defined as those with an MCI or CN
diagnosis who were diagnosed with AD or MCI, respectively, at the end of a 12, 24,
36, 48 or 60 month follow up period. I used the EBM stage that maximises balanced
accuracy to classify subjects. Balanced accuracy is the average of the sensitivity and
specificity, which is similar to accuracy but does not depend on disease prevalence.
To test the effect of increasing EBM stage on the probability of conversion from
MCI to AD and CN to MCI (Table 3.3 and Figure 3.4) I used Cox proportional
hazards Models where the event was conversion to AD or MCI respectively and
the input variables were patient EBM stage and demographic factors: age, sex,
education and APOE4 carrier status (presence of an APOE4 allele). Time to event
data for subjects who did not convert was considered censored at their last available
diagnosis. Statistical significance was set at P < 0.05.
3.3.4 Staging using cross-sectional data alone
To demonstrate the EBM’s ability to stage patients using purely cross-sectional
measures I repeated the patient staging by fitting the EBM for a subset of 12 events
(Tables 3.4, 3.5, 3.6, Figures 3.5, 3.6, 3.7, 3.8), excluding atrophy rates. The in-
clusion criteria were the same as used previously except follow up MRI scans at 12
months were not required. As before, patient staging results were evaluated for the
whole population using the maximum likelihood event sequence determined over
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all subjects, but with atrophy rates removed (Figure 3.5 A).
3.4 Results
3.4.1 Subjects
Study subject demographics are summarised in Table 3.1. Of the 285 sub-
jects that met the inclusion criteria, 189 were amyloid positive (Aβ+), 139 were
APOE4 positive (APOE4+), and 123 were amyloid positive and APOE4 positive
(Aβ+APOE4+).
Demographics CN MCI AD
N 92 129 64
All Sex M/F 48/44 (52%) 82/47 (64%) 34/30 (53%)
subjects Age 75 ± 5 73 ± 7 75 ± 8
Education 15.6 ± 2.9 15.9 ± 3 15 ± 3
APOE4 +/- 22/70 (24%) 72/57 (56%) 45/19 (70%)
N 34 96 59
Aβ+ Sex M/F 19/15 (56%) 58/38 (60%) 31/28 (53%)
Age 76 ± 5 73 ±7 74 ± 8
Education 15.8 ± 3.3 15.7 ± 3.1 15 ± 3.1
APOE4 +/- 15/19 (44%) 63/33 (66%) 45/14 (76%)
N 22 72 45
APOE4+ Sex M/F 15/7 (68%) 39/33 (54%) 25/20 (56%)
Age 75 ± 6 73 ± 6 75 ± 7
Education 15.6 ± 3.4 15.8 ± 2.9 14.6 ± 3
APOE4 +/- 22/0 (100%) 72/0 (100%) 45/0 (100%)
N 15 63 45
Aβ+ Sex M/F 10/5 (67%) 35/28 (56%) 25/20 (56%)
APOE4+ Age 77 ± 6 73 ± 6 75 ± 7
Education 15.5 ± 3.8 15.8 ± 2.9 14.6 ± 3
APOE4 +/- 15/0 (100%) 63/0 (100%) 45/0 (100%)
Table 3.1: Baseline demographics for the whole population and population subgroups. Age
and education are in years (mean± standard deviation). Reproduced from [134].
CC BY 3.0.
3.4.2 Event sequences
Figures 3.1 A-D show positional variance diagrams for each population subgroup.
Each positional variance diagram shows the maximum likelihood event sequence
and its uncertainty. Figures 3.1 E-H show positional variance diagrams obtained
3.4. Results 73
from cross-validation of the maximum likelihood ordering.
The event sequences in all four populations (Figure 3.1 A-D) showed broad
agreement with hypothetical models such as Jack et al. [74]: CSF biomarkers were
shown to be early events, followed by atrophy rates, then cognitive test scores
and hippocampal and entorhinal volume, and finally other regional brain volumes.
Cross-validation (Figure 3.1 E-H) confirmed high confidence in the ordering of
these sets of events: for all populations, the ordering strongly placed CSF and atro-
phy rates before cognitive test scores and hippocampal and entorhinal volume, and
the remaining regional volume changes last.
3.4.2.1 Whole population
The maximum likelihood ordering for the whole population (Figure 3.1 A) showed
some departures from current thinking in neurology [74], although the uncertainty
was high (Figure 3.1 E). First, CSF t-tau occurred prior to p-tau. It might be ex-
pected that p-tau is an earlier marker of AD than t-tau [75], being a more specific
measure of the build up of NFTs than t-tau [62], which measures associated neu-
ronal damage. Second, both t-tau and p-tau occurred before Aβ1−42, whereas amy-
loid plaque deposition is widely considered to be the initiating event in AD [144].
Third, brain atrophy rate came before hippocampal atrophy rate, which is at odds
with the findings of MRI regional atrophy rate studies (e.g. [114]).
3.4.2.2 Aβ+ and APOE4+ subjects
The Aβ+, APOE4+ and Aβ+APOE4+ groups (Figures 3.1 B-D) showed a distinct
ordering of the CSF biomarkers: Aβ1−42, p-tau, t-tau, which replicated the ordering
described by hypothetical models [74,75]. Cross-validation (Figure 3.1 F-H) of the
event sequence in these groups showed a much greater confidence in the ordering
of CSF biomarkers compared to the whole population (Figure 3.1 E), which is more
heterogeneous. In the Aβ+ group (Figure 3.1 B), brain atrophy rate was ordered
before hippocampal atrophy rate, but the ordering was weaker than the whole pop-
ulation. In the APOE4+ and Aβ+APOE4+ groups (Figures 3.1 C-D) hippocampal
atrophy rate clearly occurred before brain atrophy rate.
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Figure 3.1: Positional variance diagrams showing the distribution of event sequences in
population subgroups. (A-D) Positional variance diagrams of the uncertainty in
the maximum likelihood event ordering estimated by taking MCMC (Markov
chain Monte Carlo) samples using the EBM. (E-H) Positional variance dia-
grams from cross-validation of the maximum likelihood event sequence by
bootstrap resampling of the data. These diagrams overestimate the uncertainty,
giving a more conservative picture than the left hand column. Each entry in
the positional variance diagram represents the proportion of MCMC samples,
in A-D, or bootstrap samples, in E-H, in which events appear at a particular po-
sition in the sequence (x-axis). This proportion ranges from 0 in white to 1 in
black. The y-axis orders events by the maximum likelihood sequence. Where
rows have a single black block on the diagonal, such as the top five events in the
diagram for the whole population, the ordering is strong and permutations of
those events are unlikely. Grey blocks, such as the Mini-Mental State Examina-
tion (MMSE) score, entorhinal volume and hippocampal volume in the whole
population, show that permuting the order of the events has little effect on the
likelihood so their ordering is weak. Aβ+ = amyloid+; Abeta = amyloid-β ;
P-tau = phosphorylated tau; T-tau = total tau; RAVLT = Rey Auditory Verbal
Learning Test. Reproduced from [134]. CC BY 3.0.
3.4.3 Patient staging
3.4.3.1 Cross-sectional distribution of stages
Figure 3.2 shows the distribution of patient stages for the whole population. All
patient staging results were evaluated for the whole population using the maximum
likelihood event sequence determined over all subjects (Figure 3.1 A). The distribu-
tions of EBM stages for CN and AD subjects were strongly separated and thresholds
at middle stages classify CN vs. AD with accuracy greater than 99%. The majority
of CN subjects have no biomarker abnormalities, so are assigned stage 0, or abnor-
malities only in CSF, so are assigned stages 1-3. A small number of CN subjects
also showed rates of atrophy events, so are assigned stages 4-6. Most AD subjects
have abnormal CSF, atrophy rate, cognitive symptoms and low hippocampal and
entorhinal volume so are assigned later stages. The majority of AD subjects were
assigned the final stage in the progression, showing that the model configuration
that fits their data best is where all of the events have occurred. The distribution of
MCI stages overlapped with the distribution of stages for CN and AD subjects but
with a greater concentration of subjects around the middle stages, suggesting that
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these subjects show CSF abnormalities, abnormal rates of atrophy, and some cog-
nitive symptoms. To explore the extent to which choice of cognitive test affects the
staging (and event sequence) output, I assessed the effect of adding in an additional
memory test, the Logical Memory II subscale (delayed paragraph recall) from the
Wechsler Memory Scale - Revised. Results (not shown) confirm that using this
additional cognitive test score provides a very similar distribution of patient EBM
stages, with logical memory occurring immediately prior to the RAVLT in the event
sequence.
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Figure 3.2: Proportion of patients in each diagnostic category at each EBM stage. Propor-
tion of cognitively normal in light blue, mild cognitive impairment in black,
and Alzheimers disease in orange. Each EBM stage on the x-axis corresponds
to the occurrence of a new biomarker transition event. Stage 0 corresponds
to no events having occurred and stage 14 is when all events have occurred.
Events are ordered by the maximum likelihood event sequence for the whole
population as shown in Fig. 3.1 A. Reproduced from [134]. CC BY 3.0.
3.4.3.2 Longitudinal consistency
Figure 3.3 compares each subject’s EBM stage at baseline with their EBM stage at
12 and 24 month follow ups. Patient staging showed good longitudinal consistency,
with the EBM stage of each subject generally increasing or remaining stable at each
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follow up (most points are within or above the grey shaded area, which represents
the uncertainty estimated by the EBM, as shown in figure 3.1 A). The small number
of individuals whose EBM stage decreased longitudinally (below the diagonal) by
more than the uncertainty estimated by the EBM (shaded in grey) were all subjects
who improved from an abnormal to a normal score on one or more of the three
cognitive tests (MMSE, RAVLT, and ADAS-Cog) and/or two atrophy rates (brain
atrophy rate and hippocampal atrophy rate) with the exception of one subject (cir-
cled in green) whose CSF Aβ1−42 levels increased from a clearly abnormal level
of 139 pg/ml at baseline to a more borderline level of 207 pg/ml at the 12 month
follow up.
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Figure 3.3: Longitudinal consistency of patient staging in the whole population over a (A)
12-month and (B) 24-month follow-up period. The size of the dot plotted at
each point corresponds to the number of subjects with that particular baseline
and follow-up EBM stage. The largest dot, at (0,0) represents 19 subjects in A
and seven subjects in B, and the smallest dots represent one subject. The grey
shaded area visualizes the uncertainty in the sequence estimated by the EBM
(as shown in Fig. 3.1 A). Subjects whose EBM stage is longitudinally consis-
tent are on or above the line y = x and/or within the grey shaded area. Subjects
whose CSF levels (CSF amyloid-β1−42 and/or phosphorylated tau and/or to-
tal tau) change from an abnormal to a normal level at follow-up are circled in
green. Reproduced from [134]. CC BY 3.0.
3.4.3.3 Prediction of clinical outcomes
Table 3.2 A shows the balanced accuracy, sensitivity, specificity, area under the
ROC curve (AUC), and maximum accuracy threshold EBM stage for classification
of MCI-stable vs. MCI-converters over different follow up durations. The balanced
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accuracy and AUC of the classification were comparable to state of the art classifi-
cation techniques [121]. As the duration of the follow up increased, the maximum
balanced accuracy threshold decreased, i.e. later EBM stages were better at predict-
ing faster conversion times. These optimal stage thresholds suggest that abnormal
CSF measures, atrophy rate, cognitive test scores and hippocampal and entorhinal
volume provide the best prediction of conversion in 2 years or less, whereas just
abnormal CSF, atrophy rate and ADAS-Cog and RAVLT scores is the combination
that best predicts conversion over a period of 3 to 5 years.
The same statistics are shown in Table 3.2 B for classification of CN-stable
vs. CN-converters. Again the threshold EBM stage decreased for increasing follow
up durations, with abnormal CSF t-tau, p-tau and Aβ1−42 levels best predicting
conversion from CN to MCI over a period of 4 years or less, but just abnormal CSF
t-tau and p-tau best predicting conversion over 5 years.
A. MCI-stable vs. MCI-converters
Balanced
Acc. (%)
Sensitivity
(%)
Specificity
(%) AUC
Threshold
Stage N-c/N-s
12 months 67 60 73 0.69 12 30/96
24 months 68 57 80 0.71 12 53/64
36 months 77 86 69 0.78 7 65/48
48 months 78 83 72 0.76 7 70/18
60 months 76 84 69 0.77 7 73/16
B. CN-stable vs. CN-converters
Balanced
Acc. (%)
Sensitivity
(%)
Specificity
(%) AUC
Threshold
Stage N-c/N-s
12 months 84 100 68 0.76 3 2/90
24 months 66 67 66 0.62 3 6/83
36 months 68 63 73 0.62 3 8/73
48 months 66 58 74 0.65 3 12/49
60 months 76 75 76 0.75 2 16/38
Table 3.2: Classification results for discriminating MCI-stable versus MCI-converters and
CN-stable versus CN-converters using patient stage at baseline. CN = cogni-
tively normal; MCI = mild cognitive impairment. Reproduced from [134]. CC
BY 3.0.
Table 3.3 shows the hazard ratio and statistical significance of each variable
in the Cox proportional hazards models. Increasing EBM stage was a significant
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hazard for conversion from both MCI to AD and CN to MCI. Figure 3.4 shows the
estimated probability of remaining CN or MCI depending on baseline EBM stage.
A. MCI to AD progression
HR (CI) p-value
Corrected
HR (CI)
Corrected
p-value
EBM Stage 1.15 (1.09-1.21) 1.58 × 10−7∗ 1.15 (1.09-1.21) 2.06 × 10−7∗
Age 0.99 (0.96-1.03) 0.68 0.99 (0.96-1.02) 0.49
Education 0.98 (0.91-1.05) 0.55 0.98 (0.90-1.05) 0.51
APOE4 Carrier 1.55 (0.97-2.48) 0.065 1.19 (0.73-1.94) 0.49
Male 0.77 (0.49-1.23) 0.28 0.85 (0.50-1.45) 0.55
B. CN to MCI progression
HR (CI) p-value
Corrected
HR (CI)
Corrected
p-value
EBM Stage 1.34 (1.07-1.69) 0.012∗ 1.31 (1.02-1.68) 0.033∗
Age 0.99 (0.90-1.09) 0.84 0.98 (0.89-1.08) 0.67
Education 1.03 (0.88-1.22) 0.69 1.02 (0.86-1.20) 0.83
APOE4 Carrier 3.15 (1.19-8.30) 0.021∗ 2.47 (0.85-7.17) 0.096
Male 1.75 (0.65-4.74) 0.27 1.45 (0.49-4.28) 0.5
Table 3.3: Hazard ratios with 95% confidence intervals (CI) for conversion from MCI to
AD, and CN to MCI, obtained by fitting uncorrected and corrected Cox pro-
portional hazards models. ∗P < 0.05. CN = cognitively normal; MCI = mild
cognitive impairment; AD = Alzheimer’s disease. Reproduced from [134]. CC
BY 3.0.
3.4.4 Staging using cross-sectional data alone
I repeated all analyses for purely cross-sectional measures, i.e. excluding rates of
atrophy, to demonstrate the clinical application of the EBM’s staging system, where
patients need to be staged at one point in time. Table 3.4 gives demographic infor-
mation for the 325 subjects that met the inclusion criteria, of which 216 were Aβ+,
159 were APOE4+, and 141 were Aβ+APOE4+.
Removing atrophy rates had little effect on biomarker ordering (Figure 3.5)
or the cross-sectional distribution (Figure 3.6) and longitudinal consistency (Figure
3.7) of staging. Again, individuals whose EBM stage decreased longitudinally (be-
low the diagonal) by more than the uncertainty estimated by the EBM (shaded in
grey) improved from a clearly abnormal to a more normal score on one or more of
the three cognitive tests (MMSE, RAVLT, and ADAS-Cog) with the exception of
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0 12 24 36 48 60 72
All 129 119 88 64 33 23 13
Stage 0 22 22 18 15 11 8 4
Stage 1-3 12 12 11 10 4 4 2
Stage 4-5 9 9 7 7 3 2 2
Stage 6-10 37 33 28 18 9 6 4
Stage 11-14 49 43 24 14 6 3 1
Number of MCI subjects at risk at each follow up:
0 12 24 36 48 60 72
All 92 91 89 77 58 48 34
Stage 0 47 47 46 42 31 27 20
Stage 1-3 30 29 28 23 17 14 11
Stage 4-5 13 13 13 11 9 7 3
Stage 6-10 2 2 2 1 1 0 0
Stage 11-14 0 0 0 0 0 0 0
Number of CN subjects at risk at each follow up:
Figure 3.4: Estimated probability of remaining (A) MCI or (B) CN for different baseline
EBM stages, obtained by fitting Cox proportional hazards models. These esti-
mated probabilities are shown for the average population demographics (74.1
years of age, 15.6 years of education, APOE4 negative, male sex). Stages are
grouped so that normal (blue) = stage 0, CSF (green) = stages 1-3, atrophy (or-
ange) = stages 4-5, cognition (cyan) = stages 6-10, which includes hippocam-
pal and entorhinal volume as well as cognitive test scores, volume (magenta) =
stages 11-14. The table details the number of subjects at risk at each follow-
up time point. MCI = mild cognitive impairment; CN = cognitively normal.
Reproduced from [134]. CC BY 3.0.
two subjects (circled in green) whose CSF levels (CSF Aβ1−42 and/or p-tau and/or
t-tau) changed from an abnormal to a more normal level at follow up.
The balanced accuracy for predicting conversion (Table 3.5) was slightly re-
duced when the atrophy rates were removed but was still high, giving a maximum
balanced accuracy of 71% (77% with atrophy rates) for conversion from MCI to
AD over 3 years, and 70% (76% with atrophy rates) for conversion from CN to
MCI over 5 years. On average over all follow up durations the balanced accuracy
decreased by 2.6% for predicting conversion from MCI to AD, and increased by
4% for predicting conversion from CN to MCI. Again, increasing EBM stage was a
significant hazard for conversion from both MCI to AD and CN to MCI (Table 3.6
and Figure 3.8).
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Demographics CN MCI AD
N 100 150 75
All Sex M/F 51/49 (51%) 98/52 (65%) 41/34 (55%)
subjects Age 75 ± 5 73 ± 7 75 ± 8
Education 15.7 ± 2.9 15.7 ± 3 15.1 ± 3
APOE4 +/- 22/78 (22%) 83/65 (57%) 52/23 (69%)
N 36 111 69
Aβ+ Sex M/F 20/16 (56%) 69/42 (62%) 38/31 (55%)
Age 76 ± 5 74 ± 7 74 ± 8
Education 15.9 ± 3.3 15.6 ± 3.1 15 ± 3
APOE4 +/- 15/21 (42%) 74/37 (67%) 52/17 (75%)
N 22 85 52
APOE4+ Sex M/F 15/7 (68%) 49/36 (58%) 30/22 (58%)
Age 75 ± 6 73 ± 6 74 ± 8
Education 15.6 ± 3.4 15.6 ± 3 14.8 ± 3
APOE4 +/- 22/0 (100%) 85/0 (100%) 52/0 (100%)
N 15 74 52
Aβ+ Sex M/F 10/5 (67%) 43/31 (58%) 30/22 (58%)
APOE4+ Age 77 ± 6 74 ± 7 74 ± 8
Education 15.5 ± 3.8 15.7 ± 2.9 14.8 ± 3
APOE4 +/- 15/0 (100%) 74/0 (100%) 52/0 (100%)
Table 3.4: As Table 3.1, but without using atrophy rates. Reproduced from [134]. CC BY
3.0.
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Figure 3.5: As Figure 3.1, but without using atrophy rates, i.e. using the subjects in Table
3.4. Reproduced from [134]. CC BY 3.0.
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Figure 3.6: As Figure 3.2, but without using atrophy rates. Events are ordered by the max-
imum likelihood event sequence for the whole population as shown in Figure
3.5. Reproduced from [134]. CC BY 3.0.
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Figure 3.7: As Figure 3.3, but without using atrophy rates. Two additional follow up time
points, at 36 and 48 months, met our inclusion criteria. Here, the largest dot,
at (0,0) represents 17 subjects in (A) and 9 subjects in (B). The largest dot in
(C) is at (12,12) and represents 2 subjects. In (D) all dots represent 1 subject.
Reproduced from [134]. CC BY 3.0.
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A. MCI-stable vs. MCI-converters
Balanced
Acc. (%)
Sensitivity
(%)
Specificity
(%) AUC
Threshold
Stage N-c/N-s
12 months 67 72 62 0.71 8 32/103
24 months 68 68 68 0.71 8 57/68
36 months 71 83 59 0.74 6 69/51
48 months 74 84 65 0.71 5 74/20
60 months 73 84 63 0.74 5 77/16
B. CN-stable vs. CN-converters
Balanced
Acc. (%)
Sensitivity
(%)
Specificity
(%) AUC
Threshold
Stage N-c/N-s
12 months 95 100 91 0.95 4 2/95
24 months 79 67 91 0.78 4 6/86
36 months 70 45 95 0.69 4 9/76
48 months 66 38 94 0.68 4 13/50
60 months 70 76 64 0.75 1 17/39
Table 3.5: As Table 3.2, but without using atrophy rates. Reproduced from [134]. CC BY
3.0.
3.5 Discussion
I have adapted the event-based model for use with multi-modal sporadic disease
datasets to determine the characteristic ordering of biomarker transitions and pro-
vide a staging system for disease monitoring. I use the EBM here to derive char-
acteristic biomarker orderings in AD from various subgroups of the ADNI dataset
and to provide insight into the variability of the ordering. The orderings provide de-
tailed information on the dynamics of large sets of biomarkers across the full dura-
tion of AD progression. They describe a distinct sequence of biomarker transitions
in which CSF measures are the earliest to become abnormal, followed by atrophy
rates, and finally cognitive test scores and regional brain volumes. The recovered
ordering shows less variation in the sequence for Aβ+, APOE4+ or Aβ+APOE4+
individuals than for the whole population, most likely reflecting that the former
are a more homogeneous group with archetypical AD pathology. The results of
the EBM provide entirely data-driven support for hypothetical models of AD pro-
gression, such as [74, 78, 79], without the requirement for determining biomarker
cut-points [108].
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A. MCI to AD progression
HR (CI) p-value
Corrected
HR (CI)
Corrected
p-value
EBM Stage 1.16 (1.10-1.23) 3.34 × 10−7∗ 1.17 (1.10-1.24) 3.55 × 10−7∗
Age 1.00 (0.97-1.03) 0.98 0.99 (0.96-1.02) 0.51
Education 0.98 (0.91-1.06) 0.65 0.98 (0.91-1.06) 0.6
APOE4 Carrier 1.56 (0.98-2.46) 0.059 1.32 (0.82-2.13) 0.25
Male 0.78 (0.49-1.22) 0.27 0.84 (0.50-1.43) 0.52
B. CN to MCI progression
HR (CI) p-value
Corrected
HR (CI)
Corrected
p-value
EBM Stage 1.66 (1.29-2.14) 1.01 × 10−4∗ 1.59 (1.22-2.09) 6.72 × 10−4∗
Age 1.00 (0.91-1.10) 0.99 0.99 (0.90-1.09) 0.83
Education 1.02 (0.88-1.21) 0.76 0.99 (0.84-1.15) 0.85
APOE4 Carrier 3.00 (1.16-7.78) 0.024∗ 2.02 (0.68-6.00) 0.21
Male 2.00 (0.75-5.33) 0.17 1.38 (0.46-4.14) 0.57
Table 3.6: As Table 3.3, but without using atrophy rates. Reproduced from [134]. CC BY
3.0.
The staging system provides a much more detailed evaluation of patient state
than clinical diagnoses. Importantly, it has clear clinical relevance, providing a high
accuracy classification of CN vs. AD subjects, predicting conversion from MCI
to AD and CN to MCI, and being applicable not only to short-term longitudinal
datasets (allowing atrophy measurements), but also to fully cross-sectional datasets
(one visit).
3.5.1 Event sequence
3.5.1.1 Ordering of CSF biomarkers
The ordering of the CSF biomarkers in Aβ+ and APOE4+ individuals supports
the ordering of CSF biomarkers predicted by earlier hypothetical models of AD
progression: CSF Aβ1−42, p-tau, t-tau. Since Aβ+ individuals are likely to have
early AD, this group should represent a much purer AD population than the whole
population and thus the biomarker ordering should reflect the AD ordering more
closely. Similarly, APOE4 carriers would also be predicted to shown this pattern,
given the very strong association between APOE4 and Aβ deposition [145].
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Stage 1-3 17 17 15 12 6 4 3
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Stage 9-12 63 48 27 17 8 4 1
Number of MCI subjects at risk at each follow up:
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All 100 96 93 81 59 49 35
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Stage 1-3 38 38 37 32 23 18 12
Stage 4-8 11 10 9 5 5 4 3
Stage 9-12 0 0 0 0 0 0 0
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Figure 3.8: As Figure 3.4, but without using atrophy rates. These estimated probabilities
are shown for the average population demographics (74.2 years of age, 15.6
years of education, APOE4 negative, male sex). Stages are grouped analo-
gously to Figure 3.4, so that here Normal (blue) = stage 0, CSF (green) = stages
1-3, Cognition (cyan) = stages 4-8, which includes hippocampal and entorhinal
cortex volume as well as cognitive test scores, Volume (magenta) = stages 9-12.
Reproduced from [134]. CC BY 3.0.
In the broader population, however, the results suggest that CSF t-tau and p-tau
may become abnormal prior to Aβ1−42, i.e. that there are a significant proportion
of subjects who have CSF t-tau and p-tau but not Aβ1−42 abnormalities, although
cross-validation shows higher uncertainty. Given the results in the APOE4+ and
Aβ+ populations, it seems likely that these subjects reside predominantly in the
APOE4- and Aβ - populations, and indeed estimation of the ordering using the
APOE4- and Aβ - subject groups alone supports this hypothesis, confirming that
CSF t-tau and p-tau events appear earlier than CSF Aβ1−42 (data not shown). As
discussed by Jack et al. [75, 146], there are several potential explanations for this
finding. First, that tau accumulation is a common feature of aging. Braak et al. [147]
found tau pathology to be present in healthy individuals at autopsy from as early as
20 years of age. These findings are replicated by the study of Kok et al. [148],
which found NFT deposition in a significant proportion of APOE4 negative indi-
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viduals between 30 and 59 years of age. These results, which demonstrate discrep-
ancies between the ordering in APOE4 positive and negative individuals, would be
entirely consistent with these findings, with the pattern observed in the population
as a whole reflecting a mixture of two populations - one already on the path to de-
veloping AD, the other undergoing normal ageing, with t-tau and p-tau a common
early feature in both. A second alternative is that accumulation of tau pathology
may be a very early feature of AD either for some or all subjects. Early tau pathol-
ogy may be more prevalent in APOE4- and Aβ - individuals, or alternatively, as the
subjects recruited for ADNI are age matched, early tau pathology might not be ob-
served in the APOE4+ and Aβ+ populations who would be likely to develop AD at
a younger age, and thus already have abnormal amyloid levels. A third possibility
is that amyloid accumulation does precede tau deposition, but that either current
CSF Aβ1−42 assays are less sensitive than the CSF t-tau and p-tau assays, or do
not detect the very earliest (e.g. oligomeric) abnormal Aβ moieties. Finally, as
CSF t-tau is not specific to AD and is found in other neurodegenerative diseases,
stroke, trauma and encephalitis [149], a further alternative is that individuals have
other, perhaps presymptomatic neurodegenerative diseases, such as frontotemporal
dementia (FTD), or dementia with Lewy bodies (DLB). Such individuals might be
under-represented in the APOE4+ and/or Aβ+ groups, which are enriched for AD,
and thus more prevalent in the APOE4- and Aβ - groups.
3.5.1.2 Ordering of MRI biomarkers
The ordering of MRI biomarkers from the EBM agrees with previous findings
(e.g. [113, 114]), with atrophy rates becoming abnormal prior to overall volume
changes, and volume changes occurring in a distinct sequence, starting in the hip-
pocampus and entorhinal cortex, progressing to other temporal lobe areas, the mid-
dle temporal gyrus and the fusiform gyrus, with resulting overall brain volume loss
and ventricular expansion. Results in APOE4+ subjects also support previous find-
ings [109, 150], suggesting earlier hippocampal and entorhinal volume loss, which
occur prior to MMSE reduction in the APOE4+ population and after MMSE in the
whole population and Aβ+ population.
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One perhaps surprising result of the MRI biomarker ordering is that the in-
creasing whole brain atrophy rate event occurs prior to the hippocampal atrophy
rate event both in the whole and Aβ+ population. In common with any data-driven
model of biomarker changes, the EBM orders events based on when the correspond-
ing measurements become discernibly different between cases and controls. This
may not reflect the order of appearance of underlying pathology as the precision
of the measurements may vary [98]. Thus, this result might simply reflect the in-
creased variability associated with measurement of hippocampal over whole brain
atrophy rates [151]. Other possible factors are that the results are influenced by
subjects who have a mixture of pathologies, where other processes occur alongside
AD which contribute to brain atrophy rate but not hippocampal atrophy rate, such
as vascular disease [152], or other neurodegenerative diseases [153]. Alternatively,
excess whole brain atrophy may be a core feature of all patients with AD, noting
that some individuals with pathologically confirmed AD have relatively hippocam-
pal sparing disease [154].
3.5.1.3 Uncertainty in the event sequence
The uncertainty in the event sequence, as shown by the positional variance diagrams
and cross-validation results, potentially provides useful information about the varia-
tion of biomarker ordering across the population. However, three main factors con-
tribute to the uncertainty. First, natural variation: some events may occur in differ-
ent orders in different individuals. For example, for APOE4+ subjects, hippocampal
volume loss may occur earlier than in APOE4 negative subjects [109, 150]; thus in
the whole population that combines both groups, uncertainty is higher. Second,
sampling density: when events occur in close succession, there are likely to be
fewer of the data points, which are required to determine their ordering, that sep-
arate them. Third, outliers: the dataset may include subjects who do not follow
any typical progression pattern of AD, e.g. subjects with other neurodegenerative
diseases. Although the model fitting procedure I use is somewhat robust to these
outliers, they can still affect the posterior distribution on the ordering, which mani-
fests as uncertainty.
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3.5.1.4 Using the event-based model to define cut points
A major advantage of the EBM is that the ordering of biomarkers is not dependent
on cut points. Instead, the EBM is probabilistic, calculating the probability that
each event has occurred from models of the distributions of normal and abnormal
biomarkers learned from the data rather than assuming an event has occurred when
a certain threshold value is reached. However, for comparison I derived cut point
values, given in Table 3.7, which represent the point at which the biomarker value is
equally likely to be normal or abnormal, and should therefore be similar to existing
biomarker cut points. The resulting cut points for the CSF biomarkers are very
similar to those reported by Shaw et al. [139], which were derived using a maximum
accuracy classification of autopsy confirmed AD vs. healthy controls. Importantly,
the ordering provided by the EBM can be seen not merely to reflect the ordering of
the sensitivity or specificity of these cut points.
3.5.2 Patient staging
A more directly practical output of the EBM is the data-driven staging system it
provides. Here I demonstrate, for the first time, the use of such a patient staging
measure to predict clinical outcomes. The EBM’s staging measure strongly sepa-
rates CN and AD subjects and gives comparable results to state of the art classifi-
cation techniques for prediction of conversion from MCI to AD [121] albeit with
a larger set of biomarkers. The major advantage of the EBM, a generative model,
is that it explicitly provides useful information on what drives the classification un-
like the discriminative models used in [121]. I used the EBM’s staging system to
predict conversion from CN to MCI, as well as MCI to AD, and over different fol-
low up durations. The classification results are supported by the results of the Cox
proportional hazards models, which find EBM stage to be a significant hazard for
conversion from both MCI to AD and CN to MCI. This suggests that the EBM, once
sufficient control/AD data are available, might have clinical application, providing
valuable prognostic information on an individual patient basis, and potentially for
clinical trial stratification.
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Biomarker Cut Point Sensitivity (%) Specificity (%)
Abeta (pg/ml) 189 92 63
P-tau (pg/ml) 25 88 71
T-tau (pg/ml) 80 77 73
Hippo. Atrophy (ml/year) 0.138 72 75
Brain Atrophy (ml/year) 11.9 64 78
RAVLT 33 92 91
ADAS-Cog 17 97 97
MMSE 27 100 97
Hippocampus (% TIV) 0.423 81 82
Entorhinal (% TIV) 0.214 84 83
Mid Temporal (% TIV) 1.19 75 78
Whole Brain (% TIV) 64.6 73 66
Fusiform (% TIV) 1.05 73 73
Ventricles (% TIV) 3.04 48 85
Table 3.7: Cut point values derived using the event distributions estimated by the EBM.
Volume measurements (hippocampus, entorhinal, mid temporal, fusiform,
whole brain, ventricles) are summed over the left and right hemisphere and
total intracranial volume normalized, and are recorded as a percentage of the
total intracranial volume. The sensitivity is the percentage of Alzheimers dis-
ease subjects with abnormal measurements, and specificity is the percentage of
cognitively normal subjects with normal measurements, when subjects are clas-
sified using these cut points. MMSE = Mini-Mental State Examination; RAVLT
= Rey Auditory Verbal Learning Test; TIV = total intracranial volume. Repro-
duced from [134]. CC BY 3.0.
3.5.3 Model assumptions
When interpreting these results, it is important to stress that the EBM is based on
strong assumptions, which are explicitly designed to simplify reality in order to
determine major trends in data. This section summarises the key assumptions made
in the modelling process, their potential influence on results, and possibilities to
relax the assumptions in future work.
3.5.3.1 Event Sequence
The EBM, like other data-driven models [49, 80, 81, 83, 104–106], assumes that all
subjects follow a single progression pattern. While this may be reasonable for the
Aβ+ and APOE4+ groups, the wider sporadic AD is likely to show more variability
in the event sequence due to the inherent disease heterogeneity, driven perhaps by
genetic, e.g. the presence or absence of APOE4 [155], or lifestyle factors. The sin-
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gle sequence the EBM identifies maximises compatibility within the set of subjects.
It is thus important to consider not only the most likely sequence, but also the posi-
tional variance diagram and cross-validation output, which explicitly highlight areas
of uncertainty, aiding interpretation particularly where the data departs from the as-
sumptions, for example in heterogeneous groups. The positional variance diagrams
generated directly from the EBM (Figure 3.1 A-D) underestimate the uncertainty
in the event ordering, as they do not account for uncertainty in the biomarker dis-
tribution models. The cross-validation results (Figure 3.1 E-H), on the other hand,
tend to overestimate the uncertainty, because each iteration considers only a subset
of the data. In the whole-population analysis, both mechanisms show reasonable
stability of the results, which gives some confidence to the conclusions. However,
it is important to remember that the single sequence does not represent all subjects
and the positional variance diagrams are only a crude indicator of heterogeneity of
the event sequence. More sophisticated models that can relax the assumption of a
single event ordering, see for example [156, 157], and/or provide uncertainty esti-
mates by modelling the uncertainty in the biomarker distribution parameters, are
important areas for future study.
3.5.3.2 Patient Staging
Whilst the modelling approach provides a powerful potential means of patient stag-
ing it is important that such staging information is interpreted correctly. While the
idealised model for, say, stage 3 is that all CSF biomarkers are abnormal and all
others are normal, a patient assigned stage 3 need not fit this profile exactly; stage
3 is simply the idealised stage most compatible with a given individual’s biomarker
measurements. This formulation enables the EBM to stage subjects who do not
conform to the maximum likelihood event sequence, which is important given the
heterogeneity of sporadic AD. Despite its idealised nature, the staging system has
clear clinical relevance, as demonstrated by the strong classification performance
and Cox proportional hazards Model results; those results also add confidence to
the event sequence derived from the whole population, which underpins the staging.
The probabilistic nature of the staging system presents opportunities for refinement
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in future work. Here I assign only the most likely stage, but using equation (3.2)
I can quantify the uncertainty in the stage assignment, which may contain useful
additional diagnostic and prognostic information. Moreover, also using equation
(3.2), I can obtain an overall likelihood of conforming to the event sequence, which
should be useful for detecting misdiagnoses or choosing the most likely diagnosis
from a selection of models for different diseases.
3.6 Conclusion
I have developed a data-driven model for determining biomarker ordering in spo-
radic AD (contribution 1.3.1 (a), Chapter 1, page 39). I have used the model with
the ADNI data set to support currently hypothetical models (contribution 1.3.1 (b),
Chapter 1, page 39), but further to highlight uncertainty in those orderings and vari-
ation among different subgroups. I also demonstrate that such a model can provide
a practical and effective staging system for patient prognosis.
Chapter 4
A data-driven model of biomarker
changes in dominantly-inherited
Alzheimer’s disease
This chapter details sub-contributions (c) and (d) of contribution 1.3.1 (see Chapter
1, page 39). The work presented in this chapter forms part of a collaboration led by
Neil Oxtoby to look at biomarker changes in dominantly-inherited AD using two
types of data-driven model: event-based models and differential equation models.
We analysed data from the Dominantly Inherited Alzheimer Network (DIAN): I
performed the event-based model analyses, the results of which are presented in
this chapter; Neil performed the differential equation model analyses (not included
here). I wrote the initial drafts of the event-based model sections of the manuscript,
but Neil and our co-authors contributed to the refinement of the text. This work was
presented at the Alzheimer’s Association International Conference in 2016 and is
currently in preparation for publication.
4.1 Associated publications
N. P. Oxtoby, A. L. Young, D. M. Cash, T. Benzinger, A. M. Fagan, J. C. Morris,
R. J. Bateman, N. C. Fox, J. M. Schott, and D. C. Alexander. Data-driven models
for predicting fine-grained disease progression and symptom onset in dominantly-
inherited Alzheimer’s disease without reliance upon familial age of onset. In Prepa-
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4.2 Introduction
Dominantly-inherited Alzheimer’s disease (DIAD) is a rare early onset form of
AD in which subjects can be identified presymptomatically by the presence of a
pathogenic mutation in one of three genes: amyloid precursor protein (APP), pre-
senellin 1 (PSEN1) or presenellin 2 (PSEN2). As such, it provides a window into
the presymptomatic phase of AD, which is of great interest as it is likely that treat-
ments will be most efficacious if given early.
Quantitative models of AD biomarker changes can provide a detailed picture
of disease progression and a potential mechanism to identify and stage patients
presymptomatically. Previous studies of biomarker changes in DIAD consider
biomarker values as a function of estimated years from onset (EYO) of clinical
symptoms (e.g. [49]), which can be estimated using parental age of onset, or mean
family age of onset. There is considerable uncertainty in this estimate of famil-
ial age of onset because (1) it is difficult to ascertain when an individual became
affected, and (2) there can be substantial differences in actual age of onset within
families and mutations. This uncertainty limits the utility of EYO for estimating
disease progression in presymptomatic DIAD individuals, reducing the resolution
at which biomarker ordering can be determined.
This work uses a data-driven model of disease progression to explore the
sequence of biomarker changes in DIAD without reliance upon EYO. I extend
the event-based model (EBM) for use with missing data, facilitating its applica-
tion to multi-modal DIAD data from the Dominantly Inherited Alzheimer Network
(DIAN). I further explore the utility of this model for patient staging.
4.3 Materials and methods
4.3.1 Data description
For detailed descriptive summaries of the DIAN cohort see [159]. At the sixth data
freeze, the DIAN cohort included 338 individuals with known mutation status and
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a baseline visit, aged 19-66 at baseline with up to four visits each (1.1±1.9 years
in duration), spanning up to 30 years before and up to 21 years after parental age
of symptom onset. Of these, 211 individuals carry DIAD mutations: 163 PSEN1;
17 PSEN2; and 31 APP. Mutation carriers were further subdivided into diagnos-
tic groups: ‘Cognitively Normal’ (CN), ‘Mild Cognitive Impairment’ (MCI), and
‘Alzheimer’s Disease’ (AD). The definition of these diagnostic groups is slightly
different to that of the ADNI cohort in Chapters 3, 5, 6, and 7. Here the definition
is based on the Clinical Dementia Rating (CDR) scale alone: CN is defined as a
global CDR of 0, MCI is defined as a global CDR of 0.5, AD is defined as a global
CDR of ≥ 1. In ADNI the definition is based not only on the CDR, but also on the
Mini Mental State Examination (MMSE) score, and various other clinical criteria1.
AD biomarkers were selected based on specificity to the disease, or if disease
‘signal’ is present, i.e. quantifiable distinction between mutation carriers and non-
carriers. The biomarkers include CSF measures of molecular pathology (amyloid
proteins and neurofibrillary tangles); a cognitive test score (MMSE); regional brain
volumetry from MRI, e.g. hippocampus, middle-temporal region, temporo-parietal
cortex; PiB-PET imaging measures of amyloid accumulation; and FDG-PET imag-
ing measures of glucose hypometabolism. The full set of biomarkers included in
the EBM is listed on the vertical axis of Figure 4.1. Eight biomarkers (regional
MRI volumes of the caudate, entorhinal cortex, pallidum and thalamus, and FDG
standard uptake value ratio (SUVR) measurements in the accumbens, caudate, puta-
men and thalamus) were excluded from the EBM because there were no statistically
significant differences (Bonferroni corrected p-value of p < 0.01N , where N - the to-
tal number of biomarkers considered for inclusion in the EBM - equals 29) on a
two-sample t-test comparing the sample mean of the non-carriers with the sample
mean of the mutation carriers that have an AD diagnosis. Baseline data for mutation
carriers and non-carriers was used to fit EBMs.
I used stepwise regression to remove the influence of age, years of education,
sex, and head size (total intracranial volume) prior to fitting the models. Individuals
1For details see www.adni-info.org/Scientists/Pdfs/adniproceduresmanual12.pdf.
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with missing genetic, gender, and education data were excluded. I also excluded 21
structural MRI scans from 10 participants due to image artefacts or non-AD pathol-
ogy. Table 4.1 summarises the included participant data and their demographics.
Stepwise regression is a simple statistical method for performing linear regres-
sion when it is not known beforehand if there is a statistical relationship between
the predictor variables and the measured data. Common critiscisms of stepwise re-
gression are that it is used incorrectly - in cases where there are many predictor
variables but not enough data to estimate the coefficients meaningfully, and that it
may not provide the globally optimal model. Here, there are only a few predictor
variables (age, years of education, sex, and head size), so there is enough data to
estimate meaningful coefficients if there is a relationship between the predictor and
the measured data, and a locally optimal model should be sufficient to broadly re-
move the influence of a particular variable. Using stepwise regression means that
the predictor variables are only corrected for when they reach statistical signifi-
cance. Although a lack of statistical significance does not necessarily mean there
is no relationship between the predictor variable and the measured data, only cor-
recting for statistically significant predictors does prevent unnecessary confounds
from being introduced, as well as avoiding the correction model becoming overly
complex. A complex correction model reduces the interpretability of the corrected
values of the measured data (biomarkers).
Demographic NC MC [PSEN1, PSEN2, APP]
n analysed 127 211 [163 (77%), 17 (8%), 31 (15%)]
Female (%) 75 (59%) 117 (55%) [92 (79%), 5 (4%), 20 (17%)]
ApoE4-positive (%) 37 (29%) 61 (29%) [47 (77%), 7 (11.5%), 7 (11.5%)]
ApoE4-negative (%) 90 (71%) 150 (71%) [116 (77%), 10 (7%), 24 (16%)]
Baseline Age (SD) 39 (10) 39 (10) [39 (10), 39 (10), 43 (10)]
Baseline Education (SD) 15 (3) 14 (3) [14 (3), 15 (3), 14 (3)]
Baseline EYO (SD) -7 (12) -7 (10) [-7 (10), -12 (10), -6 (9)]
Table 4.1: Demographics for DIAN participants having cross-sectional data at Data Freeze
6, used to build Event-Based Models of DIAD. Age, education and EYO mea-
sured in years. EYO = estimated years from onset; SD = standard deviation; NC
= non-carriers; MC = mutation carriers.
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4.3.2 Event-based models
I fitted an EBM to determine the most probable sequence of biomarker abnormality
events and the uncertainty in this sequence [98]. Each event represents the transi-
tion of a biomarker from a normal (as seen in non-carriers) to an abnormal level.
The probability a biomarker measurement is normal is modelled as a gaussian dis-
tribution, and estimated using data from non-carriers. The distribution of abnormal
measurements is also modelled as a gaussian distribution, but estimated by fitting a
mixture of two gaussians [98] to data from all mutation carriers: the first gaussian
models the distribution of normal measurements, and is kept fixed to the values es-
timated from non-carriers; the second gaussian models the distribution of abnormal
measurements, and is optimised using data from mutation carriers.
The sequence of events was estimated in various population subgroups: all
191 mutation carriers; 150 PSEN1 mutation carriers; 14 PSEN2 mutation carriers;
and 26 APP mutation carriers. I also considered separate EBM models by APOE4
status: 58 mutation carriers who were APOE4-positive (with one or more APOE4
alleles), and 133 mutation carriers who were APOE4-negative. I accounted for
missing data by imputing biomarker values such that missing measurements had
an equal probability of being normal or abnormal, and thus do not influence the
population sequence. I found the value for imputation by simply computing the
points at which the distribution of normal and abnormal measurements intersect,
and choosing the value that was between the means of the two distributions. The
uncertainty in the event sequence was estimated by taking Markov Chain Monte
Carlo (MCMC) samples from the EBM [98]. Cross-validation of the event sequence
was performed by refitting the biomarker event distributions and the event sequence
for 100 bootstrap samples from each data subset.
I assigned subjects to patient stages based on their most probable position along
the most probable event sequence [134] for all mutation carriers combined. I as-
sessed the efficacy of the patient staging system using only subjects with data avail-
able for all biomarkers (n = 30, total of 42 followup visits), as missing entries cause
uncertainty in a subject’s model stage.
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4.3.3 Implementation
All experiments were performed using Matlab on a standard workstation (Intel Core
i7, 3.1 GHz, 8GB memory). Stepwise regression was implemented using the Matlab
‘stepwiselm’ algorithm. The event distribution (gaussian mixture model) parame-
ters were optimised using the ‘fmincon’ constrained optimisation solver with the
‘sqp’ - sequential quadratic programming - method. All of the gaussian mixture
model fits were assessed visually to ensure the solutions were physically plausible.
To find the characteristic event sequence S¯, I performed 2,500 iterations of a greedy
ascent algorithm (as in [98]), initialised from 25 random start points. I checked
that the start points converged to a single maximum to ensure the global optimum
had been found. I then ran an MCMC algorithm (as in [98]) to draw samples from
the posterior distribution P(S|X). I ran the MCMC algorithm for 100,000 itera-
tions, checking that the MCMC trace showed good mixing properties. I initialised
the MCMC algorithm at S¯ so a burn-in period was not required. Computational
complexity is as in Chapter 3.
4.4 Results
4.4.1 Event sequences
4.4.1.1 All mutation carriers
Figure 4.1 is a positional variance diagram of the maximum likelihood sequence
of biomarker abnormality events (top to bottom), and its uncertainty (left to right),
across all available 211 mutation carriers in the DIAN dataset. Grayscale intensity
represents confidence in each events position within the sequence, and is calculated
from MCMC samples from the EBM [134].
The EBM reveals a distinct sequence of biomarker abnormality in DIAD: re-
gional (cortical then striatal) amyloid deposition on PiB-PET scans; CSF measures
of neuronal injury/neurofibrillary tangles (total tau and phosphorylated tau levels)
and amyloid plaques (Aβ42 and Aβ40/42 ratio); MR measures of volume loss
in the putamen and nucleus accumbens; global cognition (MMSE score). There-
after the ordering in which FDG-PET hypometabolism and other MRI measures
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Figure 4.1: EBM progression of DIAD represented as positional variance diagrams. Left:
EBM estimated on all mutation carriers in the DIAN dataset. Right: cross-
validation through bootstrapping. The vertical ordering (top to bottom) is given
by the maximum likelihood sequence estimated by the model. Grayscale in-
tensity (left to right) represents MCMC-sampled posterior confidence in each
events position.
become abnormal is less certain. The ordering shows high certainty early in the
ordering of these biomarkers (as reflected by the more solid blocks along the diag-
onal), with lower certainty later in the ordering of regional volumes (more diffuse
grey blocks straying from the diagonal). This pattern (left) persists under cross-
validation (right).
4.4.1.2 Population subgroups
I also fit the EBM to subgroups of the mutation carriers in the DIAN data set. Fig-
ure 4.2 shows positional variance diagrams of the biomarker abnormality event se-
quence in APOE4-positive and APOE4-negative participants (those with and with-
out the apolipoprotein-ε4 allele), and Figure 4.3 shows equivalent results for the
three DIAD mutation types in DIAN: PSEN1, PSEN2, and APP. For ease of com-
parison, the sequence ordering on the vertical axes of each plot is chosen to be the
most probable ordering from Figure 4.1 (all mutation carriers).
Broadly speaking, there is good agreement of the event sequences across sub-
groups in Figures 4.2 and 4.3, with some subtle differences between groups: ear-
lier CSF Aβ42 and Aβ40/42 ratio in the APOE4-positive and APP groups; earlier
fusiform volume for the PSEN2 group; earlier putamen volume abnormality for the
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Figure 4.2: As figure 4.1, but for APOE4-positive and APOE4-negative mutation carriers.
APP group. The uncertainty is high in the subgroup orderings, due in part to the
low numbers of participants in these groups, which reduces power to draw concrete
conclusions based on these subtle differences between groups.
4.4.2 Patient staging
Figure 4.4 demonstrates the fine-grained staging capabilities of the EBM. Using
the model for all mutation types (Figure 4.1), each individual in the DIAN dataset
was assigned a disease stage that best reflects their measurements (see Methods
section and [134]). The staging proportions are shown in Figure 4.4 A, differenti-
ated by broad diagnostic groups (CN: Cognitively Normal, global CDR = 0; MCI:
Mild Cognitive Impairment, global CDR = 0.5; AD: probable dementia due to AD,
global CDR ≥ 1). Longitudinal consistency of staging is shown in Figure 4.4 B,
where each individual’s baseline stage is plotted against available follow-up stages
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Figure 4.3: As figure 4.1, but for PSEN1, PSEN2, and APP mutation carriers.
between baseline and months 12/24/36.
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A. B.
Figure 4.4: DIAD: EBM staging results. A. Proportions grouped by diagnostic group: all
noncarriers are at stage zero (black), and advancing disease stage is correlated
strongly with cognitive impairment (green to blue to red). B. Staging consis-
tency across visits within three years of baseline for the n = 30 participants with
complete longitudinal data (18 MCs; 16 PSEN1, 2 APP). Most individuals ad-
vance to a later stage (disease progresses towards the right). Green circles show
the two individuals who regressed to earlier EBM stages, which arises in both
cases due to discordant amyloid measurements between CSF and PiB-PET. The
triangles indicate clinical progressors (CN to MCI in blue; MCI to AD in red).
BL: baseline; M: month; CN: Cognitively Normal (global CDR = 0); MCI:
Mild Cognitive Impairment (global CDR = 0.5); AD: probable dementia due to
DIAD (global CDR ≥ 1).
4.4.2.1 Cross-sectional distribution of stages
The baseline staging in Figure 4.4 A shows good separation of diagnostic groups:
all of the non-carriers are assigned to stage 0 (black), CN mutation carriers (green)
are at earlier model stages, mutation carriers diagnosed with probable AD dementia
(red) are at late model stages, and mutation carriers diagnosed with MCI (blue) are
more spread out across the stages. Within carriers, the model shows high classifica-
tion accuracy for separating those who are CN from those with probable dementia:
a balanced accuracy of 93% is achieved by classifying participants above stage 10
(putamen volume abnormality) as having probable dementia.
4.4.2.2 Longitudinal consistency
The follow-up staging in Figure 4.4 B shows good longitudinal consistency: at 32
of 36 (89%) follow-up time points the model stage is the same or it increased; at
34 of 36 (94%) follow-up time points the stage was either unchanged, it increased,
or it decreased within the uncertainty of the ordering. This included the clinical
converters, which are shown with triangles (CN to MCI in green; MCI to AD in
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red). The remaining two follow-up time points at which the model stage decreased
(green circles in Figure 4.4 B) have inconsistent amyloid levels between CSF and
regional PiB-PET, potentially due to discord between these biomarkers as has been
observed in some individuals [160, 161].
4.5 Discussion
I have reported data-driven estimates of DIAD progression using an event-based
modelling approach without reliance upon the use of familial age of onset as a mea-
sure of disease progression. The model reveals the sequence in which biomarkers
of DIAD become abnormal. The resulting sequence broadly agrees with current
understanding of DIAD, but provides superior detail compared to previous studies.
4.5.1 Event sequences
The EBM finds a distinct ordering of biomarker abnormality events in mutation car-
riers: amyloid deposition measured by PiB-PET, neurofibrillary tangles and amy-
loid plaques in CSF, followed by an AD-characteristic pattern of regional volume
loss on MRI, which is interspersed with declining cognitive test scores and hy-
pometabolism measured by FDG-PET. Although the sequence shows strong agree-
ment across different mutation types (APP, PSEN1, PSEN2), and APOE4 positiv-
ity and negativity, I found some small, subtle differences that warrant further in-
vestigation. For example, there was earlier abnormality in CSF Aβ42 (than CSF
tau) in the APP and APOE4-positive groups, but the reverse was found in other
groups. The latter could be explained by non-monotonic dynamics of CSF Aβ42
in DIAD (an increase followed by a decrease) as suggested by results in previ-
ous investigations [162, 163]. Previous multimodal biomarker studies of DIAD,
e.g. [49, 164, 165], are in general agreement with the EBM sequence: amyloidosis
precedes hypometabolism and atrophy. Importantly, all previous approaches relied
upon a familial age of symptom onset as a proxy for disease progression, which in-
trinsically limits the accuracy of predictions due to the known imprecision in such
estimates [166].
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4.5.2 Patient staging
The staging system provided by the EBM has potential practical utility. In partic-
ular, it provides high classification accuracy for discriminating between presymp-
tomatic and symptomatic DIAD mutation carriers; it correctly assigned all non-
carriers to the ‘completely normal’ category (stage 0); and it showed good longi-
tudinal consistency, with EBM stage generally increasing or remaining stable at
patient follow-up. Thus it may be useful for identifying and monitoring presymp-
tomatic individuals for clinical trials.
The EBM stages correlate strongly with cognitive status: CN participants were
assigned early model stages, symptomatic AD participants late model stages, and
MCI participants were more spread out across the stages. The MCI group in DIAD
were the most heterogeneous, which is in agreement with the EBM results for spo-
radic AD [134], but possibly for different reasons. One contributing factor in DIAD
is that the MCI group may include unaffected mutation carriers whose anxiety about
their mutation status manifested as apparent cognitive abnormality and contributed
to a diagnosis of MCI. In any case, the fine-grained disease staging offered by the
EBM can shed light upon the heterogeneity contained within the MCI diagnostic
stage.
4.6 Conclusion
I have proposed an extension of the EBM to account for missing data (contribution
1.3.1 (c), Chapter 1, page 39), facilitating the application of the EBM in DIAD to
determine the sequence of biomarker changes without reliance upon EYO (contri-
bution 1.3.1 (d), Chapter 1, page 39). I have reported estimates of this sequence in
various population subgroups, and demonstrated the ability of the EBM to provide
fine-grained patient staging.
Chapter 5
A simulation system for biomarker
evolution in neurodegenerative
disease
This chapter details contribution 1.3.2 (see Chapter 1, page 40). The work presented
in this chapter was published in Medical Image Analysis in 2015. I developed the
methodology, performed the analysis and wrote the manuscript; my co-authors pro-
vided feedback on the methodology and the manuscript.
5.1 Associated publications
A. L. Young, N. P. Oxtoby, S. Ourselin, J. M. Schott, and D. C. Alexander. A
simulation system for biomarker evolution in neurodegenerative disease. Medical
Image Analysis, 26(1):47–56, 2015
5.2 Introduction
Data-driven models of disease progression allow longitudinal trends to be recon-
structed from cross-sectional or short-term longitudinal datasets. Basic techniques
to analyse biomarker trajectories involve staging subjects and then comparing
biomarker levels across different disease stages [49,83,84,104–106,109,110,168].
This limits the temporal resolution of the model to the accuracy of the patient stag-
ing. Data-driven models do not require prior knowledge of the stage of a patient
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along the disease, allowing the reconstruction of a much more fine-grained pic-
ture of disease progression. Differential equation models (DEMs) [81,82,110,131]
model short-term longitudinal patient data as a differential cross-section of a com-
mon longitudinal biomarker trajectory; the overall biomarker trajectory is obtained
by integrating all of the subject’s differential cross-sections. Jedynak et al. [132] and
Donohue et al. [128] make a similar set of assumptions to formulate their disease
progression models, again modelling each subject’s biomarker data as a snapshot of
a common progression curve, but further allowing for variation in individual pro-
gression rates. Another data-driven model, the event-based model (EBM) [98, 134]
considers disease progression as a sequence of events at which biomarkers become
abnormal, thereby allowing direct determination of biomarker ordering from en-
tirely cross-sectional data.
However, such data-driven models typically depend on idealised assumptions
about the data that they are modelling. First, that all subjects follow the same pro-
gression pattern. This is not true in general as large cross-sectional datasets will
contain subjects who have different disease subtypes, mixed pathology, have been
misdiagnosed, are yet to develop other diseases, or who are aging healthily. Such
outliers are particularly prevalent in presymptomatic populations where the diag-
nostic outcome is unknown. Second, a set of parameters that define normal and
abnormal biomarker levels. This is difficult to determine due to the high propor-
tions of presymptomatic subjects in typical control populations (for example, a sig-
nificant proportion of cognitively normal (CN) elderly subjects have been found to
have biomarker changes consistent with AD [135, 136]), and misdiagnosis in dis-
eased populations. Third, that the underlying disease time course is well sampled.
In reality, presymptomatic subjects may not go on to develop the neurodegenera-
tive disease being investigated and therefore the early disease stages might be under
sampled or misrepresented, and diseased subjects may not be representative of the
very late disease stages where the population thins and severe illness can make data
hard to collect.
Here I present a simulation system to generate synthetic biomarker datasets
5.3. Materials and methods 107
that represent the heterogeneity of sporadic neurodegenerative diseases. Although
still based on a model of disease progression, it encapsulates many more variables
than the simpler models that are parsimonious enough to fit to current data sets.
Thus it provides a platform to evaluate the effect of more brutal simplifications
necessary to obtain robust fitting results from working models. I demonstrate this
simulation system by evaluating the performance of the EBM and a DEM in deter-
mining the sequence of biomarker abnormality from simulated data.
5.3 Materials and methods
5.3.1 Generative model of data
I assume the following generative model of sporadic disease datasets (Figure 5.1). A
set of subjects with: follow-up time points, ~f , from a follow-up distribution P(~f );
disease subtypes, s, from a subtype distribution P(s); each set of follow-up time
points correspond to a set of time points along the disease, ~t, from a time point
distribution P(~t|~f ). At each time point a subset, ~e, of the biomarkers included in
the study are measured for a particular subject according to a biomarker collection
distribution P(~e|~f ), i.e. a subset of the biomarkers included in the study are mea-
sured in the subset of subjects that have a particular follow-up visit. Each subject
has a set of biomarker measurements, ~x~e, at each time point t ∈~t. The collected
biomarker measurements are simulated from a trajectory evolution function z(t,~θ)
with parameters ~θ from a trajectory parameter distribution P(~θ |s, t), and measure-
ment noise ε perturbation from a measurement noise distribution P(ε). The data for
each collected biomarker for each patient for each time point is then x= z(t,~θ)+ε;
biomarkers that are not collected are recorded as missing data. Each subject is given
a particular diagnosis d from a diagnosis distribution P(d|~xe).
5.3.2 Simulating sporadic Alzheimer’s disease
5.3.2.1 ADNI dataset
I downloaded baseline and follow-up data from all subjects in ADNI-1 giving a
set of 819 subjects, (229 CN, 398 mild cognitive impairment (MCI), 192 AD). I
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Figure 5.1: Generative model of sporadic disease datasets used by the simulation system.
Reproduced from [167]. CC BY 4.0.
included the following set of biomarker data: CSF Aβ1−42, CSF t-tau, CSF p-tau;
the Mini Mental State Examination (MMSE) [85]; baseline MRI volumes of whole
brain, hippocampus and ventricles; FDG-PET. I selected these biomarkers to repre-
sent the different types of measurements that are routinely collected in AD research,
and to include biomarkers that become dynamic during the pre-symptomatic and
symptomatic phases of AD. MRI volumes were corrected for differences in head
size by regressing against total intracranial volume (TIV). FDG-PET uptake values
were averaged over the angular gyrus, inferior temporal gyrus, and posterior cin-
gulate gyrus. For simplicity I only model baseline CSF, as modelling longitudinal
CSF requires a new set of measurements for each time point to be modelled, as all
the CSF measurements are re-processed once a new follow up is completed.
5.3.2.2 Generic Alzheimer’s disease simulation model
I start from a generic model of AD, adapting the settings to perform a stability
analysis of the EBM and DEM. I develop a generic model of AD that is based on
the following assumptions:
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• At baseline a set of time points ~t0 are sampled from a uniform baseline time
point distribution P(t0)=Unif(0, tr), where tr is the range of the initial subject
time points.
• The follow-up time points are sampled sequentially from a set of possible
follow-up times under the assumption that a proportion, r f , of subjects drop
out per year.
• The time points are assumed to follow a normal distribution centred around
the time after follow-up, i.e. P(t| f ) = Norm( f + t0,σt).
• The subtype distribution is P(s) =Cat(ps,m), where ps is the probability that a
subject is assigned subtype s. By default there is only one disease subtype and
so all subjects follow the typical AD set of biomarker trajectories. Alternative
subtypes are used to simulate subjects that do not follow the typical AD se-
quence of biomarker abnormality, e.g. subjects with other neurodegenerative
diseases or who are aging normally.
• The collected subset of biomarkers, ~e, is sampled sequentially for the avail-
able time points by modelling an initial proportion of subjects, pe, in which
the biomarker is collected and a drop out rate per year, re, i.e. of the subjects
that remain in the study, only a proportion of these have a measurement for a
particular biomarker.
• The trajectory evolution function is sigmoidal, as has been hypothesized by
Jack et al. [74], with parameters ~θ = (a,r,c,g), where a is the trajectory min-
imum, r the range (difference between trajectory maximum and minimum
value), c the centre point and g the gradient. To make the magnitude of
the gradient a more intuitive quantity, I re-parameterise g so that it is the
biomarker ‘transition time’. I define this as τ = 4g , i.e. it is the time taken for
the tangent to the sigmoid at the centre point, c, to transition from the mini-
mum biomarker value, a, to the maximum biomarker value, a+ r. Hence, I
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have
z(t,~θ) = a+
r
1+ exp
(−4τ (t− c)) ,
with parameters ~θ = (a,r,c,τ).
• The trajectory parameters are normally distributed according to the trajectory
parameter distributions:
– P(a) = Norm(µa,Σa)
– P(s) = Norm(µr,Σr)
– P(c|s) = Norm(µc,s,Σc)
– P(τ) = Norm(µτ ,Στ)
The parameters µa, µr, µc,s, µτ are the trajectory parameter means; Σa, Σr,
Σc,s, Στ are the inter-subject covariances of the trajectory parameters.
• The measurement noise distribution follows a normal distribution with mean
0 and standard deviation ν , i.e. P(ε) = Norm(0,ν).
• There are three diagnoses, d = {CN,MCI,AD}, as there are in ADNI,
that follow a categorical distribution: P(d|x) = Cat(pCN, pMCI, pAD), where
pCN is the probability that a subject is assigned a CN diagnosis, pMCI is
the probability that a subject is assigned a MCI diagnosis, and pAD is the
probability that a subject is assigned an AD diagnosis. The probability of
each diagnosis pd is evaluated using each subjects biomarker data, x, as
pd ∝∏Ii=1 Norm(xi,µd,i,σd,i).
I tested the agreement between data sets generated using the default parameter val-
ues and ADNI by calculating the Bhattacharyya coefficient [169], BC, between sim-
ulated data sets and data from ADNI. The Bhattacharyya coefficient measures the
similarity between two probability distributions, ranging from 0 to 1, where a Bhat-
tacharyya coefficient of 0 corresponds to no overlap.
DB =
1
8
µTΣ−1µ+
1
2
ln
(
det(Σ)√
det(ΣADNI)det(Σsimulated)
)
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where
µ = µADNI−µsimulated,
and
Σ=
ΣADNI+Σsimulated
2
.
The Bhattacharyya coefficient, BC, is BC = exp(−DB).
I find that data sets generated using the default parameters values show good
agreement with the ADNI data set, giving an average Bhattacharyya coefficient
across 25 sample data sets of 0.99 when considering the biomarkers to be indepen-
dent, and 0.83 when considering the dependence between biomarkers.
5.3.2.3 Datasets for event-based model stability analysis
I use the generic AD model to perform a set of simulations to assess how robust the
EBM and DEM are to different choices of parameters.
For these experiments I assume the following set of default parameters (Table
5.1, Figure 5.2). These default parameters are intended as an idealized basis for the
stability analysis, from which each parameter can be varied individually so as to
explore the robustness of the models to variations in a particular parameter, inde-
pendently of other effects. For each experiment I generate synthetic datasets that
have 800 subjects and the biomarker set: CSF Aβ1−42, CSF t-tau, CSF p-tau, FDG,
MMSE, hippocampal volume, brain volume, ventricular volume.
• Baseline time points: tr = 20, i.e. there is a range of 20 years in which a
subject’s baseline visit might lie.
• Follow-ups: There are 11 possible follow-up times, as there are in ADNI, at
0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, and 9 years from baseline. The drop out rate per
year, r f , is estimated from ADNI as 10%.
• Time points: the standard deviation, σt , of the actual time at which each
follow-up is taken is approximated from ADNI as σt = 0.05 for t = 0.5,1,1.5,
and σt = 0.1 for t ≥ 2 (at baseline σt = 0).
• Subtype: ps=1 = 1, i.e. all subjects have the same disease subtype by default.
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• Biomarker collection: The proportion of subjects in which each biomarker
is collected at baseline, pe, and the drop out rate per year, re, are estimated
from ADNI as pe = 100%,85%,55%,50%, and re = 0%,10%,5%,100% for
cognitive test scores, MRI volumes, FDG-PET hypometabolism, and CSF
levels respectively (i.e. only baseline CSF modelled).
• Trajectory parameters: µa is estimated from the mean biomarker value in
CN subjects from ADNI (Table 5.1). µr is estimated as the difference be-
tween the mean biomarker value in AD and CN subjects from ADNI. (Table
5.1) For CSF Aβ1−42 I use only amyloid negative CN subjects, and amy-
loid positive AD subjects (amyloid positive is defined as CSF Aβ1−42 < 192
pg/ml). I chose settings for µc so that the biomarkers become abnormal in the
order: Abeta, P-tau, T-tau, FDG-PET, Hippocampal volume, MMSE, Ventri-
cles, Whole brain volume (Table 5.1). I set µτ to 5 years for all biomarkers
(Table 5.1).
• Trajectory inter-subject covariance: Σa is estimated from the set of 28 amy-
loid negative CN ADNI subjects at baseline that have measurements for all
biomarkers (Table 5.1), I remove the contribution of measurement noise by
subtracting the estimated measurement variance level (see next bullet point).
By default I set Σr = 0, Σc = 0, Στ = 0.
• Measurement noise: I estimate the measurement noise level ν for each
biomarker using baseline and 6 month follow-up measurements in CN sub-
jects from ADNI (Table 5.1) under the assumption that fluctuations in con-
trols over a 6 month period are representative of measurement noise. For
CSF I only have baseline measurements and so I set the measurement noise
to 0, i.e. I model the variance as being purely inter-subject covariance rather
than removing the contribution of measurement noise as I do for the other
biomarkers.
• Diagnosis: I estimate µd and σd for each diagnostic group using the available
data for each biomarker from ADNI.
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In the experiments I vary each of the following parameters of the simulations in
turn, and set the rest of the parameters to their default value, generating 25 synthetic
datasets for each new parameter value, and fitting the EBM to each sample dataset.
Abeta P-tau T-tau FDG Hippo MMSE Vents Brain
µa 243 20 63 6.39 903 29.1 -7400 34300
µr -110 23 63 -1.01 -1630 -5.78 13600 -64000
µc 5 6 7 8 10 12 14 15
µτ 5 5 5 5 5 5 5 5
ν2
µ2r
0 0 0 0.030 0.006 0.013 0.004 0.022
Abeta 0.058 0.001 -0.004 0.014 -0.001 0.002 0.013 0.007
P-tau 0.150 0.126 0.041 -0.069 -0.015 0.048 -0.106
T-tau 0.178 0.031 -0.084 -0.003 -0.013 -0.068
Σa
µrµTr
FDG 0.308 0.064 0.008 -0.191 0.109
Hippo 0.198 -0.007 -0.320 0.326
MMSE 0.055 0.009 -0.031
Vents 1.519 -0.896
Brain 0.960
Table 5.1: Default parameter values for the EBM. µa = mean trajectory minimum, µr =
mean trajectory range, µc = mean trajectory centre point (years), µτ = mean
trajectory transition time (years). ν
2
µ2r
= biomarker measurement variance, nor-
malised by the range of the trajectory. ΣaµrµTr = covariance of the trajectory min-
imum, normalised by the range of the trajectory. All other covariance matrices
are set to 0 by default. Reproduced from [167]. CC BY 4.0.
5.3.2.4 Datasets for differential equation model stability analysis
For the DEM experiments I initially fitted a DEM to each biomarker using the de-
fault simulation settings for the EBM. However, these experiments show that the
DEM does not perform well for the levels of noise estimated from ADNI. I there-
fore simplify the default settings for the DEM to characterise the types of noise the
DEM is most sensitive to. By default I instead generate a single idealized (zero
noise) biomarker trajectory with the following settings.
• Biomarker collection: pe = 100%, re = 0%.
• Trajectory parameters: µa = 0, µr = 1, µc = 10, µτ = 5.
• Trajectory inter-subject covariance: Σa = 0, Σr = 0,Σc = 0, Στ = 0.
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Figure 5.2: Example simulated FDG-PET, subject diagnosis, and time point data generated
using default parameter values for the EBM (Table 5.1). (A) Simulated base-
line FDG-PET data (curve shows mean trajectory); (B) simulated FDG-PET
follow-up data for cognitively normal subjects (green), mild cognitive impair-
ment subjects (blue), and Alzheimer’s disease subjects (red); (C) same as (B)
but plotted against follow up time rather than time point along the disease.
(D)-(F) Histogram of the number of (D) cognitively normal, (E) mild cognitive
impairment and (F) Alzheimer’s disease subjects, at each time point at baseline.
Reproduced from [167]. CC BY 4.0.
5.3. Materials and methods 115
• Measurement noise: ν = 0.
In the experiments I again vary each of the following parameters of the simulations
in turn, and set the rest of the parameters to their default value, generating 25 syn-
thetic datasets for each new parameter value, and fitting the DEM to each sample
dataset.
5.3.3 The event-based model
The EBM [98] considers disease progression as a sequence of events at which
biomarkers transition from a normal level, i.e. as seen in healthy controls, to an
abnormal level, i.e. as seen in AD subjects. The maximum likelihood (ML) order-
ing of these events can be determined by finding the sequence S that maximizes the
data likelihood
P(X |S) =
J
∏
j=1
[
I
∑
k=0
(
P(k)
k
∏
i=1
P(xi j|Ei)
I
∏
i=k+1
P(xi j|¬Ei)
)]
Here, Ei, i = 1 . . . I, are events, whose occurrence is informed by the correspond-
ing measurements xi j of biomarker i in subject j, j = 1 . . .J via the biomarker
distributions: the likelihood that an event has occurred and thus the correspond-
ing biomarker measurement xi j is abnormal, P(xi j|Ei), or has yet to occur and so
the corresponding biomarker measurement is normal, P(xi j|¬Ei). P(k) is the prior
likelihood of being at stage k, where events E1, . . . ,Ek have occurred, and events
Ek+1, . . . ,EK have yet to occur. I assume no prior knowledge of disease stage
by choosing the prior P(k) to be uniform. I fit a mixture of normal distributions
to determine the mean, µE and µ¬E , and standard deviation, σE and σ¬E , of the
biomarker distributions P(x|E), and P(x|¬E). To guide the fitting in cases where the
biomarker distributions overlap significantly, I constrain the parameters so that the
standard deviation of each distribution is less than or equal to the standard deviation
of biomarker measurements in the AD and control (CN) population respectively.
For missing biomarker values I impute the value of x such that P(x|E) = P(x|¬E).
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5.3.4 Differential equation model
I fit the DEM to each biomarker separately using a similar technique to Villemagne
et al. [81]. I first calculate the rate of change in each subject by fitting a least-square
linear regression to the first three available time points for each participant. For
each simulation I compared fitting a linear model to the first three available time
points (baseline, 0.5 years and 1 year) with fitting a linear model to the three or
more available time points (up to a maximum of 9 years). I found that fitting the
linear model to the first three available time points produced trajectories with the
least error for all experiments, and so I only present results for fitting to the first
three available time points. I fit a quadratic differential equation model (representa-
tive of the sigmoidal biomarker dynamics modelled in the simulations) to the mean
biomarker value of each subject xi, and rate of change of each subject ∂xi∂ t estimated
from the linear model, i.e. I optimise for A, B and C over all subjects i such that:
∂xi
∂ t
= Ax2i +Bxi+C
I then integrate this quadratic differential equation model to get the average trajec-
tory across the population:
x(t) =
√
4AC−B2 tan
(
1
2(k+ t)
√
4AC−B2
)
−B
2A
Where k is an unknown constant to be specified by choosing an initial condition.
5.3.5 Evaluation metrics
5.3.5.1 Event-based model biomarker distribution parameters
Defining a ground truth for the biomarker distribution parameters when the
biomarker trajectories are not binary is not straightforward, requiring the portion
of the biomarker trajectory belonging to the ‘normal’ and ‘abnormal’ biomarker
distribution to be defined. However, to explore the effect of the accuracy of the
biomarker distribution on the estimation of the event sequence I ran each of the ex-
periments for two settings: one where I estimated the biomarker distributions and
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another where these were fixed. I fix the biomarker distributions so that µ¬E = µa,
µE = µa + µr, σ¬E = σE =
√
diag(Σa)+ν2, where diag(Σ) is the diagonal of the
covariance matrix Σ. µa,m and µb,m are calculated from the average subject de-
mographics. Whilst these may not be the ‘true’ biomarker distribution parameters,
they provide an estimate of how the EBM behaves for a reasonable setting of the
biomarker distribution parameters.
5.3.5.2 Event-based model Kendall’s tau distance
A key outcome measure I am interested in is the model’s ability to recover the ML
sequence from the simulated data. This can be evaluated by measuring the Kendall’s
tau distance (a measure of the similarity of two sequences) between the recovered
sequence and a ground truth event sequence. The Kendall’s tau distance is the total
number of pairwise disagreements between two sequences, pi and pi0:
dK(pi,pi0) = ∑
l≺pi j
1 j≺pi0 l
Where pi and pi0 are permutations and l ≺pi j means that l precedes j in the per-
mutation pi . Here I use the normalized Kendall’s tau distance, i.e. I divide by the
maximum distance, which is the total number of possible pairs: n!2!(n−2)! , where n is
the number of events in the sequence.
5.3.5.3 Event-based model positional variance diagrams
I use positional variance diagrams (PVDs) to look at the location of variations in
the ML sequence (rather than just the extent, which I measure using the Kendall’s
tau distance) for each simulation. Each entry of the positional variance diagram is
the proportion of samples in which a particular event appears at that position in the
ML sequence.
5.3.5.4 Differential equation model transition time
I compare the transition time of the simulated trajectories across the population with
the ground truth simulation setting of the transition time, µτ .
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5.3.6 Implementation
All experiments were performed using Matlab on a standard workstation (Intel Core
i7, 3.1 GHz, 8GB memory). The event-based model event distribution parameters
and maximum likelihood sequence were estimated using the same procedure as
Chapters 3 and 4. All of the gaussian mixture model fits were assessed visually
to ensure the solutions were physically plausible. Here to find the characteristic
event sequence S¯, I performed 1,000 iterations of a greedy ascent algorithm (as
in [98]), initialised from 5 random start points. Less start points and iterations
were sufficient as the simulated set of events is small (only eight biomarkers). I
checked that the start points converged to a single maximum to ensure the global
optimum had been found. The differential equation model was fitted using the
Matlab ‘polyfit’ function, the integrated model fits were computed analytically.
5.4 Results
5.4.1 Event-based model stability analysis
I performed a stability analysis of the EBM to test how robust the model is to dif-
ferent types of heterogeneity that are likely to exist in sporadic AD datasets. As
outlined in Section 5.3.5.1, I consider two scenarios: (1) estimated event distribu-
tions and (2) fixed event distributions. Scenario (1) is the typical scenario for fitting
the event-based model to sporadic Alzheimer’s disease. In this scenario both the
distribution of normal and abnormal biomarker values (the event distributions) and
the sequence of biomarker abnormality events need to be estimated. Scenario (2) is
a more idealistic scenario in which I fix the event distributions to a reasonable value
using the parameters of the simulated data. Together these two scenarios allow the
effect of the accuracy of the event distributions on the accuracy of the sequence to
be disentangled.
5.4.1.1 Default parameter values
Fitting the EBM to datasets generated using the default parameter values (Figure
5.3) gives a Kendall’s tau distance of 0.11 ± 0.05 when estimating the event dis-
tributions from the data, and 0.01 ± 0.01 for fixed event distributions. Repeating
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this experiment without any missing biomarker values only slightly improves the
Kendall’s tau distance despite the increase in the number of data points; 0.10 ±
0.09 for estimated event distributions, and 0.00 ± 0.01 for fixed event distributions,
showing that imputing the data such that P(x|E) = P(x|¬E) (see Section 5.3.3) is
a valid technique for fitting the EBM to data with missing biomarker values. It is
worth noting that in all the simulations the inter-subject variation setting, which is
estimated from ADNI, may be larger than the actual level of inter-subject variation.
This is because CN subjects in ADNI may originate from a range of underlying
time points along the biomarker trajectories.
A" B"
C" D"
Figure 5.3: Results of applying the EBM to synthetic data with missing values (A)-(B)
and without missing values (C)-(D) generated using the default parameters. In
(A) and (C) the event distributions are estimated, and in (B) and (D) the event
distributions are fixed. Reproduced from [167]. CC BY 4.0.
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5.4.1.2 Experiment 1: Noise levels
I ran five simulations to look at the effect of different levels of: (A) measurement
noise ν , (B) inter-subject covariance of the trajectory minimum Σa, (C) inter-subject
covariance of the trajectory range Σr, (D) inter-subject covariance of the trajectory
centre Σc,s, (E) inter-subject covariance of the trajectory transition time Στ . For
each of the respective simulations I vary the noise level as a proportion p of (A)
the estimated measurement noise from ADNI (see Section 5.3.2.3 and Table 5.1),
and as a proportion p2 of the covariance matrices: (B) the estimated inter-subject
covariance of the trajectory minimum from ADNI (see Section 5.3.2.3 and Table
5.1), (C) the square of the mean of the trajectory range µ2r estimated from ADNI
(see Section 5.3.2.3 and Table 5.1), (D) the range of the trajectory centre points
squared, 102 years, (E) the range of the baseline time points squared, 202 years.
For simulations (C), (D), and (E) I assume a diagonal covariance matrix. Vary-
ing the measurement noise ν (Table 5.2 A: Experiment A) has little effect on the
Kendall’s tau distance between the sample event sequences and the ground truth
as the estimated measurement noise level is small compared to the inter-subject
covariance of the trajectory minimum (Table 5.1). Varying the inter-subject covari-
ance of the trajectory minimum Σa (Table 5.2 A: Experiment B) has a large effect
on the Kendall’s tau distance for the estimated event distributions, but little effect
for fixed event distributions. This shows that it is difficult to estimate the parameters
of the event distributions for high biomarker inter-subject variance levels. For very
low variance levels on Σa the Kendall’s tau distance increases again for both fixed
and estimated event distributions. This is probably because at very low variance
the event distributions don’t model the biomarker values over the central portion of
the biomarker trajectory, where the trajectory transitions from the minimum to the
maximum value. This makes it ambiguous as to whether the biomarker is normal
or abnormal during the trajectory transition, making it difficult for the EBM to or-
der the biomarkers. The EBM is robust to inter-subject variation in the trajectory
range Σr (Table 5.2 A: Experiment C), giving a similar Kendall’s tau distance to
the default settings for noise levels up to 50% of the range µr. The EBM is quite
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robust to variation in the trajectory centre points Σc,s (Table 5.2 A: Experiment D)
and transition time Στ (Table 5.2 A: Experiment E).
A. Noise Levels
0.01 0.1 0.5 1 2
A 0.10(0.06) 0.09(0.05) 0.11(0.06) 0.10(0.05) 0.12(0.05)
B 0.12(0.06) 0.00(0.01) 0.02(0.02) 0.09(0.05) 0.36(0.16)
Estimated C 0.11(0.05) 0.11(0.06) 0.13(0.06) 0.20(0.17) 0.18(0.17)
D 0.09(0.05) 0.13(0.04) 0.24(0.17) 0.32(0.12) 0.47(0.18)
E 0.10(0.05) 0.09(0.04) 0.15(0.10) 0.26(0.12) 0.40(0.11)
A 0.00(0.01) 0.00(0.01) 0.01(0.02) 0.01(0.01) 0.01(0.02)
B 0.17(0.04) 0(0) 0.00(0.01) 0.00(0.01) 0.07(0.04)
Fixed C 0.00(0.01) 0.01(0.01) 0.03(0.04) 0.11(0.04) 0.17(0.10)
D 0.00(0.01) 0.01(0.01) 0.05(0.04) 0.09(0.05) 0.17(0.05)
E 0.01(0.02) 0.01(0.01) 0.01(0.02) 0.10(0.06) 0.19(0.06)
B. Trajectory Parameters
1 5 10 15 20
Estimated A 0.44(0.21) 0.19(0.04) 0.09(0.04) 0.08(0.15) 0.20(0.22)
B 0.03(0.02) 0.11(0.05) 0.19(0.04) 0.24(0.05) 0.30(0.12)
Fixed A 0.38(0.22) 0.09(0.04) 0.01(0.01) 0(0) 0.01(0.01)
B 0.00(0.01) 0.00(0.01) 0.01(0.03) 0.04(0.04) 0.05(0.03)
C. Time Sampling
0 1 2.5 5
Estimated 0.12(0.06) 0.10(0.06) 0.11(0.07) 0.10(0.04)
Fixed 0(0) 0.00(0.01) 0(0) 0.00(0.01)
D. Subtypes
0 0.25 0.5 0.75 1
Estimated 0.10(0.04) 0.17(0.20) 0.50(0.36) 0.91(0.06) 0.96(0.05)
Fixed 0.01(0.01) 0.04(0.04) 0.45(0.39) 0.95(0.04) 1.00(0.01)
Table 5.2: Mean (standard deviation of the mean in brackets) Kendall’s tau distance be-
tween ground truth event sequence and event sequence returned by the EBM for
synthetic data with varying: (A) noise levels, (B) trajectory parameters, (C) time
sampling, (D) subtypes. In all tables each column is a new parameter value, and
‘estimated’ and ‘fixed’ refer to whether the event distributions are estimated by
the EBM or fixed to known values. Bold values represent the default parameters
of the EBM. In part (A), experiments A-E represent varying: A. measurement
noise; B. inter-subject covariance of trajectory minimum; C. inter-subject co-
variance of trajectory range; D. inter-subject covariance of trajectory centre; E.
inter-subject covariance of trajectory transition time. In part (B), experiments
A-B represent varying: A. trajectory centre points, B. trajectory transition times.
Reproduced from [167]. CC BY 4.0.
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5.4.1.3 Experiment 2: Trajectory parameters
I performed two experiments to test the robustness of the EBM to different values
of the trajectory parameters: (A) varying the centre points of the trajectories, µc,
and (B) varying the transition time of the trajectories µτ . In (A) I assume an evenly
spaced set of trajectory centre points over a segment of the disease time course. I
vary the duration of this segment as a fraction of 10 years. The trajectory centre
points are centred about the middle point along the disease time course (10 years).
In (B) I vary the transition time as a fraction of the overall range of the disease
time course (20 years), keeping the transition time the same for all biomarkers. The
EBM has difficulty estimating the event sequence for both fixed and estimated event
distributions when the trajectory centres are close together (Table 5.2 B: Experiment
A), and for longer transition times (Table 5.2 B: Experiment B), which violate the
assumption of the EBM that an event has either occurred or not occurred. For
estimated event distributions the EBM also has difficulty ordering the events when
the trajectory centres are spread over the full disease time course (Table 5.2 B:
Experiment A). This is because the portion of the trajectory where the biomarker is
normal (for early biomarkers) or abnormal (for late biomarkers) is not observed. As
in the previous experiments, fixing the event distributions improves the estimation
of the event sequence.
5.4.1.4 Experiment 3: Time sampling
In this experiment I look at how under-sampling of the disease time course affects
the ability of the EBM to recover the sequence of biomarker abnormality. I assume
that the time points are sampled from a mixture of three Gaussian distributions,
with means at 5 years, 10 years and 15 years respectively. I vary the standard
deviation of these distributions, assuming that all of the gaussians have the same
standard deviation. This allows simulation of CN, MCI and AD subjects being at
entirely different points along the disease time course. The EBM is robust to under-
sampling of the disease time course (Table 5.2 C), giving a similar Kendall’s tau
distance to the default settings for all simulations.
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5.4.1.5 Experiment 4: Subtypes
To explore the effect of including a set of subjects that follow a different event
sequence I modelled two disease subtypes, varying the fraction of subjects that
belong to each subtype. For both subtypes the trajectory centre points are evenly
spaced from a minimum of 5 years to a maximum of 15 years. In subtype 1 the
biomarkers become abnormal in the same order as the default settings: Abeta, P-tau,
T-tau, FDG-PET, hippocampal volume, MMSE, ventricles, whole brain volume. In
subtype 2 the biomarkers become abnormal in the reverse sequence. This sequence
has a Kendall’s tau distance of 1 from the sequence of subtype 1. The EBM is robust
up to a proportion of 25% of subjects that follow an alternative event sequence
(Table 5.2 D): at 25% outliers the Kendall’s tau distance is similar to the result for
0% outliers for estimated event distributions, and only slightly increased for fixed
event distributions. Likewise, at 75% outliers, when the majority of subjects are
subtype 2 the Kendall’s tau distance is only slightly worse than for 100% outliers. At
50% outliers the EBM alternates between estimating a sequence similar to subtype
1 and subtype 2.
5.4.2 Differential equation model stability analysis
I performed a stability analysis of the DEM to test how robust the model is to vary-
ing the noise levels on the trajectory parameters.
5.4.2.1 Default parameter values
Fitting a DEM to each biomarker in turn (see Figure 5.4 for estimated synthetic
trajectories for FDG-PET) using the default parameter values for the EBM gives
an average across biomarkers (excluding CSF for which I only modelled baseline
collection) of a mean sample transition time 12.8± 1.1 years and standard deviation
of this sample transition time of 2.2 ± 1.2 years. This is more than double the
simulated trajectory transition time of 5 years. For biomarkers with more data points
available (higher biomarker collection rate, e.g. MMSE) the standard deviation of
the transition time reduces but the mean transition time remains similar, i.e. the
DEM becomes more confident in the biased estimate of the trajectory transition
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time. In subsequent experiments I simplify the default parameter settings for the
DEM to a zero noise case (see Section 5.3.2.4) to characterise the types of parameter
noise that the DEM is most sensitive to.
Figure 5.4: Integrated DEM trajectories for FDG-PET uptake generated using synthetic
data with the default settings for the EBM (Table 5.1). The ground truth tra-
jectory is in red, and the median estimated trajectory is in black with the inter-
quartile range shaded in grey. Reproduced from [167]. CC BY 4.0.
5.4.2.2 Stability of the differential equation model to noise
For the DEM default parameter values (zero noise case) the DEM is able to recover
the trajectory transition time much more accurately (sample transition time is 5.1±
0.0 years for a simulated trajectory with a transition time of 5 years). As with
the EBM, I ran five simulations to look at the effect of different levels of: (A)
measurement noise ν , (B) inter-subject variance of the trajectory minimum Σa, (C)
inter-subject variance of the trajectory range Σr, (D) inter-subject variance of the
trajectory centre Σc,s, (E) inter-subject variance of the trajectory transition time Στ .
I vary the noise level as a proportion p of (A) µr, and a proportion p2 of the variance:
(B) µ2r , (C) µ2r , (D) µ2τ , (E) µ2τ . The DEM is sensitive to measurement noise (Table
5.3: Experiment A), and variance of the trajectory minimum (Table 5.3: Experiment
B) and range (Table 5.3: Experiment C), with 25% measurement noise giving a
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transition time of around twice as long as the actual transition time. The DEM is less
sensitive to variance of the trajectory transition time (Table 5.3: Experiment E). The
DEM is unaffected by noise in the trajectory centre point (Table 5.3: Experiment
D), as this is removed by differentiating.
0.1 0.25 0.5 1
A 5.9(0.4) 9.8(3.1) 12.7(4.7) 15.0(5.2)
B 7.5(0.2) 11.4(0.5) 13.3(0.5) 14.4(0.7)
C 6.6(0.2) 9.8(0.5) 11.6(0.7) 12.3(1.0)
D 5.1(0.0) 5.1(0.0) 5.1(0.0) 5.1(0.0)
E 5.1(0.0) 5.1(0.1) 5.4(0.3) 8.7(0.9)
Table 5.3: Mean (standard deviation of the mean in brackets) estimated transition time
(years) for DEM fitted to synthetic data with varying: A. measurement noise;
B. inter-subject variance of trajectory minimum; C. inter-subject variance of tra-
jectory range; D. inter-subject variance of trajectory centre; E. inter-subject vari-
ance of trajectory transition time. For all simulations the ground truth transition
time is 5 years. Each column is a new parameter value. Reproduced from [167].
CC BY 4.0.
5.5 Discussion
I have presented a framework for the simulation of sporadic neurodegenerative dis-
ease datasets. I applied the framework to generate synthetic AD data, and thereby
provide insight into the robustness of the EBM and a DEM to the likely variation in
sporadic disease datasets.
5.5.1 Simulation framework
The simulation framework I have presented is simple and flexible. For example, it
is easily extendible to include subjects with a range of demographics, for example
age, gender, and education, or genetic risk factors. Such effects can be modelled
as a transformation of the trajectory parameters. Here I simplify the diagnosis as a
relationship with the biomarker values, however, a more realistic diagnosis proce-
dure could be simulated that is based on, for example, cognitive test results. It is
also possible to add in a screening procedure that post-selects subjects with a sim-
ilar set of demographics to the dataset being simulated, for example age matching
across diagnostic categories. Here I only consider inter-subject variance, however,
126 Chapter 5. A simulation system for neurodegenerative disease
intra-subject variance for longitudinal datasets could also be modelled.
5.5.2 Stability analysis
5.5.2.1 Event-based model stability analysis
The EBM stability analysis shows that the EBM is sensitive to the estimation of the
event distribution parameters. However, when the event distribution parameters are
estimated accurately, the EBM is very robust to the likely heterogeneity in sporadic
disease datasets. I find that the EBM is robust to noise in the trajectory parameters,
different choices of trajectory parameters, under-sampling of the underlying disease
time course, and outliers who follow different event sequences.
5.5.2.2 Differential equation model stability analysis
For all simulations the DEM under estimates the trajectory gradient leading to an
over estimation of the trajectory transition time. For the level of noise estimated
from the ADNI data this over estimate is more than twice as long as the ground
truth trajectory transition time. Whilst this result may be in part due to an over
estimation of the amount of inter-subject variation from ADNI, the stability analysis
of the DEM shows the DEM will severely over-estimate the trajectory transition
time even when the inter-subject variation is much lower. The DEM is very sensitive
to measurement noise and inter-subject variation of the trajectory minimum (normal
biomarker level) and range (difference between a normal and abnormal level). I
further find that using three time points to fit the DEM rather than all available time
points, for which the approximation to the derivative is less valid, gives a better
estimate of the trajectory transition time, even under high noise levels.
5.5.2.3 Limitations
In the set of experiments presented I vary each parameter in turn. However, there
will likely be multiplicative effects of varying these parameters in combination. I
further make a set of assumptions that are specific to hypothetical models of AD,
such as sigmoidal trajectories, and to the design of the ADNI dataset, such as the
proportion of subjects that drop out per year, and the proportion of subjects in which
each biomarker is collected. I also assume that measurement errors are Gaussian,
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which may not be the best choice of noise distribution for all of the biomarkers.
Therefore, although these simulations do provide an insight into the types of effects
which can be expected from different datasets, the simulations should be re-run
with dataset specific parameters to assess the performance of the EBM and DEM
on alternative datasets. I chose the DEM to be similar to [81], however other DEM
approaches (e.g. [131]) may recover a more accurate estimate of the trajectory tran-
sition time for heterogeneous data sets, and should be tested in future work.
5.5.3 Implications for the application and development of data-
driven models
5.5.3.1 The event-based model
The results of the EBM stability analysis show that the EBM is sensitive to the accu-
racy of the estimated biomarker distribution models, P(x|E), and P(x|¬E). There-
fore the application of the EBM is most effective when the biomarkers have distinct
control and case distributions. The results further show that the EBM is robust to
25% outlier corruption, which is higher than the proportion of misdiagnoses I expect
in typical sporadic neurodegenerative disease cohorts. The simulations highlight
several key areas for improvement of the EBM. First, better estimation techniques
for the biomarker distribution parameters should aid recovery of the event sequence
when the control and case distributions are not well defined. Adaptation of the
EBM to take into account the uncertainty in the biomarker distribution parameters,
e.g. by sampling the distribution parameters simultaneously with the ordering, may
also help to ameliorate this problem. Second, although the EBM can estimate the
ML event sequence for a modest proportion of outliers, it is unable to distinguish
other likely event sequences in the data. Future work will look at fitting mixture
models with multiple event sequence modes to the data.
5.5.3.2 Differential equation models
The simulations show that the DEM is sensitive to noise, leading to over estimation
of the trajectory transition time, meaning that the DEM should only be applied to
biomarkers with low measurement noise and inter-subject variance. Alternatively,
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robust fitting techniques need to be developed that can correct for the bias encoun-
tered when fitting a DEM to noisy biomarker trajectories. The simulations further
show that it is important that the duration of follow up for each individual is a good
approximation to the derivative (short with respect to the full disease time course).
This is shown to be more important than the inclusion of lots of follow up time
points, which improves the accuracy of the estimated derivative, suggesting that
follow up data over a longer time period should be discarded when fitting a DEM.
5.6 Conclusion
I have presented a framework for generating synthetic neurodegenerative disease
datasets (contribution 1.3.2 (a), Chapter 1, page 40), which can be used to evaluate
the robustness of data-driven models to likely variations in sporadic disease datasets,
and to directly compare them. I have demonstrated the use of this framework to
evaluate the stability of the EBM and a DEM of disease progression to heterogeneity
in the ADNI dataset (contribution 1.3.2 (b), Chapter 1, page 40). Future work will
use the simulation framework to evaluate the stability of other data-driven models,
such as self-modelling regression approaches [128]. The simulation framework can
further be used as a technique for validating extensions to data-driven models, to
determine model weaknesses, and to highlight areas for improvement.
Chapter 6
Multiple orderings of events in
disease progression
This chapter presents an initial formulation of the dynamic clustering technique
developed in Chapter 7. The work presented in this chapter was presented at the
Information Processing in Medical Imaging conference in 2015, the proceedings
of which were published in Lecture Notes in Computer Science. I developed the
methodology, performed the analysis and wrote the manuscript; my co-authors pro-
vided feedback on the methodology and the manuscript. My co-author Razvan
Marinescu made the visualisations for Figures 6.2, 6.3 and 6.5.
6.1 Associated publications
A. L. Young, N. P. Oxtoby, J. Huang, R. V. Marinescu, P. Daga, D. M. Cash, N. C.
Fox, S. Ourselin, J. M. Schott, and D. C. Alexander. Multiple Orderings of Events in
Disease Progression. In Information Processing in Medical Imaging, volume 9123
of Lecture Notes in Computer Science, pages 711–722, 2015
6.2 Introduction
The sequence in which biomarkers become abnormal provides a simple, intuitive
description of disease progression, giving insights into the underlying disease bi-
ology and a potential mechanism for disease staging. The sequence of biomarker
abnormality in sporadic neurodegenerative diseases, e.g. AD, has been a topic of
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intense debate amongst neurologists [74]. Reconstructing this sequence for spo-
radic neurodegenerative diseases is difficult because the position of subjects with
respect to the full disease time course is unknown. Typically clinical diagnoses are
used as a time proxy, but this limits the temporal resolution of the sequence, e.g.
in AD there are usually only three clinical diagnosis categories: cognitively normal
(CN), mild cognitive impairment (MCI) and AD [85]. Additional complications
arise due to the long disease time course [81] and inherent heterogeneity of sporadic
disease datasets. Many different factors contribute to this heterogeneity [75, 146],
for example genetic disease subtypes, mixed pathology, environmental factors, and
misdiagnosed subjects.
The event-based model (EBM) [98] considers disease progression as a series
of events, where each event corresponds to a new biomarker becoming abnormal.
By considering cross-sectional patient data as snapshots of a single common event
sequence, the EBM is able to probabilistically reconstruct the ordering of events
across subjects, without relying on a-priori disease staging. Taking samples of
the posterior probability of this sequence provides insight into the uncertainty in
this single event ordering. The application of this model has been demonstrated in
dominantly-inherited AD and Huntington’s disease [98] to determine the sequence
in which regional brain volumes become abnormal, and in sporadic AD to deter-
mine the sequence in which cerebrospinal fluid (CSF) markers, cognitive test scores,
and a limited set of regional atrophy and brain volume biomarkers become abnor-
mal [134]. Young et al. [134] found that this sequence is different in APOE4 positive
individuals, with increased genetic risk of AD, compared to the whole population,
suggesting that the whole population contains a proportion of subjects who do not
follow the single ordering of events encoded by the EBM.
The assumption made by the EBM in [98] and [134] of a single ordering of
events in all subjects is a major simplification for heterogeneous sporadic disease
datasets. In this work I relax this assumption by considering a family of models
that allow for multiple and distributed orderings of events. The first is a gener-
alised Mallows model [171], which parameterises the variance in the single order-
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ing, allowing subjects to deviate from the central event sequence. The second is
a Dirichlet process mixture model [172], which allows for subgroups of subjects
that follow different event sequences. Previous work [157] on generalised Mallows
EBMs relied on a well-defined control population and a complete set of biomark-
ers for each subject. Here I re-formulate this model to remove the reliance on a
well-defined control population, allowing the model to be fitted to heterogeneous
sporadic disease datasets, and to handle missing data, providing a multi-modal pic-
ture of disease progression. I formulate a Gibbs sampling technique that further
provides samples of the uncertainty in the model parameters. I additionally intro-
duce a new model: Dirichlet process mixtures of generalised Mallows EBMs, and
develop a Gibbs sampler to estimate its parameters [173]. I apply these models to
determine the sequence in which FDG-PET, CSF markers, cognitive test scores, and
a large set of regional brain volumes become abnormal in sporadic AD.
6.3 Models
6.3.1 The event-based model
The EBM of disease progression [98] consists of a set of events {e1, . . . ,eN}
and an ordering σ = (σ(1), . . . ,σ(N)), where σ(k) = i means that event ei oc-
curs in position k. In practise I only observe a snapshot of the event sequence
for each subject, taken at an unknown stage k. If a subject is at stage k in the
sequence σ the events eσ(1) . . .eσ(k) have occurred and events eσ(k+1) . . .eσ(N)
have yet to occur. This adduces a partition of the event set, or partial ranking,
γk = eσ(1), . . . ,eσ(k)|eσ(k+1), . . . ,eσ(N), where the vertical bar indicates that the first
set of events precedes the second. The occurrence of event ei in subject j is in-
formed by biomarker measurement xi j. The generative model of the biomarker data
is
k j ∼ P(k),
xσ(i), j ∼ p(xσ(i), j|eσ(i)) if i≤ k j,
xσ(i), j ∼ p(xσ(i), j|¬eσ(i)) otherwise.
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p(x|e) and p(x|¬e) are probability density functions on observing biomarker mea-
surement x given that event e has or has not occurred respectively. P(k) is a prior
on the disease stage k.
6.3.2 The generalised Mallows event-based model
I formulate the generalised Mallows EBM by using a generalised Mallows model to
parameterise the variance in a central event sequence pi through the spread parame-
ter ~θ = (θ1, . . . ,θN−1). Each subject then has their own latent ordering σ j, which is
assumed to be a sample from a generalised Mallows model. The generative model
of the biomarker data in the EBM is therefore preceded by
pi,~θ ∼ P(pi,~θ |ν ,~r),
σ j ∼ GM(pi,~θ).
GM(pi,~θ) = 1
ψ(~θ)
exp
[−d~θ (pi,σ)] is a generalised Mallows distribution with
ψ(~θ) =∏n−1j=1ψn− j(θ j) =∏
n−1
j=1
1−e−(n− j+1)θ j
1−e−θ j . d~θ (pi,σ) is the generalised Kendalls
tau distance [171], which penalises the number of pairwise disagreements between
sequences. P(pi,~θ |ν ,~r) is a conjugate prior over the generalised Mallows distribu-
tion parameters of the form P(pi,~θ |ν ,~r) ∝ exp(−ν∑ j[θ jr j + lnψn− j(θ j)]) [174].
6.3.3 Dirichlet process mixtures of generalised Mallows event-
based models
Dirichlet process mixtures of generalised Mallows models assume that each subject
has their own central ordering pi j and spread parameters ~θ j, which are sampled from
a discrete distribution G that is drawn from a Dirichlet process [172]. A Dirichlet
process mixture is a generative clustering model where the number of clusters is a
random variable, meaning that the number of clusters is detected automatically de-
pending on the concentration parameter α . The generative model of the biomarker
data in the EBM is now preceded by the process
G∼ DP(α,P(pi,~θ |ν ,~r)),
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pi j,~θ j ∼ G,
σ j ∼ GM(pi j,~θ j),
where DP(α,P(pi,~θ |ν ,~r)) is a Dirichlet process [172]. Each data point pi j can be
characterised by an association with a cluster label c j ∈ 1, . . . ,C and each cluster c
with a set of generalised Mallows parameters σc and ~θc.
6.4 Inference
6.4.1 The event-based model
Inference in the EBM can be performed by taking Markov Chain Monte Carlo
(MCMC) samples of P(σ |X) = P(X |σ)P(σ)P(X) where
P(X |σ) =
J
∏
j=1
[
K
∑
k=0
P(k)
(
k
∏
i=1
p(xσ(i), j|eσ(i))
N
∏
i=k+1
p(xσ(i), j|¬eσ(i))
)]
. (6.1)
6.4.2 The generalised Mallows event-based model
I use Gibbs sampling to infer the parameters of the generalised Mallows EBM. This
consists of two stages. First, generating a set of sample event sequences σ1:J . I sam-
ple from an augmented model [157], by alternating between sampling a subject’s
ordering σ j and disease stage k j, which are used to deterministically reconstruct
their partial ranking γ j. The Gibbs sampling updates are therefore
σ ( j) ∼ P(σ |~γ = γ j,pi,~θ),
k( j) ∼ P(k|~σ = σ j,X j).
Second, sampling the model parameters given the set of sample orderings σ1:J using
the updates
pi ∼ P(pi|~θ ,ν ,~r,σ1:J),
θk ∼ P(θk|pi,ν ,~r,σ1:J).
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6.4.3 Dirichlet process mixtures of generalised Mallows event-
based models
I formulate another Gibbs sampler to infer the parameters of Dirichlet process mix-
tures of generalised Mallows EBMs. I generate a set of candidate sample orderings
σ1:J,1:C, disease stages k1:J,1:C, and partial rankings γ1:J,1:C, which are conditioned
on the parameters for each cluster via the updates
σ ( j,c) ∼ P(σ |~γ = γ jc,pic,~θc),
k( j,c) ∼ P(k|~σ = σ jc,X j).
From these samples I sample the cluster assignment c j of each subject conditioned
on the cluster assignments of the other subjects c− j, where c− j is the set of cluster
assignments for all subjects except subject j, the subject’s sample ordering for each
cluster σ j,1:C, disease stage k j,1:C and their biomarker data X j. I then update the
generalised Mallows model parameters for each cluster, pic and ~θc, from the set of
subject orderings assigned to each cluster, ~σc. So I have the updates
c( j) ∼ P(c|c− j,σ j,1:C,~θ ,α,ν ,~r,X j,k j,1:C),
pi(c) ∼ P(pi|~θ = ~θc,ν ,~r,~σc),
θ (c)k ∼ P(θk|~pi = pic,ν ,~r,~σc).
6.5 Implementation
6.5.1 ADNI dataset
I considered 382 subjects (135 CN subjects, 149 MCI, 98 AD) who had a 1.5T struc-
tural MRI (T1) scan at baseline. I calculated the total volume (left plus right hemi-
sphere) of 82 regions in the Neuromorphometrics parcellation1 for each subject, cor-
recting for head size variance by regressing against total intracranial volume. Seg-
1http://neuromorphometrics.org:8080/
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mentation was performed using the Geodesic Information Flow framework [175].
I retained the 35 regions having significant differences between CN and AD sub-
jects using the Wilcoxon rank sum test with p < 0.01. I downloaded biomarker
values from the ADNI database (adni.loni.usc.edu) for CSF markers (Aβ1−42, tau,
p-tau), cognitive test scores (MMSE, RAVLT, ADAS-Cog), and global FDG-PET
metabolism.
6.5.2 Model fitting
I compare the result of fitting the EBM, generalised Mallows EBM and Dirichlet
process mixtures of generalised Mallows EBMs to the ADNI data set for the set of
42 biomarker abnormality events described. Following previous work [98] I model
the probability that a biomarker is normal, p(x|¬e), as a Gaussian distribution, and
the probability that a biomarker is abnormal, p(x|e), as a uniform distribution cover-
ing the full range of observed values to reflect the range of severity that corresponds
to an abnormal biomarker. I use a mixture model to fit these distributions to the data
to account for a proportion of outliers in the control population, and visually assess
the fit of the Gaussian mixture models. In subjects that had missing data points I
imputed the biomarker values such that p(x|e) = p(x|¬e), i.e. it is equally proba-
ble that the event e has or has not occurred. The prior probability that a subject is
at a particular disease stage P(k) is assumed to be uniform. To fit the generalised
Mallows model I need to sample σ from P(σ |γ,pi,~θ). I approximate this by sam-
pling from a generalised Mallows model for each of the event sets in the partial
ranking γ separately; the set of events γe that have occurred and the set of events
γ¬e that have yet to occur. I sample σe ∼ GM(piγe ,~θγe), and σ¬e ∼ GM(piγ¬e ,~θγ¬e).
This means that the precedence of events specified by the partial ranking is pre-
served, and that the central ordering of the generalised Mallows model for each
event set, piγe and piγ¬e , has the minimal Kendalls tau distance [171] from the cen-
tral ordering pi of the full generalised Mallows model. I sample k from P(k|σ ,X j)
using equation 6.1, i.e. P(k|σ ,X j) ∝ ∏ki=1 p(xσ(i), j|eσ(i))∏Ni=k+1 p(xσ(i), j|¬eσ(i)).
The remaining sampling updates follow the algorithm in [173]. I sample pi exactly
using a stage-wise algorithm, and ~θ using a beta function approximation. I used the
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Beta-Gibbs algorithm [173] to update the Dirichlet process mixture model cluster
assignments c j, weighting the probability each subject belongs to each cluster by
P(X j|σ j,c,k j,c), and the generalised Mallows model parameters pic, ~θc for each clus-
ter. I fix the priors to be ν = 1,~r =~1, α = 1. I initialise pi randomly, γe as the set
of events with p(x|e)> p(x|¬e), γ¬e as the set of events with p(x|e)≤ p(x|¬e), and
the Dirichlet process mixture to have 25 clusters. The computational time required
for the generalised Mallows EBM and the Dirichlet process mixture of generalised
Mallows EBM grows rapidly as the number of subjects and biomarkers increases
because of the requirement to update several individual subject parameters at each
iteration, in addition to estimating overall population parameters for each cluster.
For the present experiments each iteration takes around a minute using Matlab on a
standard workstation (Intel Core i7, 3.1 GHz, 8GB memory).
6.6 Results and discussion
6.6.1 The event-based model
Figure 6.1 shows a positional variance diagram of the MCMC samples of the single
ordering of events returned by the EBM. I visualise a few key stages of this sequence
in the top row of Figure 6.3 to show the spatial correspondence of the sequence of
regional volume loss estimated by the model. I find that CSF markers are the first
to become abnormal, followed by cognitive test scores, then memory-related brain
regions, then FDG-PET, and then other AD-related brain regions. This sequence
complements the findings of other studies, but provides a much more detailed pic-
ture of the regional progression of volume changes than has been seen previously in
sporadic AD, and a direct comparison of the sequence of regional changes relative
to a multi-modal set of biomarkers. Fonteijn et al. [98] looked at the regional pro-
gression of volume loss but in familial AD and using atrophy rates. The results in
Young et al. [134] show a multi-modal sequence of biomarker abnormality in spo-
radic disease but for a small set of regional volumes, and hippocampal and whole
brain atrophy rates from short-term longitudinal MRI. Here I show the first multi-
modal sequence of biomarker abnormality in sporadic AD, including a large set of
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regional volumes. I am able to construct this picture from entirely cross-sectional
data, and incorporate biomarkers with missing values.
Figure 6.1: Central ordering estimated by the EBM: Positional variance diagram of the
MCMC samples of the maximum likelihood event sequence σ . The events on
the y-axis are ordered by the maximum likelihood sequence estimated by the
model. Each entry of the positional variance diagram represents the propor-
tion of samples in which a particular event appears in a particular position in
the central ordering, ranging from 0 in white to 1 in black. A black diagonal
corresponds to high certainty in the ordering of events, whereas grey blocks
in the diagram mean that the events permute. Reproduced from [170] with
permission from Springer. The final publication is available at Springer via
http://dx.doi.org/10.1007/978-3-319-19992-4_56.
6.6.2 The generalised Mallows event-based model
The generalised Mallows EBM estimates both the central ordering of the events
and the variance in this single event ordering across the population (Figure 6.3).
Figure 6.3 compares the central ordering pi and variance ~θ estimated by the gener-
alised Mallows EBM, i.e. the range of event sequences across the population, with
the central ordering estimated by the EBM. The central event sequence has a similar
ordering to the EBM, but the variance in this central ordering of events increases,
as shown by the increase in the number of orange regions in Figure 6.3. By using
Gibbs sampling I further obtain estimates of the uncertainty in each of the model
parameters, as well as the latent variables included in the model, for example a sub-
ject’s disease stage (Figure 6.4). Fitting the generalised Mallows EBM means that
138 Chapter 6. Multiple orderings of events in disease progression
the uncertainty in this stage accounts for the variance in the ordering of the events
across the population.
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Figure 6.2: Key for Figures 6.3 and 6.5, generated using the BrainColorMap software2.
Reproduced from [170] with permission from Springer. The final pub-
lication is available at Springer via http://dx.doi.org/10.1007/
978-3-319-19992-4_56.
6.6.3 Dirichlet process mixtures of generalised Mallows event-
based models
I fitted a Dirichlet process mixture of generalised Mallows EBMs to allow for clus-
ters of subjects that follow different sequences of events, of which each cluster has
its own central ordering pic and variance ~θc. The Dirichlet process mixture model
identifies three main clusters in the data, with an average proportion of 0.48 (±
0.02), 0.24 (± 0.10), and 0.29 (± 0.10) subjects being assigned to each cluster
respectively over the Gibbs samples. Figure 6.5 compares the estimated central
ordering and variance for each of the clusters. The first two clusters look more
AD-like than the third cluster, producing a similar event sequence to the EBM and
generalised Mallows model (Figure 6.3), with CSF biomarkers and memory-related
brain regions becoming abnormal early in the sequence. The third cluster likely
captures outliers that do not fit the AD sequence of events. The ordering of events
for the third cluster consists of only mild cognitive deficits and no CSF abnormali-
ties, perhaps representing a normal aging event sequence, or simply reflecting that
regional volume loss is a noisy measure on a cross-sectional level. The variance
~θc is greater for the clusters of the Dirichlet process mixture model than the gen-
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Figure 6.3: Comparison of the central ordering estimated by the event-based model (top)
with the generalised Mallows model (bottom) (see key in Figure 6.2). We
display the results for six stages: stage 6, 12, 18, 24 and 36, where each
stage number corresponds to the number of biomarkers that have become ab-
normal. Each biomarker (brain region, CSF, cognitive test or FDG-PET) is
coloured according to the proportion of the population in which it has be-
come abnormal by a particular stage along the central ordering. This propor-
tion is estimated for the event-based model by the number of MCMC sam-
ples (Figure 6.1), and for the generalised Mallows model by the probability
(calculated using the central ordering pi and spread ~θ ) of an event appear-
ing at or before a particular stage. This proportion ranges from 0 in yellow
to 1 in red. Regions not included in the model are shown in grey. At each
stage yellow biomarkers can be interpreted as being normal, red biomark-
ers as being abnormal, and orange biomarkers as varying in whether they
have become abnormal across the population. Reproduced from [170] with
permission from Springer. The final publication is available at Springer via
http://dx.doi.org/10.1007/978-3-319-19992-4_56.
eralised Mallows model (as shown by an increase in the number of orange regions
in Figure 6.5 compared to Figure 6.3), likely because each cluster only contains a
proportion of the population, meaning that there are fewer subjects to fit the model
to, and due to the uncertainty in the cluster assignment of each subject. The Gibbs
sampling technique returns samples of all of the model parameters. For example, I
am able to estimate the uncertainty in the disease stage of each subject for both mod-
els, and the cluster assignment of each subject from the Dirichlet process mixture,
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Figure 6.4: Estimate of the uncertainty in a subject’s disease stage obtained by using Gibbs
sampling to fit the generalised Mallows EBM. I show an estimate of the prob-
ability of each stage for an example CN subject (green), MCI subject (blue),
and AD subject (red). Each stage corresponds to the number of biomarkers
in the sequence that have become abnormal. Reproduced from [170] with
permission from Springer. The final publication is available at Springer via
http://dx.doi.org/10.1007/978-3-319-19992-4_56.
producing a similar diagram to Figure 6.4.
6.7 Conclusion
I proposed a generalised family of EBMs that relax the assumption of a common
event sequence over the population in different ways. I formulated these models
so that they work for a large multi-modal set of sporadic disease biomarkers, and
developed a Gibbs sampler that provides an estimate of the uncertainty on each
model parameter. I fitted this family of models to the ADNI dataset to determine
the ordering of a much more extensive, multi-modal set of biomarkers than has been
seen previously. I find that the generalised Mallows model estimates a similar event
sequence to the original EBM, but with a larger variation across subjects. Fitting a
Dirichlet process mixture model detects subgroups of the population with different
event sequences.
The models developed in this chapter provide an interesting first attempt at
modelling heterogeneity in biomarker progression patterns. However, a major con-
cern is that the variance parameter ~θ of the generalised Malllows EBMs (and the
variance parameter ~θc of the Dirichlet process mixture of generalised Mallows
EBMs), greatly increases model complexity with no real gain in clinical utility. The
parameter ~θ describes the variance in the progression pattern across the population,
2http://braincolor.mindboggle.info/.
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Figure 6.5: As Figure 6.3, but for the clusters identified by the Dirichlet process mix-
ture of generalised Mallows event-based models (top to bottom: clusters 1
to 3). Reproduced from [170] with permission from Springer. The final
publication is available at Springer via http://dx.doi.org/10.1007/
978-3-319-19992-4_56.
which will always be very large given that subjects are only observed at a single time
point, and therefore the possible sequences they could have gone through to reach
that point are all of the possible permutations of the events that have occurred at
that time point. Estimating this variance doesn’t provide any additional information
that is clinically useful.
In the subsequent chapter I develop a more parsimonious model of heteroge-
neous biomarker progression patterns.

Chapter 7
A data-driven model of disease
subtypes with distinct patterns of
biomarker evolution in
frontotemporal dementia and
Alzheimer’s disease
This chapter details contribution 1.3.3 (see Chapter 1, page 41). My colleague
Razvan Marinescu made the visualisations for Figures 7.1, 7.2, 7.3, 7.4 and 7.5,
and Supplementary Figures A.5 and A.12.
7.1 Introduction
Neurodegenerative diseases, such as AD and frontotemporal lobar degeneration
(FTLD), are often heterogeneous in their pathology, genetics and clinical presen-
tation. The identification of data-driven disease sub-populations and quantification
of their patterns of biomarker evolution can elucidate relationships between differ-
ent biomarker measurements that contribute to this observed heterogeneity, provid-
ing insights into underlying disease mechanisms. Moreover, quantitative models of
the evolution of biomarkers in different disease subtypes can be used for precision
medicine by providing a quantitative tool for patient stratification and prognostica-
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tion, with application in clinical trials and healthcare.
Frontotemporal dementia (FTD) is the clinical presentation of FTLD, a highly
heritable set of neurodegenerative diseases that are characterised by progressive
frontal and temporal lobe atrophy. FTD comprises three major clinical subtypes:
behavioural variant FTD, semantic dementia, and primary progressive aphasia.
Around a third of FTD cases are inherited on an autosomal dominant pair, with
mutations in progranulin (GRN), microtubule-associated protein tau (MAPT) and
chromosome 9 open reading frame 72 (C9orf72) being the most common causes.
FTLD is pathologically heterogeneous, consisting of neuronal inclusions contain-
ing abnormal forms of either tau, TDP-43, or fused in sarcoma (FUS) proteins,
with each of these proteinopathies having further sub classifications. Of the major
familial subgroups, patients with GRN mutations have TDP-43 type A pathology,
patients with MAPT mutations having tauopathies, and patients with expansions in
C9orf72 have type A or type B TDP-43 pathology [176].
AD is characterised pathologically by the accumulation of amyloid plaques and
neurofibrillary tangles in brain tissue. These pathologies are thought to trigger sub-
sequence neuropathological processes leading to downstream neurodegeneration,
affecting the medial temporal lobe structures first, with the progression of atrophy
reflecting the pattern of increase in neurofibrillary tangles. This neurodegeneration
gives rise to the clinical symptoms experienced by a patient, the earliest of which is
typically memory loss. However, the pattern of neurofibrillary tangles observed at
autopsy is heterogeneous, with 25% of patients not having the typical distribution
of neurofibrillary tangles. This observation has lead to the suggestion that there
are three pathological subtypes of AD: typical, hippocampal-sparing, and limbic-
predominant [27]. In hippocampal-sparing AD neurofibrillary tangles are relatively
numerous in the cortex and reduced in the hippocampus, whereas at the other end of
the spectrum, in limbic-predominant AD, neurofibrillary tangle counts are greater
in the hippocampus and reduced in the cortex.
Pathological subtypes at post-mortem can be associated with distinct ante-
mortem biomarker profiles, such as characteristic patterns of brain volume loss on
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magnetic resonance imaging (MRI) [154]. In FTLD, each of the proteinopathies has
shown a fairly distinct atrophy pattern on MRI [177, 178]. In genetic FTD, distinct
patterns of atrophy are observed in the different mutation types [179], in addition
to pathology type [178]. In AD, more severe cortical atrophy has been observed in
patients with hippocampal-sparing AD, compared to more severe medial temporal
lobe atrophy in limbic-predominant AD [154].
Reconstructing patterns of biomarker evolution from in vivo data is challeng-
ing in the presence of heterogeneity in both the disease process and the disease
stage. The majority of previous studies reconstructing longitudinal patterns of
biomarker evolution assume a single common progression pattern across subjects,
and so cannot characterise heterogeneous progression patterns. Estimating longitu-
dinal patterns of biomarker evolution in neurodegenerative diseases is in itself chal-
lenging, as the duration of individual follow-up is short-term, typically a few years,
in comparison to the long time course the diseases emerge over, which is estimated
to be over a decade. One approach to estimating longitudinal biomarker patterns
from cross-sectional data is to regress longitudinal biomarker values against clini-
cal diagnosis [104–106], or some other clinical staging measure [49, 80, 112], such
as a cognitive test score. The temporal resolution of such approaches is limited by
the accuracy of the staging measure, typically to only a few stages. Data-driven
models of disease progression (e.g. [98, 127, 128, 132, 134]) have been proposed
to allow the estimation of fine-grained biomarker evolution patterns by realigning
subject’s biomarker measurements to a data-driven time axis. However, all of these
studies assume that subjects belong to a single biomarker evolution pattern.
Previous attempts to disentangle heterogeneity in the disease process of AD or
FTD [180–186] focus on clustering data from a single static disease stage. Such
studies are fundamentally limited by the quality of the staging measure used to
select subjects, and can only provide insights into disease subtypes at one stage
in the disease process. Additionally, this stage may not be common across all the
subtypes as the choice of disease staging measure may be more sensitive to one
subtype than another.
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The work of Guerrero et al. [112] reconstructs longitudinal disease progres-
sion patterns that incorporate heterogeneity in biomarker trajectories, however the
time axis of their model is not data-driven, instead being indexed by time to clinical
diagnosis. This means that the temporal resolution of their model is limited by the
accuracy of the diagnosis, and that the model can only be applied to subjects who
convert between diagnostic categories, and so requires a large amount of follow-up
data, reducing subject numbers. Additionally their model does not directly propose
a categorisation of the data into subgroups. In Young et al. [170], a data-driven
subtyping model was proposed that describes disease progression as groups of sub-
jects that have distinct orderings of biomarker abnormality events. However, these
biomarker abnormality events constitute a binary switch, from a normal to an abnor-
mal level, meaning that more complex dynamic behaviour of different biomarkers
cannot be estimated.
In this work I present a dynamic clustering model that integrates clustering and
data-driven disease progress estimation to characterise neurodegenerative disease
subtypes with distinct patterns of biomarker evolution. I first validate the technique
by demonstrating the ability of the model to recover known genetic subtypes of FTD
using volumetric MRI data from the Genetic Frontotemporal dementia Initiative
(GENFI). I show that the dynamic clustering model is able to recover the cascade
of volumetric MRI loss for GRN, MAPT and C9orf72 mutation carriers without
knowledge of the genetic labels. In addition, the model provides new insights into
the disease process in the C9orf72 mutation carriers by revealing that this group
is best modelled as two subgroups with distinct patterns of volume loss. I further
apply the dynamic clustering technique to AD using volumetric MRI data from
the Alzheimer’s Disease Neuroimaging Initiative (ADNI) to determine data-driven
subtypes of AD and their patterns of volume loss. I demonstrate the ability of the
model to provide fine-grained staging and subtyping information that independently
contributes to predicting conversion from mild cognitive impairment (MCI) to AD.
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7.2 Methods
7.2.1 Data description
7.2.1.1 GENFI dataset
I used cross-sectional volumetric MRI data from GENFI1 to fit the dynamic clus-
tering model. Subjects were included from the second data freeze of GENFI which
in total consisted of 365 participants recruited across 13 centres in the United King-
dom, Canada, Italy, Netherlands, Sweden, and Portugal. 324 had a usable volu-
metric T1-weighted MRI scan for analysis (15 participants did not have a scan and
the other participants were excluded as the scans were of unsuitable quality due to
motion, other imaging artefacts, or pathology unlikely to be attributed to FTD). The
324 participants included 144 non-carriers, 129 unaffected carriers, and 51 affected
carriers. Of the 129 unaffected presymptomatic mutation carriers there were 64
GRN, 41 C9orf72, and 24 MAPT carriers. Of the 51 affected symptomatic carriers,
there were 14 GRN, 26 C9orf72, and 11 MAPT carriers. The acquisition and post-
processing procedures for GENFI have been previously described in [187]. Briefly,
cortical and subcortical volumes were generated using a multiatlas segmentation
propagation approach [175], combining cortical regions of interest to calculate grey
matter volumes of the entire cortex, separated into the frontal, temporal, parietal,
occipital, cingulate, and insula cortices. Because the dynamic clustering model
expresses disease progression patterns in terms of z-scores relative to a control pop-
ulation, there is no requirement to pre-select the biomarkers according to whether
they have disease signal. I therefore included all of the regions of interest in the
study.
7.2.1.2 ADNI dataset
I downloaded data from LONI2 on 11 May 2016 and constructed two volumetric
MRI datasets: those with higher (3T) and lower (1.5T) field strength. The inclu-
sion criteria for the 3T and 1.5T datasets were having cross-sectional FreeSurfer
volumes available that passed overall quality control from either a 3T (processed
1www.genfi.org.uk
2www.loni.ucla.edu/ADNI/
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using FreeSurfer Version 5.1) or a 1.5T (processed using FreeSurfer Version 4.3)
MRI scan. The particular regional volumes selected for the study were chosen to
be similar to those in GENFI. The 3T dataset consisted of 793 subjects (183 cog-
nitively normal (CN), 86 significant memory concern (SMC), 243 early mild cog-
nitive impairment (EMCI), 164 late mild cognitive impairment (LMCI), 117 AD),
of which 73 were enrolled in ADNI-1, 99 were enrolled in ADNI-GO, and 621
were enrolled in ADNI-2. The 1.5T dataset consisted of 576 ADNI-1 subjects (180
CN, 274 LMCI, 122 AD). I corrected the volumes for variations in head size by
regressing against total intracranial volume (TIV). I further downloaded age, sex,
education, and APOE genotype from the ADNImerge table. I downloaded follow-
up information to test the association of the dynamic clustering model subtypes
and stages with longitudinal outcomes, consisting of diagnostic follow-up data and
cognitive test scores from the mini-mental state examination (MMSE). I also down-
loaded baseline CSF measurements of Aβ1−42, which I used to identify a control
population.
7.2.1.3 Z-scores
I expressed each regional volume measurement as a z-score relative to a control
population: in GENFI I used data from all non-carriers, in ADNI I used amyloid-
negative CN subjects, defined as those with a CSF Aβ1−42 measurement greater
than 192 pg/mL [139]. This gave a control population of 48 amyloid-negative
CN subjects for the 3T dataset, and 56 amyloid-negative CN subjects for the 1.5T
dataset. I used these control populations to determine whether the effects of age,
sex or education were significant, and if so to regress them out. I then normalised
each dataset relative to its control population, so that the control population had a
mean of 0 and standard deviation of 1. Because regional brain volumes decrease
over time the z-scores become negative with disease progression, so for simplicity
I took the negative value of the z-scores so that the z-scores would increase as the
brain volumes became more abnormal.
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7.2.2 Mathematical modelling overview
7.2.2.1 Mathematical model for dynamic clustering
I formulate a probabilistic generative model of disease progression that consists of
groups of subjects with distinct patterns of biomarker evolution. The biomarker
evolution of each subgroup is described as a series of events, where each event cor-
responds to a biomarker reaching a particular z-score compared to a control group.
This model is based on the event-based model (EBM) in [98, 134, 170], but refor-
mulates the events so that they represent the continuous linear accumulation of a
biomarker from one z-score to another, rather than an instantaneous switch from a
normal to an abnormal level. The resulting model describes the biomarker evolution
of each subgroup as a piecewise linear trajectory, with a constant noise level that is
derived from a control population. For details of the mathematical formulation of
the model and model fitting procedure see Mathematical model and Model fitting.
The model assumes a fixed number of clusters C, for which I estimate the proportion
of subjects f that belong to each cluster, and the order Sc in which biomarkers reach
each z-score for each cluster c = 1 . . .C. I determine the optimal number of clusters
C for a particular dataset through 10-fold cross-validation (see Cross-validation).
7.2.2.2 Uncertainty estimation
In addition to estimating the most probable sequence Sc for each cluster, I can de-
termine the relative likelihood of all sequences for each cluster by evaluating the
probability of each possible sequence. This provides an estimate of the uncertainty
in the ordering Sc, which I summarise by plotting positional variance diagrams of
the probability that each z-score event appears at each position in the sequence for
each cluster. In practise the number of sequences is too large to evaluate all possi-
ble sequences so I use Markov Chain Monte Carlo (MCMC) sampling to provide
an approximation to this uncertainty, as in [98, 134].
7.2.2.3 Cross-validation
I performed 10-fold cross validation of the dynamic clustering results by dividing
the data into 10 folds and re-fitting the model to each subset of the data, with one
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of the folds retained for testing each time. I evaluated the optimal number of clus-
ters using the Cross-Validation Information Criterion [188], i.e. by evaluating the
likelihood of each c-cluster model from c= 1 . . .C on the test data for each fold and
choosing the model with the highest out-of-sample likelihood across all folds.
7.2.2.4 Patient subtyping and staging
I assigned subjects to subtypes and stages predicted by the dynamic clustering
model by evaluating the likelihood that they belonged to each stage of each sub-
type and choosing the combination of subtype and stage with the highest likeli-
hood. When evaluating the likelihood I integrated over the set of MCMC samples
to account for the uncertainty in the model parameters, rather than just evaluating
the likelihood at the maximum likelihood parameters. This means that a patient’s
model stage indicates the average number of z-score events in the sequence that
have occurred. In the experiments I added in a normal-appearing cluster to separate
out subjects with normal-appearing brain volumes, i.e. to avoid the situation where
subjects with normal appearing brain volumes have equal probability of belonging
to the initial stage of any subtype. I classified subjects with a stage of 0 as normal-
appearing, but harsher model stage thresholds can be used for a more conservative
classification.
7.2.2.5 Static clustering
I compared the dynamic clustering model to a static clustering model, which con-
sists of a mixture of gaussians with unknown mean and variance using expectation-
maximisation. The dynamic clustering model depends on a known control popula-
tion so o ensure a fair comparison between static and dynamic clustering I included
a fixed normal-appearing cluster in the static clustering model, with a mean of 0 and
a standard deviation of 1 for all biomarkers. As for the dynamic clustering model,
I evaluated the optimal number of clusters using the Cross-Validation Information
Criterion [188].
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7.2.3 Mathematical model
The dynamic clustering model is formulated as a mixture of linear z-score EBMs.
The linear z-score EBM is based on a continuous generalisation of the EBM in
[98, 134], which I describe first.
The EBM in [98,134] describes disease progression as a series of events, where
each event corresponds to a biomarker transitioning from a normal to an abnormal
level. The occurrence of an event, Ei, for biomarker i = 1 . . . I, is informed by
the measurements xi j of biomarker i in subject j, j = 1 . . .J. The whole dataset
X = {xi j|i= 1 . . . I, j = 1 . . .J} is the set of measurements of each biomarker in each
subject. The most likely ordering of the events is the sequence S that maximises the
data likelihood
P(X |S) =
J
∏
j=1
[
I
∑
k=0
(
P(k)
k
∏
i=1
P(xi j|Ei)
I
∏
i=k+1
P(xi j|¬Ei)
)]
, (7.1)
where P(x|Ei) and P(x|¬Ei) are the likelihoods of measurement x given that
biomarker i has or has not become abnormal, respectively. P(k) is the prior like-
lihood of being at stage k, at which the events E1, . . . ,Ek have occurred, and the
events Ek+1, . . . ,EI have yet to occur. The prior P(k) is assumed to be uniform. The
likelihoods P(x|Ei) and P(x|¬Ei) are modelled as normal distributions.
In this work I reformulate the EBM in (7.1) by replacing the instantaneous
normal to abnormal events with events that represent the linear accumulation of
a biomarker from one z-score to another. The linear z-score EBM consists of a
set of N z-score events Eiz, which indicate the linear accumulation of biomarker
i = 1 . . . I to a z-score zir = zi1 . . .ziRi , i.e. each biomarker is associated with its own
set of z-scores, and so N = ∑i Ri. Each biomarker is additionally associated with a
maximum z-score, zmax, which it accumulates to at the end of stage N. I consider a
continuous time axis, t, which I choose to go from t = 0 to t = 1 for simplicity (the
scaling is arbitrary). At each disease stage k, which has a duration from t = kN+1
to t = k+1N+1 , a z-score event Eiz occurs. The biomarkers evolve as time t progresses
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according to a piecewise linear function fi(t), where
f (t) =

z1
tEz1
t for 0 < t ≤ tEz1
z1+
z2−z1
tEz2−tEz1
(t− tEz1 ) for tEz1 < t ≤ tEz2
...
zR−1+ zR−zR−1tEzR−tEzR−1
(t− tEzR−1 ) for tEzR−1 < t ≤ tEzR
zR+ zmax−zR1−tEzR
(t− tEzR ) for tEzR < t ≤ 1
To clarify, the times tEizare determined by the position of the z-score event Eiz in the
sequence S, so if event Eiz occurs in position k in the sequence then tEiz =
k+1
N+1 .
To formulate the model likelihood for the linear z-score EBM I replace (7.1)
with
P(X |S) =
J
∏
j=1
[
N
∑
k=0
(∫ k+1
N+1
k
N+1
(
P(t)
I
∏
i=1
P(xi j|t)
)
dt
)]
, (7.2)
where,
P(xi j|t) = NormPDF(xi j, fi(t),σi).
NormPDF(x,µ,σ) is the normal probability distribution function, with mean µ and
standard deviation σ , evaluated at x. I assume the prior on the disease stage P(t) is
uniform, i.e. P(t) = 1, as in the original EBM.
The overall model, M, is a mixture of linear z-score event-based models, hence
we have
P(X |M) =
C
∑
c=1
fcP(X |Sc)
here, C is the number of clusters (subtypes), and f is the proportion of subjects
assigned to a particular cluster (subtype)
7.2.4 Model fitting
7.2.4.1 Hierarchical estimation
I fit the dynamic clustering model hierarchically by initialising the fitting of the
C cluster model from the C− 1 cluster model, i.e. I solve the clustering problem
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sequentially from C = 1 . . .Cmax, where Cmax is the maximum number of clusters
I would like to fit, initialising each model using the previous model. To fit the C
cluster model using the C− 1 cluster model, I generate C− 1 candidate C cluster
models by going through each of the C− 1 clusters in turn and finding their op-
timal split into two clusters, I then use this two cluster solution together with the
other C− 2 clusters to initialise the fitting of the C cluster model. To optimise the
C cluster model I perform an expectation maximisation algorithm, alternating be-
tween updating the sequences Sc for each cluster and the fraction fc. Of these C−1
candidate C cluster models, I choose the model with the highest likelihood as the
solution to the clustering problem.
7.2.4.2 Two-cluster estimation
To find the optimal split of a cluster into two clusters, I initialise the assignments
of data points to the two clusters randomly, find the optimal model parameters for
these two data subsets, and use these cluster parameters to initialise the fitting of the
two clusters. I repeat this procedure for different random cluster assignments until
the algorithm converges to the maximum likelihood solution.
7.2.4.3 Single cluster estimation
To find the optimal model parameters (the sequence S in which the biomarkers reach
each z-score) for a single cluster I perform a greedy procedure whereby I initialise
the sequence S randomly and then I go through each z-score event e in turn and find
its optimal position in the sequence relative to the other z-score events, i.e. I fix
the order of the subsequence T = S \ e and evaluate the likelihood of the sequence
in which the event e is placed at each possible position in the subsequence T . I
keep updating the sequence S until convergence. Again I optimise the single cluster
sequence S from different random starting sequences until the algorithm converges
to the maximum likelihood solution.
7.2.5 Implementation
All experiments were performed using Matlab on a standard workstation (Intel Core
i7, 3.1 GHz, 8GB memory). For each of the model fitting procedures (hierarchical,
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two-cluster, and single cluster estimation), I repeated the optimisation for 25 start-
ing points to find the maximum likelihood solution, checking that the optimisation
displayed good convergence. I found that all start points converge to a solution that
is within a 1×10−4% tolerance level (as a percentage of the maximum likelihood),
and within the uncertainty estimated by the uncertainty estimation procedure (de-
scribed subsequently), meaning that each solution is sufficiently close to the max-
imum likelihood solution to be used for initialisation of the uncertainty estimation
procedure (MCMC algorithm). I ran an MCMC algorithm (as in [98]) to draw sam-
ples from the posterior P(M|X), taking 1,000,000 MCMC samples and checking
that the MCMC trace showed good mixing properties. I initialised the MCMC al-
gorithm at the optimal solution found using the hierarchical estimation procedure
so a burn-in period was not required. I further performed 10-fold cross-validation
of the model fitting and MCMC results to check that they were reproducible.
The computational complexity of the model fitting varies depending on three
factors. The first factor is the time taken to calculate P(M|X), which is of order
O(INJC), where I is the number of biomarkers, N is the number of biomarker
events, J is the number of subjects, and C is the number of clusters. The second
factor is the maximum number of clusters being fitted Cmax. The total time taken
for the full hierarchical optimisation scales with order O(∑Cmaxc=1 c)≈ O(c2), as each
time there is an additional cluster to estimate the parameters for. The third factor is
the time taken for the expectation maximisation and MCMC algorithms to converge.
As discussed in Chapter 3, although the space of all possible sequences has a size
of N!, where N is the number of biomarker events, the maximum pairwise distance
between any pair of sequences is N(N−1)2 . This means that the number of iterations
required for convergence of the expectation maximisation algorithm, and for the
MCMC chain to sample P(M|X), should scale with approximately O(N2C). For
the set of biomarker events and number of subjects used here, fitting 5 clusters takes
approximately 3 hours in total, and performing MCMC sampling for all 5 models
takes around 15 hours.
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7.3 Results
7.3.1 Genetic frontotemporal dementia
7.3.1.1 Dynamic clustering of all mutation carriers
Application of the dynamic clustering model to all mutation carriers in GENFI (see
visualisation in Figure 7.1, positional variance diagrams and cross-validation in
Supplementary Figure A.1) suggests that there are three population subgroups (the
profile of in-sample and out-of-sample model likelihood for different numbers of
clusters is shown in Supplementary Figure A.2) with distinct patterns of brain vol-
ume loss: a frontal group, a temporal group, and a subcortical group, which account
for 51%, 27%, and 22% of the data respectively.
The frontal group (Figure 7.1 A) has a progression pattern that begins with mild
(z-score of 1) frontotemporoparietal, cingulate and insula volume loss, followed by
aggressive (z-score escalates from 1 to 3 in quick succession) frontal lobe volume
loss and moderate volume loss (all approaching a z-score of 2 when frontal lobe
volume loss reaches a z-score of 3) in the temporal lobe, parietal lobe, cingulate,
insula, putamen and accumbens. There is relatively less volume loss in the temporal
lobe, hippocampus, amygdala and insula in this group compared to the temporal
group.
The temporal group (Figure 7.1 B) is characterised by volume loss that be-
gins in the hippocampus and amygdala and progresses to the insula, accumbens and
temporal lobe, with relative sparing of the frontal and parietal lobe compared to the
frontal group. The pattern of volume loss in the temporal group is most aggres-
sive (z-score escalating from 1 to 3 in fastest succession) in the temporal lobe and
amygdala, but also progresses quickly in the hippocampus, insula and accumbens.
The subcortical group (Figure 7.1 C) initially have volume loss in the insula,
cerebellum, hippocampus, putamen, pallidum and thalamus, which is followed by
frontal lobe and accumbens volume loss and then temporoparietal lobe volume loss.
10-fold cross-validation of the dynamic clustering results (Supplementary Fig-
ure A.1) shows good agreement across folds.
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Figure 7.1: Dynamic clustering of all mutation carriers in GENFI. Subfigures (A)-(C) show
the progression pattern of each of the three dynamic clusters estimated by the
model. The cumulative probability each region has reached a particular z-score
is shown for different stages along the progression; the cumulative probability
of a region going from a z-score of 0-sigma to 1-sigma ranges from 0 in white
to 1 in red, the cumulative probability of a region going from a z-score of 1-
sigma to 2-sigma ranges from 0 in red to 1 in magenta, and the cumulative
probability of a region going from a z-score of 2-sigma to 3-sigma ranges from
0 in magenta to 1 in blue.
7.3.1.2 Comparison with fitting a single dynamic cluster to each
mutation type
Fitting a single dynamic model to carriers of a mutation in GRN, MAPT and
C9orf72 separately (see visualisation in Figure 7.2, positional variance diagrams
and cross-validation in Supplementary Figure A.3) reveals a distinct sequence of
brain volume loss for each mutation type. The patterns of volume loss in the GRN
and MAPT groups (Figure 7.2 A and Figure 7.2 B) map well onto the frontal and
temporal patterns of volume loss recovered by dynamic clustering of all mutation
carriers (Figure 7.1 A and Figure 7.1 B). However, fitting a single model to the
C9orf72 group (Figure 7.2 C) does not map well onto the subcortical group in Fig-
ure 7.1 C. 10-fold cross-validation of the dynamic clustering results (Supplementary
Figure A.3) for each mutation group shows good agreement across folds.
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Figure 7.2: Fitting a single dynamic cluster to each mutation type in GENFI separately.
Subfigures (A)-(C) show the progression pattern obtained by fitting a single
dynamic cluster to each of the three mutation carrier groups separately. Dia-
grams as in Figure 7.1.
7.3.1.3 Dynamic clustering of GRN, MAPT and C9orf72 carrier
groups
I explored the hypothesis that there may be multiple phenotypes within the GRN,
MAPT and C9orf72 carriers by performing dynamic clustering on the GRN, MAPT
and C9orf72 mutation carriers respectively.
In the GRN mutation carrier group I found no evidence of there being more
than one cluster (Supplementary Figure A.4).
In the MAPT group I found that a two cluster model fitted better than a one
cluster model (see Supplementary Figures A.5, A.6 and A.7), with the first cluster
being a temporal cluster accounting for 73% of the data, in good agreement with
that in Figure 7.1 B and Figure 7.2 B, and the second cluster being a slightly fron-
totemporoparietal cluster that accounted for 27% of the data. However, the MAPT
carrier group has only 41 subjects and this cluster has high uncertainty so it is dif-
ficult to conclude much from this second cluster apart from the presence of outliers
within the MAPT carrier group.
By performing dynamic clustering of C9orf72 mutation carriers I found that
the C9orf72 group are best described by two sequences of brain volume loss (see vi-
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sualisation in Figure 7.3, positional variance diagrams and cross-validation in Sup-
plementary Figure A.8, model likelihood in Supplementary Figure A.9): the first
cluster (Figure 7.3 A) maps well onto the subcortical group recovered by dynamic
clustering of all mutation carriers (Figure 7.1 C), the second cluster (Figure 7.3 B)
has a progression pattern that begins with frontotemporoparietal, insula and hip-
pocampal volume loss, and is followed by aggressive frontal and temporal volume
loss and moderate volume loss in the cingulate, insula, putamen and accumbens,
albeit with high uncertainty in the ordering of the frontal, temporal and parietal
volume loss. 10-fold cross-validation of the dynamic clustering results (see Supple-
mentary Figure A.8) for each mutation group shows good agreement across folds.
All of the C9orf72 carriers (both affected and unaffected) that are assigned to the
subcortical cluster in Figure 7.1 C are assigned to the subcortical cluster in Figure
7.3 A.
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Figure 7.3: Dynamic clustering of C9orf72 mutation carriers. Subfigures (A)-(B) show the
progression pattern of each of the two dynamic clusters estimated by the model.
Diagrams as in Figure 7.1.
Of note is that the uncertainty in the sequence of z-score events estimated by
the positional variance diagram (Supplementary Figure A.8) encompasses the possi-
bility that the pattern of volume loss in Figure 7.3 B (see positional variance diagram
in Supplementary Figure A.8) is the same as the frontal pattern of volume loss in
Figure 7.1 A (see positional variance diagram in Supplementary Figure A.1). This
means that the cluster in Figure 7.3 B could represent a distinct frontotemporopari-
etal pattern of volume loss, or a more frontal pattern of volume loss consistent with
that in Figure 7.1 A. However, performing a post-hoc analysis of asymmetry in af-
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fected mutation carriers assigned to the frontal cluster (Figure 7.1 A) reveals that
there are significant differences between affected C9orf72 and GRN carriers as-
signed to the frontal subtype, with affected GRN carriers having significantly (two
sample t-test) more asymmetric atrophy patterns than affected C9orf72 carriers (p =
1.12× 10−5). Moreover, the asymmetry in the affected C9orf72 carriers assigned to
the frontal cluster was not significantly different (two-sample t-test) from affected
C9orf72 carriers assigned to the temporal, subcortical or normal-appearing cluster.
I performed several further post-hoc analyses to check for differences between
the two C9orf72 groups estimated in Figure 7.3. I classified subjects into fron-
totemporoparietal, subcortical or normal-appearing groups using the model shown
in Figure 7.3, as well as assigning them to a model stage along the progression pat-
tern for their cluster, which corresponds to the average number of z-score events
in the sequence that have occurred. The normal-appearing cluster contains subjects
assigned to model stage 0, which I added to the model to avoid subjects with nor-
mal appearing brain volumes having equal probability of belonging to the initial
stage of either of the two groups. I found no statistically significant differences in
age (two-sample t-test), estimated years from onset (two sample t-test), model stage
(chi-squared test), or scanner field strength (Fisher’s exact test), between affected
or unaffected C9orf72 mutation carriers assigned to the frontotemporoparietal and
subcortical atrophy patterns.
7.3.1.4 Classification of mutation type using dynamic clustering
The frontal, temporal and subcortical patterns of brain volume loss shown in Figure
7.1 can be used to classify subjects. To avoid the situation where subjects with nor-
mal appearing brain volumes have equal probability of belonging to the initial stage
of any of the three groups, I added in a normal-appearing cluster, which consists
of all subjects at stage 0 of the model. Table 7.1 shows the proportion of affected
mutation carriers assigned to each dynamic cluster using in-sample models and out-
of-sample models obtained from 10-fold cross-validation.
I found that the majority of the affected GRN and MAPT carriers are assigned
to the frontal and temporal subtypes respectively (93% of affected GRN carriers
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A.
Normal-
appearing
Frontal
(Figure 7.1 A)
Temporal
(Figure 7.1 B)
Subcortical
(Figure 7.1 C)
GRN 0% (0) 93% (13) 0% (0) 7% (1)
MAPT 0% (0) 9% (1) 91% (10) 0% (0)
C9orf72 0% (0) 46% (12) 27% (7) 27% (7)
B.
Normal-
appearing
Frontal
(Figure 7.1 A)
Temporal
(Figure 7.1 B)
Subcortical
(Figure 7.1 C)
GRN 0% (0) 93% (13) 0% (0) 7% (1)
MAPT 0% (0) 18% (2) 82% (9) 0% (0)
C9orf72 0% (0) 54% (14) 27% (7) 19% (5)
Table 7.1: Proportion of affected mutation carriers in GENFI assigned to each dynamic
cluster using (A) in-sample models, and (B) out-of-sample models obtained from
10-fold cross-validation. Each entry is the percentage (number) of subjects of a
particular mutation type assigned to that cluster.
are assigned to the frontal subtype, 91% of affected MAPT carriers are assigned to
the temporal subtype). In the affected C9orf72 mutation carriers however, I found
that the majority (46%) are assigned to the frontal subtype, with a further 27%
being assigned to each of the temporal and subcortical subtypes. In the unaffected
GRN and MAPT carriers I found that the majority (52% and 58% respectively) are
assigned to the normal-appearing group. In the unaffected C9orf72 carriers only
24% are assigned to the normal-appearing group, with 39%, 32% and 5% of the
unaffected C9orf72 carriers being assigned to the frontal, subcortical and temporal
clusters respectively.
7.3.1.5 Comparison to static clustering
I ascertained the utility of having a dynamic component to the clustering technique
by comparing the results to static clustering, i.e. estimating clusters that have a
single constant mean and standard deviation. To ensure a fair comparison between
static and dynamic clustering I included a fixed normal-appearing cluster in the
static clustering model, with a mean of 0 and a standard deviation of 1 for all
biomarkers, as I did for stage 0 of the dynamic clustering. Figure 7.4 visualises
the static clusters, Supplementary Table A.1 shows the parameter estimates for the
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static clustering, and Table 7.2 shows the proportion of affected mutation carriers
assigned to each static cluster using in-sample models and out-of-sample models
obtained from 10-fold cross-validation.
A. Severe
frontal
B. Severe
temporal
C. Mild
frontotemporal
normal
1-sigma
2-sigma
3-sigma
1Figure 7.4: Static clustering of all mutation carriers in GENFI. Subfigures (A)-(C) show
the progression pattern of each of the three static clusters estimated by static
clustering. Each static cluster consists of a single stage in which each region is
coloured according to its z-score value.
A.
Normal-
appearing
Severe
Frontal
(Figure 7.4 A)
Severe
Temporal
(Figure 7.4 B)
Mild
Frontotemporal
(Figure 7.4 C)
GRN 0% (0) 64% (9) 0% (0) 36% (5)
MAPT 0% (0) 0% (0) 82% (9) 18% (2)
C9orf72 12% (3) 15% (4) 27% (7) 46% (12)
B.
Normal-
appearing
Severe
Frontal
(Figure 7.4 A)
Severe
Temporal
(Figure 7.4 B)
Mild
Frontotemporal
(Figure 7.4 C)
GRN 0% (0) 64% (9) 0% (0) 36% (5)
MAPT 0% (0) 9% (1) 64% (7) 27% (3)
C9orf72 12% (3) 15% (4) 27% (7) 46% (12)
Table 7.2: Proportion of affected mutation carriers in GENFI assigned to each static cluster
using (A) in-sample models, and (B) out-of-sample models obtained from 10-
fold cross-validation. Each entry is the percentage (number) of subjects of a
particular mutation type assigned to that cluster.
Static clustering gives three disease clusters (Figure 7.4): a severe frontal clus-
ter, a severe temporal cluster, and a mild frontotemporal cluster. These clusters are
not dissimilar from the results of dynamic clustering. However, when I classify sub-
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jects into mutation types using static clustering, I see that the third mild frontotem-
poral cluster can represent an early stage of either the severe frontal or the severe
temporal subtype, meaning that it is more difficult to separate out the mutation types
using the static clusters. In the affected GRN and MAPT carriers, 64% and 82% of
affected carriers are assigned to the frontal and temporal clusters respectively, com-
pared with 93% and 91% for the dynamic clustering. 36% and 18% of the affected
GRN and MAPT carriers are assigned to the mild frontotemporal cluster, as the
clusters cannot separate the early stages of a frontal or temporal pattern of volume
loss from a milder, more diffuse, disease process. As with the dynamic clustering, in
the affected C9orf72 group I see heterogeneity in the cluster assignments: 46% are
assigned to the frontotemporal cluster, 15% are assigned to the frontal cluster, 27%
are assigned to the temporal cluster, and 12% are assigned to the normal-appearing
cluster. In the unaffected GRN and MAPT carriers I again find that the majority
(80% and 79% respectively) are assigned to the normal-appearing cluster. In the
unaffected C9orf72 carriers only 49% are assigned to the normal-appearing cluster,
with 49% being assigned to the frontotemporal cluster, and 2% being assigned to
the frontal cluster. Note that the high proportion of unaffected GRN and MAPT car-
riers assigned to the normal-appearing cluster can be achieved using the dynamic
clustering model if desired by simply increasing the model stage threshold that is
considered as normal-appearing. For example, assigning those with model stage
less than 5 to the normal-appearing group results in a proportion of 84% and 83%
(compared to 80% and 79% for static clustering) of the unaffected GRN and MAPT
carriers being assigned to the normal-appearing cluster, whilst still maintaining 93%
and 91% (compared to 64% and 82% for static clustering) of the affected GRN and
MAPT carriers being assigned to the frontal and temporal clusters.
7.3.2 Alzheimer’s disease
7.3.2.1 Dynamic clustering of the ADNI dataset
I applied the dynamic clustering technique to 3T data from ADNI (see visualisation
in Figure 7.5, positional variance diagrams and cross-validation in Supplementary
Figure A.10, model likelihood in Supplementary Figure A.11). I found that the 3T
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ADNI data is best described as three subtypes (Figure 7.5): a temporal subtype that
accounts for 35% of the data, a cortical subtype that accounts for 38% of the data,
and a subcortical subtype that accounts for 27% of the data. The temporal subtype in
Figure 7.5 A starts with atrophy in the hippocampus, amygdala and temporal lobe,
with these three regions also becoming more severe first. The cortical subtype in
Figure 7.5 B starts in the accumbens and cingulate and progresses to cortical regions
in the frontal, temporal, parietal and occipital lobes. The cortical subtype then goes
on to affect the hippocampus, amygdala and putamen, with atrophy in the parietal
and temporal lobe atrophy becoming more severe. The subcortical subtype in Figure
7.5 C begins with atrophy in the pallidum, accumbens and putamen, which goes on
to affect the hippocampus and amygdala, and then progresses to the temporal lobe.
10-fold cross-validation of the results (Supplementary Figure A.10) shows good
agreement across folds. For further validation I repeated the analysis on 1.5T data
from ADNI (see Supplementary Figures A.12, A.13 and A.14). Dynamic clustering
revealed 4 clusters in the 1.5T dataset, including temporal, cortical and subcortical
clusters in good agreement with the 3T data, but also a fourth parietal cluster that
accounted for 4% of the data, which is not seen in any of the 3T cluster models.
The main characteristic of the parietal cluster was aggressive parietal lobe atrophy,
but also severe, but slightly less aggressive, frontal, temporal, and occipital lobe
atrophy.
7.3.2.2 Association with conversion from mild cognitive impair-
ment to Alzheimer’s disease
I tested if model stage and subtype were associated with increased risk of conversion
from MCI to AD by fitting a Cox proportional hazards model with time of AD
diagnosis as the time to event data, and controlling for age, sex, education and
number of APOE4 alleles. Time to event data for subjects who did not convert was
considered censored at their last available diagnosis. I found statistically significant
associations (Table 7.3) between the risk of conversion from MCI to AD and model
stage (p = 2.34 × 10−6), subtype (p = 1.09 × 10−5), and number of APOE4 alleles
(p = 7.65 × 10−5) for the 3T dataset. These findings were reproducible in the 1.5T
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Figure 7.5: Dynamic clustering of 3T ADNI dataset. Subfigures (A)-(C) show the pro-
gression pattern of each of the three dynamic clusters estimated by the model.
Diagrams as in Figure 7.1. The cerebellum was not included as a region in the
ADNI analysis and so is shaded in dark grey.
dataset, where I again found statistically significant associations between the risk of
conversion from MCI to AD and model stage (p = 1.53 × 10−5), subtype (p = 6.94
× 10−3), and number of APOE4 alleles (p = 1.07 × 10−3). In both datasets I find
that the temporal subtype is associated with the fastest conversion times, followed
by the cortical, and then the subcortical subtype.
7.3.2.3 Association with decline in cognitive test scores
I tested if model stage and subtype were associated with faster decline in MMSE
score in AD subjects by fitting a linear model predicting decline in MMSE from sub-
type, model stage, MMSE at baseline, age, sex, education and number of APOE4
alleles. I estimated decline in MMSE by fitting a linear model to each individual’s
longitudinal MMSE scores. I found no statistically significant associations with
MMSE decline in the 3T dataset, however in the 1.5T dataset, which has longer
follow-up, I found statistically significant associations between decline in MMSE
and subtype (p = 1.40 × 10−5), model stage (p = 7.19 × 10−3) and age (p = 2.86
× 10−2). Across both the 1.5T and the 3T datasets the average rate of MMSE de-
cline was fastest in the cortical group, followed by the temporal group, and then the
subcortical group.
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Model cluster Model stage Age Sex Education APOE4
N-S-C-T 1.60‡ 1.10‡ 0.98 0.97 0.93 1.76‡
N-S 1.50 1.10∗ 1.02 1.53 0.86 1.91∗
S-C 1.68 1.10∗∗ 0.95 1.12 0.94 1.63∗
C-T 1.67∗ 1.10† 0.97 0.81 0.95 1.78†
N-C 3.58∗∗ 1.06 0.98 0.80 1.02 1.85∗∗
S-T 2.15∗ 1.12‡ 1.00 1.12 0.85∗∗ 1.80∗∗
N-T 2.90∗ 1.12† 1.02 0.86 0.92 1.97†
Table 7.3: Hazards ratios for risk of conversion from MCI to AD in ADNI 3T dataset. Each
row shows a different Cox proportional hazards model. For the first model (N-
S-C-T) it is assumed that the hazard ratio increases multiplicatively from the
Normal Appearing cluster (N) to the Subcortical cluster (S) to the Cortical clus-
ter (C) to the Temporal cluster (T), i.e. the N-S-C-T model predicts that each
cluster has a hazards ratio 1.60 times that of the previous cluster. In the remain-
ing models only two groups are compared at a time to remove the assumption
that there is the same multiplicative increase between each consecutive cluster.
Each column shows the estimated hazard ratio for that variable. Statistical sig-
nificance is indicated as: ∗ = p < 0.05, ∗∗ = p < 0.01, † = p < 1 ×10−3, ‡ = p <
1 ×10−4.
7.4 Discussion
I have demonstrated the use of a data-driven model to uncover disease subtypes
with distinct patterns of biomarker evolution in genetic FTD and AD. I have shown
the ability of the model to recover genetic subgroups of FTD without prior knowl-
edge of their mutation type. The model provides good separation of GRN and
MAPT groups, however, in the C9orf72 group the model predicts that there are two
population subgroups with distinct progression patterns. This result provides new
insights into the disease mechanisms related to the C9orf72 mutation. In AD, the
model predicts that there are three population subgroups with distinct progression
patterns: a temporal pattern, a cortical pattern and a subcortical pattern. Moreover,
I found that these subgroups had distinct characteristics at longitudinal follow-up,
with the temporal subtype being associated with the fastest conversion from MCI
to AD, and the cortical group being associated with the fastest decline in cognitive
test scores.
166 Chapter 7. A data-driven model of disease subtypes
7.4.1 Genetic frontotemporal dementia
7.4.1.1 Dynamic clustering of all mutation carriers
Performing dynamic clustering of all mutation carriers reveals that there are three
distinct patterns of volume loss: a frontal pattern, a temporal pattern and a sub-
cortical pattern (Figure 7.1). Comparing these clusters to the clusters obtained by
fitting a single dynamic cluster to each of the mutation types separately (Figure 7.2)
shows that the model can recover the frontal pattern of the GRN group (Figure 7.1
A similar to Figure 7.2 A) and the temporal pattern of the MAPT group (Figure 7.1
B similar to Figure 7.2 B).
In the C9orf72 group as a whole, however, the progression pattern does not
align well with the third subcortical cluster predicted by the model (Figure 7.1 C
different to Figure 7.2 C). Performing dynamic clustering of each of the mutation
carrier groups individually provides insight into the problem by revealing that the
C9orf72 group are in fact best modelled by two clusters (Figure 7.3): one with a
subcortical pattern and one with a frontotemporoparietal pattern. The subcortical
pattern in Figure 7.3 A is in agreement with the subcortical pattern found in all
mutation carriers in Figure 7.1 C.
There is still one cluster that is not recovered by the model: the frontotem-
poroparietal pattern in Figure 7.3 B. This is likely because the frontotemporoparietal
cluster (Figure 7.3 B) is similar to the frontal cluster (Figure 7.1 A), and so does not
improve the model likelihood enough for inclusion in the model. This hypothesis is
supported by the fact that increasing the number of clusters from three to four leads
to the addition of a frontotemporoparietal cluster (data not shown). The hypothesis
is further supported by previous findings, which have shown that the differences be-
tween the neuroimaging signatures of C9orf72 carriers and GRN carriers are small
when asymmetry is not taken into account [179], although previous work has only
considered the C9orf72 group as a whole, rather than as two groups with distinct
progression patterns. It has been shown that GRN mutation carriers have highly
asymmetric atrophy patterns in comparison to C9orf72 mutation carriers. Including
a measure of asymmetry would therefore likely improve the model’s ability to sepa-
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rate the frontal cluster (Figure 7.1 A) and the frontotemporoparietal cluster (Figure
7.3 B).
7.4.1.2 Dynamic clustering of GRN mutation carriers
I found that the GRN mutation carriers are best modelled by a single progression
pattern: the frontal pattern shown in Figures 7.1 A and 7.2 A. This result is in agree-
ment with previous studies, which have found that GRN mutations are associated
with the most severe frontal and parietal lobe atrophy [179], with relative sparing of
the medial temporal lobe.
7.4.1.3 Dynamic clustering of MAPT mutation carriers
The general pattern of atrophy in the MAPT carriers (Figures 7.1 B and 7.2 B) is
in agreement with previous findings, showing severe temporal lobe atrophy, with
relative sparing of the frontal and parietal lobes [179]. By performing dynamic
clustering of the MAPT mutation carriers, I found that the MAPT group are best
modelled as two groups with distinct progression patterns (Supplementary Figures
A.5 and A.6), with 73% of the MAPT carriers following a temporal progression pat-
tern (which shows good correspondence with the general pattern of atrophy shown
in Figures 7.1 B and 7.2 B), and 26% following a frontotemporoparietal pattern,
somewhat similar to that of the C9orf72 subgroup in Figure 7.3 B, but with very
high uncertainty (Supplementary Figure A.6 B). This uncertainty is likely due to
the small number of MAPT carriers (35, of which 24 are unaffected and 11 are
affected), but could also represent variation in the alternative progression pattern.
Whilst this result does suggest that there is heterogeneity within the MAPT group,
the uncertainty is too high to make any conclusions about the ordering within the
second MAPT subgroup.
7.4.1.4 Dynamic clustering of C9orf72 mutation carriers
In the C9orf72 group I found that there are two distinct progression patterns (Fig-
ure 7.3): a subcortical pattern and a frontotemporoparietal pattern. This result is
well aligned with previous work, which suggests that the C9orf72 mutation carri-
ers are the most heterogeneous [179, 189], but in contrast to previous work I am
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able to characterise this heterogeneity as two distinct progression patterns. The
subcortical progression pattern (Figure 7.3 A) is unique to the C9orf72 group, and
resembles previous findings, which have shown significant subcortical involvement
in C9orf72 mutation carriers [189]. The frontotemporoparietal pattern (Figure 7.3
B) is similar to the progression pattern of the GRN group (Figure 7.2 A), which is
interesting as previous studies have shown that it is difficult to differentiate between
C9orf72 and GRN mutation carriers [179, 189] without accounting for asymmetry.
A post-hoc analysis of asymmetry revealed that the GRN group had significantly
more asymmetric atrophy than the C9orf72 mutation carriers that were assigned to
the frontotemporoparietal pattern. This finding suggests that although the affected
regions are similar, the underlying mechanisms in the GRN and C9orf72 groups are
different, with the mechanism in the GRN mutation carriers preferentially affecting
one side of the brain.
7.4.1.5 Classification of mutation type using dynamic clustering
I demonstrated that the model can differentiate between the GRN and MAPT mu-
tation groups (Table 7.1), with 93% of affected GRN carriers being assigned to the
frontal subtype (Figure 7.1 A) and 91% of affected MAPT carriers being assigned to
the temporal subtype (Figure 7.1 B). In the affected C9orf72 mutation carriers how-
ever, I found that the majority (46%) of participants were assigned to the frontal
pattern in Figure 7.1 A, with a further 27% being assigned to the temporal pat-
tern (Figure 7.1 B), and 27% to the subcortical pattern (Figure 7.1 C). Including a
measure of asymmetry would improve the ability to differentiate between the GRN
mutation carriers and the subset of the C9orf72 mutation carriers that are assigned
to the frontal pattern of volume loss in Figure 7.1 A.
7.4.1.6 Comparison to static clustering
I compared the dynamic clustering model to a standard ‘static’ clustering model,
in which each cluster constitutes a static biomarker profile, rather than a temporal
progression pattern. Compared to static clustering, dynamic clustering provides a
much more detailed picture of disease progression, and better separates the differ-
ent genetic frontotemporal dementia subtypes. This is because dynamic clustering
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is able to separate disease subtypes from disease stages, whereas static clustering
produces clusters that are a mixture of disease subtypes and disease stages.
7.4.2 Alzheimer’s disease
7.4.2.1 Dynamic clustering of ADNI dataset
Dynamic clustering of the ADNI dataset reveals that there are three clusters with
distinct patterns of biomarker evolution: a temporal, a cortical and a subcortical
pattern. These clusters are seen in both the 1.5T and the 3T datasets. These three
clusters are somewhat in agreement with previous neuropathological findings [27],
which have defined three subtypes of AD based on the distribution of neurofibril-
lary tangles: typical, hippocampal-sparing and limbic-predominant. The temporal
cluster (Figure 7.5 A and Supplementary Figure A.12 A) resembles the pattern of
atrophy seen in typical AD; the cortical cluster (Figure 7.5 B and Supplementary
Figure A.12 B) is similar to hippocampal-sparing AD; the subcortical cluster re-
flects the atrophy pattern of limbic-predominant AD (Figure 7.5 C and Supplemen-
tary Figure A.12 C). These three distinct patterns of atrophy have been shown on
MRI previously [154, 190], both when groups are defined pathologically [154], or
in a more data-driven manner [190].
In contrast to previous studies, I am able to characterise the earliest sites of
regional volume loss for each subgroup. I find that regional volume loss in the
temporal group (typical AD, Figure 7.5 A and Supplementary Figure A.12 A) is first
detectable in the hippocampus and amygdala, whereas regional volume loss in the
cortical group (hippocampal-sparing AD, Figure 7.5 B and Supplementary Figure
A.12 B) is first detectable in the insula and cingulate, and regional volume loss in
the subcortical group (limbic-predominant AD, Figure 7.5 C and Supplementary
Figure A.12 C) is first detectable in the pallidum and putamen.
When using the 3T data I additionally found that the accumbens area is impli-
cated as one of the earliest detectable sites of regional volume loss in the cortical
and subcortical groups, which I did not find in the 1.5T data. This might be because
small areas, such as the accumbens, are more visible in the 3T data, but this result
requires further validation.
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In the 1.5T dataset I found an additional cluster with a parietal atrophy pat-
tern, accounting for 4% of the data. This cluster may represent outliers who have
posterior cortical atrophy, which is an atypical variant of AD that causes atrophy of
the posterior part of the cerebral cortex, leading to progressive disruption of visual
processing. Parietal atrophy patterns were also found as a possible fourth cluster by
the study of Zhang et al. [190], although their study found that optimal model of
sporadic AD consisted of three clusters.
7.4.2.2 Association with conversion from mild cognitive impair-
ment to Alzheimer’s disease
I found that each of the dynamic clusters of AD was associated with different pa-
tient outcomes. I found significant associations between the risk of conversion from
MCI to AD and subtype in both the 3T and 1.5T datasets. Moreover, I also found
significant associations with model stage and risk of conversion, meaning that the
staging and subtyping information provided by the model could provide comple-
mentary information for both patient staging and stratification.
7.4.2.3 Association with decline in cognitive test scores
In the 1.5T dataset, I found statistically significant associations between decline in
MMSE and subtype (p = 1.40 × 10−5), model stage (p = 7.19 × 10−3) and age
(p = 2.86 × 10−2). Across both the 1.5T and the 3T datasets the average rate of
MMSE decline was fastest in the cortical group, followed by the temporal group,
and then the subcortical group. These results are in agreement with the study of
Zhang et al. [190], which also found that cortical atrophy patterns are associated
with the fastest decline in MMSE score, followed by temporal atrophy patterns and
then subcortical atrophy patterns.
7.5 Conclusion
I have developed a dynamic clustering model that characterises disease subtypes
with distinct biomarker trajectories (contribution 1.3.3 (a), Chapter 1, page 41). I
have demonstrated the ability of the model to recover known genetic subgroups of
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FTD without prior knowledge of their mutation type for GRN and MAPT mutation
carriers (contribution 1.3.3 (b), Chapter 1, page 41). The model further provides
new insights into heterogeneity in the C9orf72 mutation carrier group by revealing
that this group are best modelled by two disease progression patterns: a subcorti-
cal pattern and a frontotemporoparietal pattern. In AD, dynamic clustering predicts
there are three longitudinal patterns of atrophy: temporal, cortical and subcorti-
cal (contribution 1.3.3 (c), Chapter 1, page 41). I further demonstrated that these
patterns are associated with distinct characteristics at longitudinal follow-up. The
dynamic clustering model presented here has wide potential further applications:
for characterising heterogeneity in other diseases, and as a patient staging and strat-
ification mechanism for precision medicine.

Chapter 8
Further work
8.1 Overview
This chapter discusses three broad areas of opportunity for future work: (1) further
applications of the models developed in this thesis; (2) opportunities for technologi-
cal enhancement of the models presented in this thesis; (3) methodological advances
that can be made in the wider spectrum of data-driven models.
8.2 Further applications
8.2.1 Application in neurodegenerative diseases
There are numerous opportunities for further application of the models developed
in this thesis in various neurodegenerative diseases.
8.2.1.1 Alzheimer’s disease
In AD, this thesis has explored the sequence of biomarker changes in both the spo-
radic and dominantly-inherited disease forms. Chapter 3 investigated the sequence
in which a multi-modal set of biomarkers become abnormal in sporadic AD. Chap-
ter 4 performed a similar study using dominantly-inherited AD biomarker data.
Chapter 7 examined the heterogeneity of biomarker trajectories of regional volume
loss in sporadic AD.
The model developed in Chapter 7 was only applied to volumetric MRI data
here. In future it will be interesting to characterise the heterogeneity in the sequence
of biomarker changes for a more multi-modal set of biomarkers that includes CSF
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measures, PIB-PET, FDG-PET, and cognitive test scores. Of particular interest
is the inclusion of cognitive test scores as the subtypes found in Chapter 7 were
shown to have different rates of decline in cognitive test scores. The incorporation
of subscales that measure more specific types of cognitive deficits will determine
whether there are observable differences in the sequence in which different areas of
cognition decline for each subtype.
In Chapter 4 I observed that there were subtle differences in the sequence
of biomarker abnormality in dominantly-inherited AD for different mutation types
(APP vs. PSEN1 and PSEN2) and genetic subgroups (APOE4 positive vs. APOE4
negative). Application of the dynamic clustering model developed in Chapter 7 will
determine whether the dominantly-inherited AD data is better described by multi-
ple trajectories. If so, it will be interesting to see whether the optimal clustering of
dominantly-inherited AD biomarker trajectories corresponds to different mutation
types or genetic subgroups, or whether the relationship is more nuanced.
8.2.1.2 Frontotemporal dementia
In Chapter 7 I developed a dynamic clustering model that finds population sub-
groups with distinct sequences of biomarker changes. Application of the model
to genetic frontotemporal dementia (FTD) revealed that the participants carrying a
C9orf72 mutation are best described by two patterns of regional MRI volume loss:
a subcortical and a frontotemporoparietal pattern.
Further analysis of the C9orf72 group including a more multi-modal set of
biomarker data will provide interesting insights into the underlying disease biology
of these two observed patterns. Of particular interest is the inclusion of neuropsy-
chological test scores and subscales. It is thought that subcortical involvement in the
C9orf72 group causes the neuropsychiatric symptoms that a subset of the C9orf72
mutation carriers present with [189]. A subset of C9orf72 mutation carriers present
with behavioural variant FTD [189]; this group may be better aligned with the fron-
totemporoparietal pattern of volume loss.
Another opportunity for future work is the clustering of sporadic FTD, in
which patients exhibit different patterns of presentation, to uncover data-driven sub-
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groups with distinct patterns of biomarker changes. These data-driven sporadic FTD
subgroups can then be compared with the genetic subgroups established in Chapter
7.
8.2.1.3 Other neurodegenerative diseases
The models proposed in this thesis are equally applicable to other neurodegenerative
diseases. Determining the sequence of biomarker changes in other neurodegenera-
tive diseases, such as Parkinson’s disease, Huntington’s disease, amytrophic lateral
sclerocis, vascular dementia and posterior cortical atrophy will allow a direct com-
parison of the progression of the different diseases and produce a set of models that
can potentially be used for differential diagnosis.
8.2.2 Application to other diseases or processes
The models developed in this thesis potentially generalise to a wider range of
diseases and processes. Examples include chronic obstructive pulmonary disease
(COPD), cancer, multiple sclerosis, normal ageing and developmental processes.
Different diseases can present specific methodological challenges however, for ex-
ample in multiple sclerosis there are both destructive and healing processes, which
violates the assumption typically made by data-driven models of monotonic pro-
gression patterns.
8.3 Methodological developments of the models pre-
sented in this thesis
This section discusses methodological developments that are more specific to the
models presented in this thesis.
8.3.1 Event distributions
All of the models presented here depend on the definition of a distribution of ‘nor-
mal’, and, in the case of the event-based models (EBMs) developed in Chapters 3, 4
and 6, ‘abnormal’ measurements. However, often the exact definition of these dis-
tributions is unclear. For example, the control population may have small numbers
or contain outliers, or it may be difficult to decide what constitutes ‘abnormal’, par-
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ticularly for biomarkers that change slowly over time, which are not well described
as a binary transition from ‘normal’ to ‘abnormal’. Future work will explore mod-
elling the uncertainty in these distributions to establish the effect of the choice of
event distribution parameters on the resulting models of biomarker evolution. An-
other key area for further development is the incorporation of non-gaussian event
distributions, this is particularly important for cognitive tests, which are typically
discrete measures.
8.3.2 Partial sequences
The models presented in this thesis assume that all biomarker events in the sequence
occur. In the case of the EBMs developed in Chapters 3, 4 and 6 this is particularly
problematic as when a biomarker has no signal the distribution of ‘normal’ and ‘ab-
normal’ measurements may overlap. This can lead to the corresponding event erro-
neously appearing early in the sequence. Development of models with partial event
sequences could resolve this problem. In such a model only biomarkers that are
better modelled as two distributions: ‘normal’ and ‘abnormal’ would be included as
events.
With the z-score model developed in Chapter 7 this problem is resolved as
the disease group will have a similar distribution of z-scores to the control group,
and therefore no change in z-score will be observed. However, it is still desirable
to develop models that do not assume all biomarker events occur in order to find
the most parsimonious model of disease progression. In the case of fitting multiple
biomarker trajectories for example, it may be that a specific sub-population, for ex-
ample a set of misdiagnosed patients, is only observed early in the disease because
later in the disease it is easier to filter out those who have been misdiagnosed. In
this case it would be nicer to be able to truncate the set of biomarker events, rather
than assuming that the other events will occur eventually.
8.3.3 Time
A more fundamental limitation of the models proposed in this thesis is that they do
not incorporate time: they are temporal in the sense that the events happen in an
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order, but there is no notion of event duration. In some cases this is desirable as
it allows the models to be fitted to purely cross-sectional datasets, but the majority
of datasets do have some short-term follow-up time points available. When longi-
tudinal follow-up is available it should be possible to determine how long it takes
for each biomarker to transition from one state to the next by observing patients in
which this transition occurs. Future work will develop a mathematical formulation
of this idea to allow the time between each transition to be determined.
8.3.4 Missing data
In Chapter 4 a simple adaptation of the EBM for use with missing data was devel-
oped. This adaptation was based upon the assumption that the data is missing at
random and is not applicable to the z-score models developed in Chapter 7. Fu-
ture work will develop more advanced techniques for handling missing data that
alleviate this assumption, for example using data imputation strategies.
8.3.5 High-dimensional biomarkers
In their current form the proposed models take as input scalar biomarker values.
This means that complex high-dimensional biomarkers, such as those from imaging,
have to be pre-processed to derive scalar measurements, such as regional volumes.
Extension of the models for use with high-dimensional biomarkers would alleviate
this problem and further provide much more spatially detailed pictures of disease
progression. There are two major methodological barriers to developing such a
model. The first is the combinatorial complexity of the problem. The models work
by searching for a sequence of biomarker changes, the space of possible sequences
is N!, where N is the number of biomarker changes being modelled. This com-
plexity becomes intractable for high-dimensional biomarkers. Future work might
develop techniques that reduce the dimensionality of this search space. The second
problem is that high-dimensional biomarkers often have complex correlation struc-
tures that are not modelled here. The recent work of Bilgel et al. [133] proposed a
set of correlation structures for images, which it may be possible to incorporate into
the models.
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8.3.6 Within-subject models
The models developed in this thesis compare biomarker measurements cross-
sectionally between subjects. In order to develop models that are optimal for ap-
plication to longitudinal within-subject data, further adaptations of the models will
need to be made that can estimate intra-subject variability in biomarker measure-
ments.
8.4 Broader technical advances
In this section I discuss technical advances that can be made to a broader range of
data-driven models.
8.4.1 Mixed pathology
Data-driven models to date have modelled a single disease process, or a set of in-
dividual disease processes, where each patient belongs to a single disease. How-
ever, neuropathological studies show that the majority of dementia cases have mixed
pathology. Models that can disentangle different pathological processes therefore
present an interesting opportunity for further methodological development.
8.4.2 Integration of data-driven and mechanistic models
There are several types of mechanistic model that have provided interesting insights
into neurodegenerative disease progression but depend on a priori disease staging
information. Future work could integrate these models with data-driven statistical
methodology to remove their reliance on a priori knowledge of disease stage. This
will allow more complex disease progression patterns to be recovered.
Network models describe disease progression as evolving along structural or
functional networks, starting from a particular region. To infer the region from
which the disease process is initiated, they compare the patterns of atrophy pre-
dicted by network models with different starting regions to the pattern of atrophy
seen in AD [125]. The choice of starting region is therefore dependent only on
how well the network model aligns with a coarse end stage pattern of atrophy, and
more complex disease mechanisms cannot be estimated. Using data-driven mod-
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els, more detailed pictures of disease progression can be recovered for the full dis-
ease time course. Incorporating these data-driven progression patterns into network
modelling approaches could allow more complex models to be fitted. For example,
current network models are typically based on the prion hypothesis, which posits
that disease proteins are physically transmitted between neurons. The alternative
hypothesis is that of selective vulnerability: that some regions are more vulnerable
to disease pathology than others. It has been proposed that there may be a com-
bination of these processes in operation [54]. Data-driven network models may
be able to determine whether one or both of these processes better models disease
progression patterns.
Spatiotemporal models describe the spatial as well as the temporal evolution of
disease progression. However, these models are dependent on a priori knowledge
of disease stage and so their temporal resolution is coarse. The development of
data-driven spatiotemporal models offers the possibility of combining the detailed
spatial pictures of disease progression recovered by spatiotemporal models with the
fine-grained temporal resolution of data-driven models.
8.4.3 Dimensionality reduction
Another potential development of data-driven models is the inclusion of dimension-
ality reduction techniques to take complex data types, such as images, and extract
key information relevant to disease progression at each stage. Sparse learning tech-
niques, for example, could be used to choose a subset of voxels of an MRI image
that are the most sensitive to disease progression at each stage. A particular ad-
vantage of combining sparse learning techniques with data-driven models would
be that at any point in time you could model only the voxels that were relevant to
that particular stage. For example, brain regions that become abnormal late in the
disease would only be modelled at the late disease stages.
8.4.4 Incorporating additional data types
To date, data-driven models have largely considered biomarker measurements
alone. The incorporation of additional data types such as genetics, demographic
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information, lifestyle factors or medical records can potentially make the models
more powerful. Such measurements might be used to reduce heterogeneity in the
biomarker measurements, thereby increasing the power for detecting disease pathol-
ogy compared to a control population. For instance, it has been shown that common
genetic variants have specific influences on the volume of subcortical brain struc-
tures [191]. By having a model of the expected volume of different brain structures
based on a subjects genetic profile, it may be possible to detect more subtle disease-
related changes in volume. Additional data types could also be used to provide
supporting information for a particular diagnosis or staging assignment, for exam-
ple medical records may be indicative of an increased risk for a particular disease.
8.4.5 Validation
The simulation system presented in Chapter 5 provides a basic framework for gener-
ating synthetic data to validate data-driven disease progression models. This frame-
work is used to test the robustness of two data-driven models: the EBM and a
differential equation model. Future work will compare a larger range of data-driven
models, and develop more complex simulation systems that can simulate MRI scans
to validate high-dimensional models. Another important aspect of the validation of
data-driven models is testing their reproducibility, and determining whether they
can be translated for use in new datasets.
8.4.6 Patient staging systems
A promising outcome of data-driven models is the natural patient staging system
they provide: subjects can be matched to their most probable point along the dis-
ease trajectory according to their biomarker measurements. However, these models
are not specifically optimised for patient staging. Further work will explore the de-
velopment of data-driven models that are designed to make optimal patient staging
and diagnostic decisions. There are several open problems in this area. One aspect
is biomarker utility (discussed in detail in the subsequent subsection), i.e. determin-
ing the most useful set of measurements to take in order to make a particular staging
or diagnostic decision. Another aspect is designing an intuitive staging system for
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clinical practice: a rich continuous model may provide more information than is
necessary, for example, confusing the diagnostic process.
8.4.7 Biomarker utility
Complex models can provide biological insights by integrating information from
multimodal biomarkers to build up a detailed picture of the progression of differ-
ent pathologies in relation to one another. For application of a biomarker in clinic
however, the cost of taking different types of measurement needs to be considered.
To date there has been relatively little work on optimising the set of measurements
that are made to inform a particular clinical decision. Data-driven models can pro-
vide a basis on which such an optimisation can be performed. For example, the
fine-grained quantitative models of biomarker evolution generated using data-driven
models can be used to determine the sensitivity of various biomarkers for measuring
changes in disease stage at a particular point along the disease time course. New
mathematical models of biomarker utility can be developed that weight this sensi-
tivity against the cost of acquiring each measurement to decide which biomarker,
or set of biomarkers, is optimal. Similar technical developments can be made that
inform differential diagnosis.
8.5 Summary
The models proposed in this thesis have wide potential application to a range of
diseases and developmental processes. There are several possible methodological
enhancements to the models presented here, of particular interest are the incorpora-
tion of time measures and extension to high dimensional biomarkers. Data-driven
models in general are an emerging technology with a broad range of opportunities
for further work, such as the incorporation of additional data types, optimal design
of patient staging systems, and determination of biomarker utility.

Chapter 9
Summary and conclusion
9.1 Chapter 1. Introduction
AD is a progressive neurodegenerative disorder that is characterised by the accu-
mulation of amyloid plaques and neurofibrillary tangles in brain tissue. These
pathologies are thought to give rise to downstream neurodegeneration and cogni-
tive deficits, however the biological mechanisms of AD are not well understood.
Biomarkers have been developed to allow the pathologies of AD to be monitored in
vivo. These biomarkers include CSF measures of Aβ1−42, phosphorylated tau and
total tau, volumetric MRI measures of neurodegeneration and cognitive test scores.
Understanding the quantitative evolution of biomarkers in AD is key to provid-
ing precision medicine, which will enable more effective clinical trials, as well as
personalised treatment plans once disease-modifying drugs are available. In clin-
ical trials, quantitative models of biomarker progression can be used to identify
and monitor the presymptomatic disease stages, during which treatments may be
more effective. Additionally, a quantitative picture of biomarker progression can
provide insights into the underlying disease biology by, for example, indicating
which is the initiating disease pathology, or elucidating interactions between differ-
ent pathogenic processes. However, reconstructing a detailed quantitative picture of
biomarker progression in AD is difficult due to the coarse disease staging measures,
which typically consist of just three stages, and the long disease time course, which
is thought to span several decades.
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This thesis developed data-driven models of biomarker progression that char-
acterise the quantitative evolution of biomarker measurements without reliance on
a priori knowledge of disease stage. The models developed in this thesis provide
a fine-grained picture of biomarker evolution, and have clinical utility for patient
staging.
9.2 Chapter 2. State of the art in Alzheimer’s disease
progression modelling
Various different progression models have been applied to AD. Neuropathological
models and animal models provide interesting biological insights but do not directly
provide quantitative measures of disease stage, limiting their utility for patient stag-
ing and monitoring. Biomarker models have been developed to allow subjects to
be monitored in vivo. Scalar biomarker models combine information from multi-
ple single dimensional biomarkers. These models are highly relevant clinically as
they integrate measurements from well established biomarkers, however their de-
pendence on a priori knowledge of disease stage limits their temporal resolution.
High dimensional models learn new biomarkers from complex data types, such as
images, but still require subjects to be indexed by disease stage. Data-driven mod-
els [99] develop novel statistical methodology to allow the temporal progression of
biomarkers to be reconstructed without prior knowledge of each individual’s posi-
tion along the disease time course. Such models can recover more detailed disease
progression patterns for fine-grained patient staging. However, data-driven mod-
els are still an emerging technology, and require further validation and refinement
before they are translated into a useful clinical tool.
9.3 Chapter 3. A data-driven model of biomarker
changes in sporadic Alzheimer’s disease
In this chapter I demonstrated the use of a probabilistic generative model to explore
the biomarker changes occurring as AD develops and progresses [134]. I enhanced
the event-based model (EBM) [98] for use with a multi-modal sporadic disease data
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set (contribution 1.3.1 (a), Chapter 1, page 39). This allowed the sequence in which
AD biomarkers become abnormal to be determined without reliance on a-priori
clinical diagnostic information or explicit biomarker cut points. The model also
characterises the uncertainty in the ordering and provides a natural patient staging
system.
I used the EBM to determine the sequence of biomarker abnormality and its
uncertainty in various population subgroups from the Alzheimer’s Disease Neu-
roimaging Initiative (ADNI) (contribution 1.3.1 (b), Chapter 1, page 39). I used
patient stages assigned by the EBM to discriminate CN from AD subjects, and pre-
dict conversion from MCI to AD and CN to MCI.
The model predicted that CSF levels become abnormal first, followed by rates
of atrophy, then cognitive test scores, and finally regional brain volumes. In amyloid
positive or APOE4 positive subjects, the model predicted with high confidence that
the CSF biomarkers become abnormal in a distinct sequence: Aβ1−42, p-tau, t-tau.
However, in the broader population t-tau and p-tau were found to be earlier CSF
markers than Aβ1−42, albeit with more uncertainty. The model’s staging system
strongly separated CN and AD subjects, and predicted conversion from MCI to
AD, and from CN to MCI. By fitting Cox Proportional Hazards models, I found
that baseline model stage was a significant risk factor for conversion from both
MCI to AD and CN to MCI.
The results support hypothetical models of biomarker ordering in amyloid pos-
itive and APOE4 positive subjects, but suggest that biomarker ordering in the wider
population may diverge from this sequence. The model provides useful disease
staging information across the full spectrum of disease progression, from CN to
MCI to AD.
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9.4 Chapter 4. A data-driven model of biomarker
changes in dominantly-inherited Alzheimer’s dis-
ease
This chapter explored the sequence in which biomarker changes occur in
dominantly-inherited AD. The EBM [98] was enhanced for use with missing data
(contribution 1.3.1 (c), Chapter 1, page 39), facilitating its application to a multi-
modal dominantly-inherited AD dataset from the Dominantly Inherited Alzheimer
Network (DIAN) study.
I estimated the sequence of biomarker abnormality for various population sub-
groups of the DIAN study (contribution 1.3.1 (d), Chapter 1, page 39). I found
that the sequence of biomarker abnormality for all mutation carriers broadly agrees
with previous work: PIB-PET deposition becomes abnormal first, followed by CSF
levels, and then regional volumetric MRI measures, cognitive test scores and FDG-
PET hypometabolism. In comparison to previous work, the sequence estimated
by the EBM does not depend on familial age of onset and provides more detailed
progression patterns than have been seen previously. Although based on small num-
bers, the results for the population subgroups suggest minor subtle differences in the
ordering for different genetic groups. In particular, CSF Aβ1−42 becomes abnormal
before CSF tau in the APP mutation carriers and APOE4-positive group, with the
reverse for the PSEN1 and PSEN2 mutation carriers and APOE4-negative group.
I further demonstrated the utility of the EBM for patient staging in dominantly-
inherited AD: the model separated non-carriers from affected mutation carriers with
a high classification accuracy and showed good longitudinal consistency at follow-
up.
9.5 Chapter 5. A simulation system for biomarker
evolution in neurodegenerative disease
In this chapter I presented a framework for simulating cross-sectional or longitu-
dinal biomarker data sets from neurodegenerative disease cohorts that reflect the
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temporal evolution of the disease and population diversity [167] (contribution 1.3.2
(a), Chapter 1, page 40). The simulation system provides a mechanism for eval-
uating the performance of data-driven models of disease progression, which bring
together biomarker measurements from large cross-sectional (or short term longitu-
dinal) cohorts to recover the average population-wide dynamics.
I demonstrated the use of the simulation framework in two different ways (con-
tribution 1.3.2 (b), Chapter 1, page 40). First, to evaluate the performance of the
EBM for recovering biomarker abnormality orderings from cross-sectional datasets.
Second, to evaluate the performance of a differential equation model (DEM) for re-
covering biomarker abnormality trajectories from short-term longitudinal datasets.
The results highlighted several important considerations when applying data-
driven models to sporadic disease datasets as well as key areas for future work. The
system revealed several important insights into the behaviour of each model. For
example, the EBM is robust to noise on the underlying biomarker trajectory param-
eters, under-sampling of the underlying disease time course and outliers who follow
alternative event sequences. However, the EBM is sensitive to accurate estimation
of the distribution of normal and abnormal biomarker measurements. In contrast, I
found that the DEM is sensitive to noise on the biomarker trajectory parameters, re-
sulting in an over estimation of the time taken for biomarker trajectories to go from
normal to abnormal. This over estimate is approximately twice as long as the actual
transition time of the trajectory for the expected noise level in neurodegenerative
disease datasets.
This simulation framework is equally applicable to a range of other models and
longitudinal analysis techniques.
9.6 Chapter 6. Multiple orderings of events in dis-
ease progression
The EBM [98] relies on the assumption that all subjects follow a single event se-
quence. This is a major simplification for sporadic disease data sets, which are
highly heterogeneous, include distinct subgroups, and contain significant propor-
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tions of outliers.
In this chapter I relaxed this assumption by considering two extensions to the
EBM [170]: a generalised Mallows model, which allows subjects to deviate from
the main event sequence, and a Dirichlet process mixture of generalised Mallows
models, which models clusters of subjects that follow different event sequences,
each of which has a corresponding variance. I developed a Gibbs sampling tech-
nique to infer the parameters of the two models from multi-modal biomarker data
sets.
I applied this technique to data from ADNI to determine the sequence in which
brain regions become abnormal in sporadic AD, as well as the heterogeneity of that
sequence in the cohort. I found that the generalised Mallows model estimates a
larger variation in the event sequence across subjects than the original EBM. Fitting
a Dirichlet process model detected three subgroups of the population with different
event sequences. The Gibbs sampler additionally provided an estimate of the uncer-
tainty in each of the model parameters, for example an individual’s latent disease
stage and cluster assignment.
A major limitation of this work is that the models are overly complex. In par-
ticular, the variance parameter required for the generalised Mallows model hugely
increases the model complexity without any gain in the clinical utility of the models.
In the subsequent chapter I developed a more parsimonious model of heterogeneous
biomarker progression patterns.
9.7 Chapter 7. A data-driven model of disease sub-
types with distinct patterns of biomarker evolu-
tion in frontotemporal dementia and Alzheimer’s
disease
Neurodegenerative diseases are often heterogeneous between and within patholo-
gies, with both different types (between) and the same type (within) of pathology
spreading with different spatial patterns. In frontotemporal dementia (FTD) differ-
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ent between and within pathology subtypes have been described. In AD three within
pathology subtypes have been defined according to the distribution of neurofibril-
lary tangle counts. However, current knowledge of neurodegenerative disease sub-
types is limited to a coarse overall pattern of volume loss in groups of subjects at a
single disease stage; little consideration has been given to the temporal progression
that leads to that pattern.
In this chapter I presented a probabilistic generative model of disease progres-
sion that uncovers population subgroups with distinct patterns of biomarker evolu-
tion (contribution 1.3.3 (a), Chapter 1, page 41). I demonstrated the ability of the
model to recover known genetic subtypes of FTD using volumetric MRI data from
the Genetic Frontotemporal Dementia Initiative (GENFI) (contribution 1.3.3 (b),
Chapter 1, page 41). The results further revealed that subjects with a pathogenic
mutation in chromosome 9 open reading frame 72 (C9orf72) are best described by
two disease progression patterns: a subcortical and a frontotemporoparietal pattern.
Application of the model to AD using volumetric MRI data from ADNI un-
covered three data-driven subtypes: temporal, cortical, and subcortical, comparable
to those observed in neuropathological studies (contribution 1.3.3 (c), Chapter 1,
page 41). In comparison to previous studies, the model characterises the evolution
of these subtypes as the disease progresses, including the earliest sites of regional
volume loss. By fitting a Cox proportional hazards model I found that the time taken
to convert from MCI to AD is significantly different between the different subtypes,
independently of model stage, with the temporal subtype being associated with the
fastest conversion times.
This approach has the potential to facilitate precision medicine by uncovering
disease subtypes and quantifying their corresponding patterns of biomarker evolu-
tion across diseases.
9.8 Chapter 8. Further work
In Chapter 8 I discussed potential opportunities for further work, covering three
main areas: (1) further applications of the models developed in this thesis; (2) op-
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portunities for technological enhancement of the models presented in this thesis;
(3) methodological advances that can be made in the wider spectrum of data-driven
models.
9.9 Conclusion
This thesis has explored the progression and heterogeneity of AD by developing
quantitative models of biomarker evolution. By proposing two adaptations to the
EBM [98], I have been able to characterise the sequence of biomarker changes
in both sporadic and dominantly-inherited AD. In sporadic AD the models pro-
vide support for hypothetical models of disease progression [74], without reliance
on a priori knowledge of disease stage or the use of cut points defining abnormal
biomarker levels. I further demonstrated the ability of the model to stage patients
throughout the full disease time course. In dominantly-inherited AD, I found that
the series of biomarker changes predicted by the models broadly agrees with current
knowledge, but provides a much more detailed picture of disease progression than
previous work. I additionally found that there may be subtle differences between
the PSEN1, PSEN2 and APP carrier groups. I then developed a simulation sys-
tem to validate data-driven models of disease progression and applied this system
to perform a stability analysis of the EBM and a DEM. Finally, I presented a dy-
namic clustering technique that reveals population subgroups with distinct patterns
of biomarker evolution. I demonstrated the ability of this model to recover known
subtypes of genetic FTD. The model further provided interesting biological insights
into the C9orf72 mutation carrier group by revealing that this group are best mod-
elled by two progression patterns: a subcortical and a frontotemporoparietal pattern.
Dynamic clustering of sporadic AD uncovered three data-driven disease subtypes:
temporal, cortical and subcortical, which were found to have different conversion
times between diagnoses. The models proposed in this thesis have made several
novel contributions to AD research and have wide potential further application to
other diseases and developmental processes.
Appendix A
Supplementary figures and tables for
Chapter 7
Normal-
appearing
Severe
Frontal
Severe
Temporal
Mild
Frontotemporal
Frontal 0.00 (1.00) 4.31 (1.00) 1.87 (1.13) 1.44 (1.06)
Temporal 0.00 (1.00) 1.74 (1.17) 4.43 (1.48) 1.29 (1.15)
Parietal 0.00 (1.00) 2.77 (0.88) 0.89 (0.94) 1.02 (0.88)
Occipital 0.00 (1.00) 0.49 (1.19) 0.38 (0.80) 0.39 (1.07)
Cingulate 0.00 (1.00) 2.67 (0.50) 1.35 (0.96) 0.70 (1.01)
Insula 0.00 (1.00) 2.36 (0.79) 3.81 (0.89) 1.40 (1.01)
Cerebellar 0.00 (1.00) 0.79 (0.74) 0.71 (1.03) 0.35 (0.80)
Hippocampus 0.00 (1.00) 0.92 (0.81) 3.48 (1.26) 1.14 (0.69)
Amygdala 0.00 (1.00) 0.25 (0.88) 4.30 (1.38) 0.68 (0.81)
Caudate 0.00 (1.00) 1.60 (0.88) 1.43 (0.88) 0.37 (1.16)
Putamen 0.00 (1.00) 2.74 (0.80) 2.27 (0.84) 1.08 (1.15)
Pallidum 0.00 (1.00) 1.14 (1.11) 1.18 (0.81) 0.53 (1.37)
Accumbens 0.00 (1.00) 1.85 (0.69) 3.15 (0.85) 0.72 (0.98)
Thalamus 0.00 (1.00) 1.83 (0.62) 1.47 (0.82) 1.15 (1.19)
Table A.1: Parameters for each of the static clusters shown in Figure 7.4. Each entry is the
mean (standard deviation) of the static cluster expressed as a z-score relative to
controls (all non-carriers).
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Figure A.1: Dynamic clustering of all mutation carriers in GENFI: MCMC samples of un-
certainty on top row, 10-fold cross-validation on bottom row. Same result as
Figure 7.1, but displayed as positional variance diagrams showing the order of
z-score events in each dynamic cluster and its uncertainty from MCMC sam-
pling (top row), and 10-fold cross-validation (bottom row). Each entry in the
positional variance diagram represents the proportion of MCMC samples (top
row), or the average of the MCMC samples across the 10 cross-validation folds
(bottom row), in which z-score events appear at a particular position in the se-
quence (x-axis). This proportion ranges from 0 in white to 1 in colour. Each
z-score is represented as a different colour: z=1 in red, z=2 in magenta, and
z=3 in blue. The y-axis keeps the order of events fixed to allow easier com-
parison across clusters. Where rows have a single coloured block, such as the
z=1 parietal lobe event in red in the group 1 positional variance diagram, the
ordering is strong and permutations of those events are unlikely.
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Figure A.2: Model likelihood for each of the dynamic cluster models fitted to all mutation
carriers in GENFI. In black is the in-sample model likelihood evaluated on the
whole dataset, in red is the out-of-sample model likelihood estimated using 10-
fold cross-validation. The out-of-sample model likelihood is used to choose
the appropriate number of clusters.
Figure A.3: Fitting a single dynamic cluster to each mutation type separately: MCMC sam-
ples of uncertainty on top row, 10-fold cross-validation on bottom row. Same
result as Figure 7.2, but displayed as positional variance diagrams. Positional
variance diagrams as in Figure A.1.
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Figure A.4: As Figure A.2, but for GRN mutation carriers.
A. Temporal
Stage 1 Stage 3 Stage 5 Stage 7 Stage 9 Stage 11 Stage 13 Stage 15 Stage 20 Stage 25
normal
1-sigma
2-sigma
3-sigma
B. Frontotemporoparietal
Stage 1 Stage 3 Stage 5 Stage 7 Stage 9 Stage 11 Stage 13 Stage 15 Stage 20 Stage 25
normal
1-sigma
2-sigma
3-sigma
1
Figure A.5: Dynamic clustering of MAPT mutation carriers. Subfigures (A)-(B) show
the progression pattern of each of the two dynamic clusters estimated by the
model. Diagrams as in Figure 7.1.
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Figure A.6: Dynamic clustering of MAPT mutation carriers: MCMC samples of uncer-
tainty on top row, 10-fold cross-validation on bottom row. Same result as
Figure A.5, but displayed as positional variance diagrams. Positional variance
diagrams as in Figure A.1.
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Figure A.7: As Figure A.2, but for MAPT mutation carriers.
Figure A.8: Dynamic clustering of C9orf72 mutation carriers: MCMC samples of uncer-
tainty on top row, 10-fold cross-validation on bottom row. Same result as
Figure 7.3, but displayed as positional variance diagrams. Positional variance
diagrams as in Figure A.1.
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Figure A.9: As Figure A.2, but for C9orf72 mutation carriers.
Figure A.10: Dynamic clustering of 3T ADNI dataset: MCMC samples of uncertainty on
top row, 10-fold cross-validation on bottom row. Same result as Figure 7.5,
but displayed as positional variance diagrams. Positional variance diagrams
as in Figure A.1.
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Figure A.11: As Figure A.2, but for 3T ADNI dataset.
A. Temporal
Stage 1 Stage 3 Stage 5 Stage 7 Stage 9 Stage 11 Stage 13 Stage 15 Stage 20 Stage 25
normal
1-sigma
2-sigma
3-sigma
B. Cortical
Stage 1 Stage 3 Stage 5 Stage 7 Stage 9 Stage 11 Stage 13 Stage 15 Stage 20 Stage 25
normal
1-sigma
2-sigma
3-sigma
C. Subcortical
Stage 1 Stage 3 Stage 5 Stage 7 Stage 9 Stage 11 Stage 13 Stage 15 Stage 20 Stage 25
normal
1-sigma
2-sigma
3-sigma
D. Parietal
Stage 1 Stage 3 Stage 5 Stage 7 Stage 9 Stage 11 Stage 13 Stage 15 Stage 20 Stage 25
normal
1-sigma
2-sigma
3-sigma
1
Figure A.12: Dynamic clustering of 1.5T ADNI dataset. Subfigures (A)-(D) show the pro-
gression pattern of each of the four dynamic clusters estimated by the model.
Diagrams as in Figure 7.1. The cerebellum was not included as a region in
the ADNI analysis and so is shaded in dark grey.
199
Figure A.13: Dynamic clustering of 1.5T ADNI dataset: MCMC samples of uncertainty
on top two rows, 10-fold cross-validation on bottom two rows. Same result
as Figure A.12, but displayed as positional variance diagrams. Positional
variance diagrams as in Figure A.1.
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Figure A.14: As Figure A.2, but for 1.5T ADNI dataset.
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